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The goal of this research was to investigate the role of Ig transgenes (Tgs) in
plasma cell tumor development as a useful means of examining potential antigen-specific
B cell precursors.  The Ig Tg M167mk (V1 mu plus Vk24) on a genetically PCT-
susceptible BALB/c background was used to determine if B cells expressing anti-
phosphorylcholine (PC) B cell receptors are more susceptible than non-Tg littermates to
pristane induction of plasma cell tumors.   The M167mk Tg mice, which express the anti-
PC M167 BCR on >97% of B cells, developed a higher percentage of plasma cell tumors
(63%) compared to non-Tg BALB/cAnPt littermates (35%), p<0.01, and had a reduced
latent period from 240 to 200 days.  Serologic and nucleic acid analysis of Igs expressed
by Tg tumors revealed co-expression of the M167-id V1-mu/Vk24 transgenes and a
rearranged endogenous VH-alpha/Vk Ig.  In an attempt to learn something of the natural
history of the PCT precursor B cell, the M167mk transgene and endogenous VH/VL Ig
mRNA from Tg PCT cells were sequenced for evidence of somatic hypermutation, a
hallmark of T-cell dependent germinal center activity.  M167mu and k Tg mRNA
transcripts revealed no evidence of mutation of the transgenes;  however, sequencing of
endogenous Ig mRNA from M167mk Tg PCTs showed that 80% contained somatic
hypermutation (SHM) and 20% had germline Ig genes.  PCTs from control groups,
BALB/c non-Tg littermates and C.B20 mice, also contained 80% SHM and 20%
germline Ig genes.
M167mk Tg mice have an increased (MZ) B cell population (15-25% B220+), a
hyper-activated TI responsive B cell phenotype, compared to non-Tg WT mice (5-10%
B220+).  These data suggest that PC-responsive M167mk B cells are a PCT-susceptible
subset, as the M167mk Tg BCR generates B cell clones that are responsive to bacterial
PC antigen that likely enhances overall proliferation of B cells during PCT development,
thereby increasing the chances of a neoplastic B cell clone to expand and increasing the
susceptibility of M167mk Tg mice to the induction of PCTS.
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A plasma cell tumor (PCT), such as multiple myeloma in humans or a
plasmacytoma in mice, is an immunoglobulin-secreting, neoplastic plasma cell that
represents a megaclonal expansion of one plasma cell, and ultimately, of one selected B
cell clone.  B lymphocytes each express a unique antibody molecule on the plasma
membrane that acts as a receptor for antigen.  Interaction with antigen triggers the B-
lymphocyte to differentiate into a plasma cell that secretes soluble antibody molecules
(Error! Reference source not found.).  Like normal plasma cells, PCTs secrete large
amounts of monoclonal immunoglobulin (Ig), the same antibody that their precursor B
cell clone rearranged and expressed on its cell surface.  Unlike normal plasma cells, the
majority of which are short-lived and die within several days of activation, PCT cells
continue to divide indefinitely in an unregulated fashion.  They expand to fill the various
microenvironments where they are supported, e.g., the bone marrow in humans and the
peritoneal cavity in mice.
Plasmacytomas can be induced in genetically susceptible mice by intraperitoneal
injection of non-metabolizable light white mineral oils, of which the chemically defined
alkane, pristane (2, 6, 10, 14-tetramethylpentadecane), is a frequent component (1).
While pristane is not thought to be a DNA damaging carcinogen that directly causes
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Figure 1. Clonal selection of B lymphocyte.  B-lymphocytes are antigen selected to
form monoclonal Ig secreting plasma cells.  Once a primitive B cell has rearranged its Ig
genes and expresses a complete H+L chain antigen-binding B cell receptor (BCR) on its
cell surface (explained in following section), it circulates throughout the body, “looking”
for antigen.  Within the total pool of heterogeneous B cells, only a small number of B
cells will have a BCR that recognizes a specific antigen.  Therefore, clonal expansion of
an antigen-selected B cell becomes important during an immune response.  Ag selection
stimulates cell proliferation and subsequent differentiation into a plasma cell that secretes
antibody that was originally expressed as the antigen receptor on the B cell.  During the
clonal expansion stage, numerous molecular changes to the Ig genes occur to make the
antibody have a higher affinity for antigen, and adopt different effector functions by
switchin its constant region from IgM to IgA, IgG, or IgE.
oncogenic mutations in maturing plasma cells, the current hypothesis is that the
phagocytic neutrophils of the oil granuloma produce large amounts of reactive oxygen
radicals that can potentially cause chromosomal damage (2, 3). In response to pristane,
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large numbers of macrophages and neutrophils are recruited to the peritoneal space where
they surround the oil droplets of various sizes in an attempt to clear this foreign substance
from the body.  The complexes of oil, macrophages, and neutrophils adhere to peritoneal
surfaces and become an oil granuloma (OG), a chronic inflammatory tissue that persists
in the peritoneum and is vascularized by out growth of mesenteric blood vessels.
Plasmacytomas arise within the peritoneal oil granuloma tissue, which provides a source
of essential factors, such as IL-6, that are important in supporting tumor growth and
survival (4-6).  IL-6 is a macrophage-derived soluble factor required for survival and
proliferation of PCTs in vivo (7).
Consistently occurring oncogenic mutations in peritoneal plasmacytomas are the
Myc-activating chromosomal translocations t(12;15) and t(6;15) that are found in over
95% of pristane–induced PCTs.
B Cell Receptor
Development and maintenance of B cells depend upon surface expression and
constitutive signaling through the IgM B cell receptor (BCR) (Figure2a) expressed on
the B cell’s surface (8).  B cells are generated in the BM and progress through several
stages of development, from pro-B to pre-B to the immature B cell stage, depending on
the status of the IgM receptor expressed on the surface of the cell.  The IgM BCR is made
from pairing two heavy and two light chain Ig polypeptides, joined together with




Figure 2. B Cell Receptor.  The B cell receptor is a rearranged immunoglobulin (or
antibody) molecule displayed on the surface of the cell, where it can to bind antigen.  A)
An example of an IgM molecule.  An Ig molecule is made from pairing 2 heavy (H) and
2 light (L) chains, joined by disulfide bonds.  Antibody molecules are made up of various
gene segments - each chain has a constant region (blue) and a variable region (purple).
The H and L chain variable regions make up the antigen-binding site.  Each B cell
produced in the bone marrow generates a unique Ig molecule from a different
combination of V region genes The idiotype of an antibody is the unique structure made
by the pairing of the H+L chain variable region. Each V region has 3 hypervariable sites
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(called complementary determining regions, or CDRs).  These regions have the greatest
impact on antigen binding ability of the antibody.  During affinity maturation of the Ig
molecules, amino acid changes resulting from somatic hypermutation have the greatest
affect in these regions.  Newly formed B cells express IgM (mu) constant region with a
transmembrane region allowing it to be inserted on the cell surface. B) The B cell
receptor is comprised of the surface IgM molecule and the Igα/β heterodimer.  Igα/β is
responsible for cytoplasmic signal transduction through its ITAM sites, which are
phosphorylated by tyrosine kinases (PTKs).  Figure of BCR complex is a modified
version based on diagram from Immunology, Kuby.
Once a complete surface IgM receptor is displayed, immature B cells leave the
bone marrow and enter the peripheral lymphoid system.  The immature B cells travel
through the blood/lymph to the spleen, where they receive further positive selection to
become mature B cell lymphocytes.  Basal levels of signaling through the BCR is
necessary to for the survival and maintenance of mature B cells in the periphery.
Further, activation and differentiation of a B cell begins with the binding of
antigen to the BCR.  Physiological and transgenic BCRs are both made up of membrane
IgM paired with the Igα/Igβ heterodimeric signal transducing molecule (9) (Figure 2b).
Transmission of signals from the BCR to the nucleus is mediated through the long
cytoplasmic tails of the Igα/β heterodimer that contain immunoreceptor tyrosine-based
activation motifs (ITAM) and depends on activation of cytoplasmic protein tyrosine
kinases (PTKs), their adaptor molecules and various secondary messengers that activate
intermediary signaling pathways (Figure 3).
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Figure 3. BCR Signaling. The Src family tyrosine kinases (Blk, Lyn, Fyn) and Syk
tyrosine kinase are all associated with the resting BCR and become activated upon
ligation of the receptor.  These kinases phosphorylate the tyrosines in the ITAM motifs
and the non-ITAM tyrosine 204 on Igα, which in turn recruits adaptor molecules to the
cytoplasmic tails of the receptor.  Syk kinase and BLNK (B-cell linker protein), an
important B-cell adaptor protein, bind the phosphorylated Igα tail.  Multiple pathways
are activated: the Src kinases activate the nuclear factor NF-κB; Btk activates
phospholipase C(PLC)γ2, leading to calcium flux and PKC activation; the GTPase, VAV,
is important in JNK activation and cytoskeleton remodeling, and the linker molecule,
Grb2, activates the extracellular signal-regulated kinase (ERK) pathway.  Figure and text
are reprinted with permission from Wang, 2003 (10).
Antigen stimulation through the BCR also results in the formation of a membrane
signaling complex that includes the BCR (mIgM/Igα/αIgβ) and a co-receptor complex
(CD19, CD21/CR2, CD81/TAPA-1).  The B cell co-receptor complex modulates B cell
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receptor signaling.  CD21 recognizes complement fragment C3d bound to antigen and the
antigen activates the BCR.  Antigen that binds the IgM receptor is internalized and
processed in specialized cytoplasmic compartments for presentation as peptides to helper
T cells by an MHC class II molecule located on the surface of a B cell.
B cell development, survival, migration and differentiation require constant
signaling through the B cell antigen receptor.  Through activation of its BCR, a B cell is
signaled to perform one or more of its effector functions: (1) Ag processing and
presentation, (2) antibody production, (3) cytokine secretion,  (4) formation of a memory
B cell and/or (5) differentiation to an Ig secreting plasma cell.
Mature B cell compartments (B-1 and B-2: FO, MZ)
There are two major B cell compartments, B-1 and B-2 cells, based on phenotypic
and functional characteristics, as well as different developmental and maintenance
requirements.  B-2 cells make up the majority of the B cell population in the mouse and
can be found in all lymphoid compartments:  spleen, lymph nodes, peyers patches in the
gut, peritoneal cavity, and peripheral blood.  B-2 B cells can be further divided into
follicular (FO) and marginal zone (MZ) B cell phenotypes. FO B cells are resting, naïve
B cells that recirculate throughout the body and are found in B cell follicles. MZ B cells
are non-recirculating B cells found only in the marginal zone of the spleen.  The marginal
zone is a distinct compartment found only in the spleen around the marginal sinus,
surrounding the B cell follicles and the periarteriolar T cell area.  MZ B cells typically
make up about 5% of splenic B cells, but are of great importance in early immune
responses to blood-borne pathogens.  The other major B cell compartment, B-1 cells, are
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found predominantly in the peritoneal and pleural cavities of the mouse and make up only
a very small percentage (1-5%) of splenic B cells.  B-1 cells are fetally-derived, self-
renewing B cells that produce low affinity, autoreactive natural IgM antibodies.
B cells are selected through ligation of their BCRs into the B-1 and B-2 subsets.
It had been unclear whether the antigen specificity of the BCR may play an role in
selecting B cell subsets (11) or whether the signaling strength through the BCR
ultimately influenced the B cell subset selection (12).  However, a recent publication by
S. Casola et al. (13) supports the conclusion that B subset selection depends primarily on
the strength of signaling through the BCR.  The major characteristics of each of these B
cell phenotypes are listed in the appendix (see ‘Summary of B Cell Subtypes’ on page
178, as reviewed by Vinuesa and Cook (14), and also by Martin and Kearney (12, 15)).
Functionally, B1 and MZ B cells appear to be close relatives.  It has been
suggested that B1 and MZ B cells have evolved to provide first line responses for
gut/peritoneum (B1) and blood-borne antigens (MZ).  Restriction of their BCR repertoire
helps to ensure rapid development of short-term antibody responses to a limited number
of conserved antigens.  MZ and B1 B cells are a part of the host’s natural immune
memory and are considered to be part of a bridge between the rapid responses of innate
immunity and the slower responses provided by adaptive immunity.
Relationship of Ig Producing PCTs to Ab Formation (Response to Ag)
The induction of paraffin oil-induced plasmacytomas in mice provided the first
source of large quantities of monoclonal Igs.  Laboratories with monoclonal Ig libraries
questioned what relationship these proteins had to “antibody”, and this led to a search for
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antigen binding activities of these homogeneous Igs.  Antibody was defined at the time as
a molecularly heterogenous collection of Ig molecules that bound to the same antigenic
macromolecules.  Binding activity for chemically defined antigens and haptens were
identified in only about 5% of these paraffin oil induced antibody proteins (16).  Many of
the haptens identified were oligosaccharides, α1-3 dextrans, β2-1 and β2-6 fructofurans,
β1-6 D galactan, phosphorylcholine and nitrophenyl (Table 1).  These antigenic
‘determinants’ are widely available on macromolecules in plants and animals.  Finding
several PCT proteins, generated independently in different mice, that bind the same
haptenic determinant (e.g. phosphorylcholine) suggests that antigens carrying these
haptens may be biologically active in the pathogenesis of the tumor.
Table 1. Hapten Binding of PCTs (16).
Associated hapten binding Plasma Cell Tumor
β1-6 D galactan J539, XRPC24, XRPC44, TEPC601
PC Choline TEPC15, HOPC8, MOPC167, MOPC511, McPC603,
CBBPC3, W3207
β2-1 and β2-6 fructofurans UPC61, ABPC64, ABPC47N, EPC109
α1-3 dextrans MOPC104E, J558, HDEX1-10;
DNP MOPC315
Arsonate ARS1, H9367, H124E1
NP (4-hydroxy-3-nitrophenylacetyl) B1-8, S43
Natural Antigens are an Important Factor in PCT Development
There are several lines of evidence that suggest that PCTs are derived from Ag-
selected B cells.  First, previous PCT induction studies in several types of defined
antigenic environments suggest the need for antigenic stimulation for development of
plasmacytomas.   Animal colonies are classified based on the status of the
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microorganisms present within the colony.  The animals in a conventional mouse colony
are raised and maintained under standard conditions, with an undetermined
microbiological status.  Animals in a specific pathogen free (SPF) colony are free of
disease-causing microbes or pathogens and are maintained in a special environment that
prevents exposure to or transmission of pathogens.  Germ-free animals are completely
free of all microorganisms, including natural gut flora, and are maintained under sterile
conditions.  In 1969, K.R. McIntire et al. showed that the incidence of plasmacytomas
was drastically reduced in mineral oil- treated germ-free mice (17).  Byrd et al. later
compared the incidence of PCTs induced in genetically susceptible BALB/c mice in both
conventional and SPF mouse colonies (18) and found a very low incidence of PCTs in
SPF mice.   The low incidence of PCTs (5%) that occurred in SPF mice compared to 58-
60% of mice in conventional colonies suggested that natural antigens provided by
microorganisms from natural gut flora and food contaminants are important sources of B
cell clone stimulation (18).
Second, a large percent (60 to 70%) of the Ig protein produced by pristane-
induced tumors are IgA class immunoglobulins (19-21).  IgA-secreting plasma cells are
infrequently found in spleen or lymph nodes, but abound in the lamina propria and
respiratory tract mucosal membranes, where they make up ~80% of the plasma cell
population (22, 23).  When the primary antigenic stimulation occurs across mucosal
surfaces of the gastrointestinal or respiratory tracts, B cells are not only activated and
selected by the antigen, but differentiate selectively to produce IgA (through a process
called isotype switching).  In the lamina propria of the gut, the primary function of these
IgA antibodies is to be secreted across the intestinal epithelium into the lumen of the gut
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where the IgA antibodies bind to potential invasive microorganisms and impedes their
entry into the internal environment of the host.  Although close in proximity, PCTs
develop in the peritoneal oil granuloma, a tissue that is not vascularly connected with the
lamina propria.  IgA committed B cells presumably respond to antigens of normal gut
flora that migrate or circulate and are diverted to the peritoneal cavity, where they
become precursors to plasmacytomas (24).
And lastly, in order to establish a link between the plasma cell tumors, their
secreted immunoglobulins, and microbial natural antigens, the homogenous Igs produced
by PCTs were screened against various antigens.  Antigen-binding specificities for about
5% of the tumors were determined.  A 1970 paper published by Potter (25) reported that
precursors of the neoplastic plasma cells were actively forming antibodies that bound
polysaccharide antigens originating from gastrointestinal microorganisms.  One recurring
Ag that was detected by Igs from several PCTs was phosphorylcholine (PC).  In early
studies, eight independently induced PCTs produced structurally and genetically related
Igs that bound PC: H8, S63, S107, T15, M167, M299, M511, and M603.  Three
subclasses of PC binding antibodies were devised based on the unique antigenic
specificities of the murine PC-reactive myeloma proteins studied: class I M167, class II
M603, and class III T15 (Table 2) (26, 27).  All three families share the common
germline VH1 heavy chain (28, 29).  In each of these tumors, the VH1 heavy chain
combines with a different light chain, Vk24 (M167), Vk8 (M603), Vk22 (T15), to form
distinct anti-PC binding antibodies with different antigenic specificities.
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I. M167 VH1 Vk24 PC on lipoproteins
II. M603 VH1 Vk8 PC on morganii LPS
III. T15, H8, M299 S63, S107 VH1 Vk22 PC on bacterial Ags
MOPC 167
The PC antibody of particular interest in this research project is M167.  M167 is
an IgA/kappa myeloma protein from a BALB/c MOPC tumor, originally described by
Potter and Leon (30).  The authors showed the M167 IgA myeloma protein was one of
several related monoclonal Igs that could specifically bind to and precipitate the
pneumococcal C polysaccharide (PnC).  Leon and Young (27) later reported that the
relevant hapten for M167 and its related myeloma proteins was phosphorylcholine found
within the structure of PnC.
Phosphorylcholine
Phosphorylcholine (PC) is a naturally occurring haptenic antigen found in many
potentially disease-causing pathogenic organisms, including bacteria such as
Streptococcus pneumoniae, Lactobacillus, and Haemophilus influenzae, as well as in
fungi, protozoa, tapeworms, and in the cuticle of certain nematodes (31, 32).  PC is
associated with teichoic acid (33), a polysaccharide constituent of bacterial cell walls, and
13
lipoteichoic acids (34), a polysaccharide in cell membranes.  In both of these
polysaccharides, PC is attached directly to the sugar residues (Figure 4), usually N-
acetylgalactosamine (GalNAc).  PC is involved in the maintenance of normal shape, size
and physiology of a cell and plays an important role in normal cell growth and cell
division in Streptococcus pneumoniae (35).  Studies have also shown that PC mediates
persistence and invasiveness of certain pathogens within host organisms.  One such study
demonstrated that PC on S. pneumoniae is important for allowing the bacteria to invade
human endothelial cells through a receptor for platelet-activating factor (PAF) (36).  In
normal unimmunized mice, IgM and IgG3 antibodies directed against PC are found in
naturally high levels (that vary depending on mouse strain) in the serum (31).  The
presence of these natural PC antibodies demonstrate the important role these natural
antibodies play in targeting PC antigen in host immune responses against bacterial
infection.   Immunization with Streptococcus pneumoniae is a well-studied mouse model
demonstrating the importance of natural PC antibodies in host protection against bacterial
infection (32).
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Figure 4. Phosphorylcholine hapten attached to a sugar ring.
Autoantigen Origin of PC: oxidized lipoproteins and apoptotic membranes
It has recently been shown that apoptotic cells are a source of PC-antigen.  Shaw,
et al (37) demonstrated that PC-antibodies, and specifically the M167 antibody, bind both
microbes as well as “neo-self” antigens linked to apoptotic cells, atherosclerosis and
autoimmune disease.  These studies have demonstrated an enrichment of PC-containing
phospholipids in apoptotic blebs (38).  Further, oxidatively modified low density
lipoproteins (oxLDLs) also display PC hapten that can be recognized by anti-PC
antibodies, whereas normal LDLs do not (38).  The OG tissue is made up of
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inflammatory macrophages and neutrophils, many of which are undergoing apoptosis,
thus creating a potential and persistent source of autogenous antigen to promote
proliferation of anti-PC specific B cells present in the peritoneum.  Further studies to
show that the oil granuloma tissue is in fact a rich source of apoptotic cellular PC antigen.
Immune Responses to PC Antigen
The innate immune system produces natural IgM antibodies that recognize PC
determinants primarily associated with the early stage of apoptosis, while the higher
affinity, hypermutated PC antibodies that are generated during T cell dependent immune
responses recognize determinants found at the late stages of apoptosis (37).  In addition
to the PC-binding natural antibodies, C-reactive protein (CRP) is another part of the
innate tier of the immune system that recognizes PC determinants. C-reactive protein has
been shown to bind PC found on microbrial pathogens, apoptotic cells (39), and
oxidatively modified low density lipoproteins (OxLDLs) (40).  PC-antibodies and CRP
are both thought to be important in protecting against microbial pathogens and clearance
of apoptotic cells and oxidatively modified moieties found in inflammatory lesions.
Ig Transgenes in Pristane-Induced Plasmacytoma Studies
To our knowledge, no one has studied pristane induction of plasmacytomas in
immunoglobulin transgenic (Ig Tg) mice.  Further, no one has studied the Ig production
in plasmacytomas generated in Ig Tg mice.  The antigen specificity of the majority of B
cells in these Tg mice is dictated by the specific Ig transgenic BCR, which can be used to
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address the role of antigen as a critical factor in plasmacytoma development.
Specifically, are there certain antigens that are more influential in promoting tumor
development in BALB/c mice?
As previously discussed, a small percentage of PCT myeloma proteins have been
shown to bind bacterial antigens.  In particular, a well-studied group of PCT tumors bind
PC in bacterial polysaccharides and apoptotic cells.   In this study we specifically ask the
question: are phosphorylcholine (PC)-specific Tg B cells more likely to cause an
increased incidence of plasmacytomas when stimulated by antigen?  For example, if the
Ig transgene forms a functional BCR, then the presence of specific antigen can stimulate
preferential survival and proliferation of the B cells that contribute to generation of
oncogenic mutations.  The net effect of pristane may be to create an inflammatory
environment that provides factors, such as IL-6, that aid in the maintenance and survival
of PCT cells.
Transgenes and Immunoglobulin Transgenes
Transgenes are genes that are introduced into an organism by microinjection of
DNA into newly fertilized eggs.  Transgenic positive animals that develop from the
injected eggs carry the foreign gene(s), which have been randomly incorporated in the
genome, and are then passed on to their progeny.  A single copy or multiple copies of the
transgene(s) are usually integrated in tandem into a single insertion site (41).  Expression
levels of the transgene are dependent upon the number of copies integrated into the
genome, as well as the site of integration within the chromosome and are heavily
dependent upon the regulatory sequences (promoters and/or enhancers) that are included
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with the transgene.  The regulatory sequences control tissue specificities of transgene
expression.
Immunoglobulin transgenes (Ig Tgs) are heavy (H) or light (L) chain Ig genes that
have had their variable regions (VDJHCH or VJLCL) previously rearranged so that they
form a productive H or L chain.  Some Ig transgenic mice carry both H and L chain
transgenes (and are referred to as double Ig Tgs).  Functional transgenic Ig molecules can
be generated using a combination of both endogenous Igs and transgenic Ig products.
When only one Tg Ig chain is introduced (i.e. IgH-only or IgL-only), the Tg can bind to
endogenous H or L chains to generate a limited antibody repertoire. The microinjected Ig
transgenic cDNA constructs can be expressed specifically on the surface of B cells as B
cell receptors (BCR) and/or as secreted Ig molecules.  In order to be expressed on the cell
surface of developing and mature B cells, the antibody molecule must have a constant
region containing a transmembrane domain so that it can be inserted into the membrane
and act as an antigen receptor.
Ig Transgenic BCR Influences B Cell Phenotype
Ig Tgs have not only been shown to be influential in designating the specificity of
the expressed BCR on the surface of B cells, but also in determining the phenotype of the
B cell on which they are expressed.  An accumulating body of evidence shows that
certain B cell clones appear to be uniquely selected into a particular mature B cell
compartment, such as B1, marginal zone (MZ) or follicular (FO) B cell populations based
upon its BCR.  For example, it has been demonstrated that M167-id and VH81X-id B
cells localize to the marginal zone of the spleen (42).  The current dogma states that the
18
specificity of the BCR as well as the strength of selective positive signaling through the
receptor determine what mature B cell subset the precursor cell enters (11).  Table 3
highlights a few of the known VH/VL clones that influence a particular B cell phenotype.
Table 3. BCR influences B cell phenotype.  The table lists specific examples of B cell
receptors that have been shown to determine B cell phenotype.  NP = anti-4-hydroxy-3-
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I used the BALB/c M167µk transgenic mouse (C.M167µk Tg) to determine if B
cells expressing the M167 anti-PC natural antibody as a B cell receptor are more
susceptible to pristane induction of plasma cell tumors.  The M167µk transgenic mouse,
originally made in Ursula Storb’s lab (47) and well-studied as reported in the literature,
expresses the M167µk (heavy and light chain) receptor on >97% of B cells in these mice,
making it a good model in which to attempt the induction of plasmacytomas from
phosphorylcholine-specific B cells.  I will further investigate the effects of the transgene
on peripheral B cell populations in the spleen and peritoneal cavity using flow cytometry
to test for transgene expression and for B cell characterization.
Since one of the main characteristics shared by a PCT and its precursor B cell is
the Ig it produces, I will characterize the Ig genes produced by the M167µk Tg PCTs.
Will the Tg PCTs secrete a monoclonal M167 Ig or will other Igs be expressed?  What
will the mutational status of the expressed Igs be? How will the M167µk Tg affect
expression of endogenous Ig genes?  Tracing the natural history of in a PCT using a
known sequence marker such as the M167µk Ig transgene would allow us to determine
whether antigen selection is indeed important in plasmacytoma development.  Somatic
hypermutation (SHM) of the Ig variable (V) region genes expressed by a B cell is a T cell
dependent process induced upon antigen stimulation of the B cell receptor and
CD40/CD40L interactions in germinal centers (GCs) and is necessary in generating high-
affinity antibodies during an immune response.  Therefore, seeing an accumulation of
somatic hypermutations in the hyper-variable regions (or CDRs) of Igs is considered a
classic hallmark of GC activity and indicating that the B cell underwent antigen selection.
20
And finally, because the M167µk Tg BCR has to be able to respond to PC
antigens in order to affect the incidence of tumors, I want to investigate the functional
ability of the Tg BCR to respond to physiological, PC antigens, such as the PC-
containing bacteria S. Pneumoniae.  Does immunization with this bacterial antigen
stimulate an anti-PC antibody response and are Tg B cells stimulated to proliferate upon
activation of the M167 BCR?
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Specific Aims
To study the effects of immunoglobulin (Ig) transgenes (Tgs) on the induction of
plasma cell tumors (PCTs) by pristane in BALB/c mice and the characterization of Igs
produced by PCTs that have been induced in these M167µk Tg mice
1. Compare the incidence of C.M167µk Tg mice and C.VH12µ Tg mice to wild-
type BALB/c littermates in a pristane plasmacytoma study.
2. Use flow cytometry to evaluate the B cell subpopulations in the spleen and
pertioneal cavity of C.M167µk Tg mice.
3. Sequence the immunoglobulin genes produced by PCTs derived from C.M167µk
Tg mice.
4. Determine if the M167µk Tgs or other expressed immunoglobulin genes have
undergone SHM, as an indication of antigen selection of the precursor B cell
clone.




Plasmacytoma Studies in C.M167µk Tg mice
The original experiment using Ig transgenics was to determine if mice that
produce an expanded population of B-1 cells were more prone (susceptible) to PCT
induction by pristane than parental BALB/c mice.  This was instigated by the finding that
BALB/c xid/xid mice, which lack B-1 cells, were refractory to PCT induction by
pristane.  Also certain monoclonal Igs produced by pristane-induced plasmacytomas, e.g.
TEPC 15, come from B-1 cells (43), and therefore led us to believe that B-1 cells could
be the primary B cell  precursors of pristane-induced PCTs.  Accordingly, transgenic
mice with the VH12 gene were imported for this purpose.  VH12 is a VH gene that is
almost exclusively expressed on B-1 cells and the VH12µ transgene generates a dominant
B-1 phenotype in VH12 Tg mice.  Due to technical difficulties in backcrossing the VH12
transgene onto BALB/c, results were delayed.  BALB/c M167µk Tg mice were also
imported and used as a control for Ig Tg mouse.  A pristane induction experiment was
underway when a substantial difference in PCT incidence between the M167µk Tg and
non-Tg littermates was noted.  I decided to further investigate this intriguing model.
Several questions emerged: 1) would M167µk Tg mice be susceptible to PCT-
induction, 2) would plasma cells derived from these mice secrete large quantities of
monoclonal M167µk antibody, and 3) would the M167 Ig transgenes carry any marks of
somatic hypermutation?  Since >95% of M167µk Tg B cells carry the M167-idiotope B
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cell receptor and can bind PC (48, 49), the targeted B cell population of interest includes
almost every B cell in the Tg mouse.
M167µk Tg BCR Increases Incidence of Pristane Induced PCTs
Figure 5 describes the protocol used in pristane induction of plasmacytomas in
M167µk Tg mice.  Induction studies in M167µk Ig Tg mice were carried out to
determine whether B cells with an anti-PC specific B cell receptor would be more
susceptible to developing plasma cell tumors.  Results of the PCT induction study
surprisingly showed that M167µk Tg mice have a consistently increased susceptibility to
developing pristane-induced peritoneal PCTs (Figure 6), with PCTs developing more
rapidly than in non-Tg (WT) littermates given pristane.  Results were confirmed in two
independent PCT induction studies, with a total of 80 Tg+ mice and 74 non-Tg
littermates.  M167µk Tg mice had a 63% PCT incidence while non-Tg littermate mice
only had a 35% incidence. Further, this was associated with a decrease in the mean latent
period from 240 days in WT to 200 days in the Tg mice.  Chi squared (χ2) analyses of the
combined results showed a significant difference (p < 0.01) in PCT development between
Tg+ and non-Tg mice.  For all PCTs from both M167µk Tg and non-Tg mice, either
ascites cells or diced tissue from solid primary (g0) tumors were transplanted into
pristane primed BALB/c mice for further analysis.
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Figure 5. Schedule of pristane (i.p.) injection for PCT induction.  M167µk Tg+ and
non-Tg littermate mice (2-3 months) were intra-peritoneally (i.p.) injected with 0.2ml, 0.5
ml, and 0.5 ml pristane on day 0, 60, and 120.  Plasmacytoma positive mice were
diagnosed by screening peritoneal ascites fluid.  Beginning at around day 125, cytospin
slides were made every 21 days in order to detect the presence of abnormal PCT cells in
the ascites.  Mice with >10 large atypical plasma cells on a slide were considered to have
a PCT.  Subsequent cytospins revealed the mice had progressively expanding numbers of
PCT cells.  Autopsy results indicated widespread PCT in the OG.
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         ↑d0        ↑d60     ↑d120     pristane injections
Figure 6. Pristane Plasmacytoma Study in C.M167µk Tg Mice.  C.M167µk Tg+ (207-
4) mice have increased incidence of PCTs.  The results of the plasmacytoma pristane
induction showed that the C.M167µk Tg mice develop a significantly (p < 0.01*) higher
percentage of plasma cell tumors (63%) as compared to non-Tg (Tg-) littermates (35%).
There was an associated decrease in the mean latent period from 240 days in non-Tg
mice to 200 days in the Tg mice.  The latent period is defined as the number of days at
which 50% of the total tumors within a group had developed.  Two independent study
results are combined, totaling 80 Tg and 74 non-Tg C.M167µk mice.
C.VH12µ Tg Pristane Plasmacytoma Induction Study
The mice used in this study were received from Steve Clarke and backcrossed
from C57/B6 to BALB/c.  Accelerated backcrossing was done using MIT chromosomal
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markers to selectively eliminate C57/B6 genes and the PCT pristane study was done on
generation (n5) BALB/c mice.  The VH12 Cµ founder line 6-1 used contains 15-20 copies
of the IgM Tg.  The construction of the VH12 Cµ transgene is specified in Table 4.
Table 4. VH12µ Tg cDNA construct.  B cells expressing the transgene have VH12
heavy chain that selectively pairs with the Vk4 light chain.  Mice with the VH12
transgene make primarily PtC binding B cells that express the CD5+ B1 phenotype (50).  
GENE ORIGIN
The VH12 Cµ Tg produces high numbers of PtC-specific peritoneal and spleen B
cells, due to VH12µ Tg heavy chains selectively pairing with endogenous Vk4 light
chains.  Exclusive segregation of the PtC specificity to the B-1 phenotype in all
peripheral B cells.  The peripheral PtC B1 cells have the following cell surface
characteristics:  most are CD5+, all are IgMhigh, B220low, CD23neg (and peritoneal B cells
are also MAC-1/CD11b+).
Several breeder lines of N5 C.VH12µ Tg mice were tested in pristane induction
of PCTs in case genetic background effects from C57/B6 genes still remained.  Figure 7
demonstrates that the VH12µ Tg did not cause any change in PCT incidence.  Tg and
non-Tg (WT) littermates developed the same number of plasma cell tumors in both
VH12-DSP2.9-JH1 segment
3.3-kb EcoR1 fragment




HyHEL10-µ-δ   (C. Goodnow)
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studies shown.  Other studies not reported here on further generations of C.VH12µ Tg
mice also support these findings.
Discussion
Finding an increased incidence of PCTs with shorter latent period in C.M167µk
Tg mice was a novel result.  Why are the PC-specific C.M167µkTg mice developing
more plasmacytomas than BALB/c non-Tg littermates?
The chromosomal integration site of the transgenes is an important factor to
consider when discussing the influence of the M167µk transgenes upon increased
plasmacytoma development.  The transgenes may have inserted into an oncogenic locus
and are deregulating a gene important in plasma cell tumor development.  Susceptibility
of mice to plasmacytomas is a complex genetic trait involving multiple loci.
Resistance/susceptibility genes have been identified on chromosomes 1, 4, and 11 (51,
52).  Previous reports of M167µk (207-4) mice in the literature have not identified the
chromosomal insertion point of the transgenes.  However, I have preliminary studies that
show the Tg M167k light chain is located on either chromosome 2 or 3 (see Figure 39
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Figure 7. Pristane Plasmacytoma Study in C.VH12µ Tg Mice.  Induction curves for 2
different breeder lines or "families" of VH12 BALB/c mice are shown.  Although PCT
incidences in non-Tg control mice were generally lower than seen in pure BALB/c mice,
the VH12µ Tg did not significantly affect the number of PCTs that developed.
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in Appendix), and I think disruption of an important gene is an unlikely probability.
Further studies need to be done to isolate the exact location of the M167µk transgenes.
Alternatively, the M167µk Tg could be causing changes in the B cell repertoire
that effect immune responsiveness and influence the ability of the B cells to become
plasmacytomas.  The abundant presence of environmental PC (or other related antigen)
found in the diet or on commensal bacteria is a likely source of antigen that is stimulating
many of the C.M167µk Tg PC-specific B cells to divide and differentiate into plasma
cells.  The inflammatory pristane OG generates a rapid turnover of cells and there are
many apoptotic cells that potentially become a source of phosphorylcholine-containing
autoantigens.
Another possible factor affecting the enhanced PCT development in these
M167µk mice if they have an increased MZ B cell population because of the M167 BCR
expression on their cell surface (see Table 3).  A high surface density of M167-id B cell
receptor confers the MZ B cell phenotype.  The MZ B cells, strategically located at the
marginal sinus of the spleen where they can filter blood born antigens, are more rapidly
activated by T-cell independent antigens and differentiate into plasma cells at a faster rate
than the follicular splenic cells (see ‘Summary of B Cell Subtypes’ in appendix on page
178).   The hyper-activated marginal zone B cells may be more susceptible to obtaining
oncogenic mutations under the pressure of inflammatory conditions peritoneal OG tissue.
My hypothesis is that the M167µk Tg changes the immune response of the B cell
repertoire, based on the antigen-specificity of the Tg B cell receptor, allowing the B cell
population as a whole to respond to the widely available environmental PC antigen.
30
Chapter 2 conclusions:
• The M167µk Tg increases the incidence of plasmacytomas (PCTs) and
shortens the latent period in conventional BALB/c An mice induced with
pristane.
• Two independent studies confirmed that there is a significant increase
(p<0.01) in PCT incidence from 35% PCTs in WT controls to 65% PCTs in
C.M167µk Tg mice (Figure 6).
• The mean latent period of PCT development decreased from 240 days in WT
controls to 200 days in Tg mice
• Pristane induction in anti-PtC C.VH12µ only Tg mice did not induce the
dramatic increase of PCTs seen in C.M167µk Tg mice
These findings led to studies designed to explain why the M167µk Tg mouse is
more prone to developing PCTs.  This was approached by studying the immunology of
the M167µk Tg mouse.
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CHAPTER 3
Characterization of B cell Subpopulations
in C.M167µk Tg Mice
Background on M167µk (207-4) Tg Mice
The M167 µ and k transgenes utilize the VH and Vk genes from a well-studied
mineral oil-induced PCT antibody (MOPC 167 or M167).  The monoclonal
immunoglobulin produced by this PCT is an IgA molecule that binds with low affinity
phosphorylcholine groups found in various antigens.
The original M167µk transgenic mouse (line 207-4) was produced in the lab of
Ursula Storb (47).  Storb et al. produced two cDNA transgenes: one of the M167 Vk L
chain and the other of a modified M167 H chain of IgM isotype.  The kappa light chain
contains the functional variable  (Vκ24-Jk2) region of the M167 gene (obtained from P.
Gearhart, Johns Hopkins University, Baltimore) ligated to the BALB/c MOPC21 kappa
constant gene (Ck a) created by Brinster et al. (53).  The heavy chain contains the VDJ
(VH1-DFL16.1-JH1) region of the rearranged plasmacytoma M167-IgA gene recombined
with a BALB/c germline IgMa (µa) constant region (Figure 8).  The M167 kappa and
M167 IgM transgenes were co-injected into (C57BL/6 x SJL)F2 ova and both genes
inserted themselves into the chromosome at the same integration site.  Integration of the
transgene was not targeted to the IgH locus but occurred at a random (and undetermined)
site
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Figure 8. M167µ and M167k transgene constructs (line 207-4).  Multiple copies of the
M167 µ heavy chain and M167 kappa light chain transgenes were tandemly integrated
into a single site in the chromosome of M167µk Tg mice.  The chromosomal integration
site is unknown.  Original estimates of copy numbers were 60 copies of the M167µ gene
and 15 copies of the M167k transgene.  Figure of M167µk transgenes are as described by
Storb et al. (47).
within the genome.  The original ratio of µ:k was 4:1 (60 copies µ and 15 copies κ),
tandemly inserted in the chromosome as determined by quantitative slot hybridization
using tail DNA of offspring (47).  The transgene-encoded M167-idiotype (VH1 plus
Vk24) IgM B cell receptor is expressed on >97% of B cells (48) and high levels of
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background anti-PC antibodies have been reported in the serum of unimmunized
transgenic mice (54 321).  Expression of the M167µk transgene was reported to be tissue
specific as high levels of µ and k RNA were detected in spleen, but not in heart, kidney
or liver tissues (47).  B cell specificity is due to the presence of Ig specific promoters and
enhancers present in the Ig gene segments used in the transgenic construct.
The BALB/c IgM constant region gene contains the transmembrane domain
sequence that allows the heavy chain to be inserted into the membrane.  Alternate mRNA
processing of the M167µk Tg heavy chain transcript allows the production of both the
membrane and secreted forms of the Tg-IgM antibody, as both RNAs are detected in
spleen (47).  In a B lymphocyte, the M167 µ heavy chain transcript is inserted into the
cell surface membrane.  Further tests have shown that RNA processing favors the
secreted form of M167µ RNA in plasma cells as demonstrated when the M167 µ gene
was transfected into the J558L myeloma (47).
No IgD constant region gene included in the rearranged M167 IgM Tg heavy
chain construct and, therefore, transgenic M167 VHDHJH-IgD expression on B cells is not
possible.  Furthermore, there is no IgM switch region (Sµ) included in the M167µ cDNA,
so isotype switching of the heavy chain transgene with the endogenous IgH constant
region on chromosome 12 would be an unlikely event.
Kenny et al. (48, 55) previously reported expression patterns of transgenic and
endogenous Ig antibodies on C57BL/6.M167µk Tg (207-4) B cells.  In the M167µk Tg
mice studied by these researchers, the transgenic BALB/C IgM a could be distinguished
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serologically from endogenous C57BL/6 IgMb using allotypic1 determinants found on the
C region.  Allotypic anti-IgM antibodies (anti-IgMa mAb and anti-IgMb mAb) were used
to determine transgenic IgM (µa) versus endogenous IgM (µb) expression in splenic B
cells.  Most B cells, 97-99% from Storb’s M167µκ Tg mice (Ig µa/µb), expressed high
surface densities of transgenic IgMa on their cell surface (48).  Only 2-11% of total
spleen cells in Tg mice stained positive for endogenous IgMb and 2-4% stained for IgD
isotype expression.  These results indicated that the expression of endogenous µb Ig
heavy chain had been suppressed, although not completely eliminated, by the presence of
the productively rearranged M167µ Ig transgene.  Co-expression of endogenous and
transgene receptors occurred on 4 to 30% of the splenic Tg B cells.  Kenny reported that
Tg+ mice typically had half the number of B cells of non-Tg littermates. Tg spleens
contain ~25% B cells, whereas non-Tg spleens are ~50% B cells.  There were also fewer
total splenic cells in Tg mice compared to non-Tg mice (3 to 4 x 10^7 Tg+ vs. 1x 10^8
non-Tg spleen cells).  My research with BALB/c.M167µk Tg mice supports these data.
Naïve M167µk Tg mice produce 10-100x more PC antibodies than normal wild-
type mice (47, 54).  Pinkert et al. conducted immunization studies in both germ-free
(described as caesarian-derived pups maintained under sterile conditions in a gnotobiotic
environment, i.e. with a carefully defined natural gut flora to aid in digestion) and
conventional mice (exposed to many environmental antigens) to investigate whether
                                                 
1 Allotypic determinants (or allotopes) are created by polymorphic differences in
the amino acid sequence of a conserved Ig constant region between strains of mice and
can be detected by anti-allotypic antibodies.
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environmental antigen was important to the spontaneous production of anti-PC serum
antibodies in Tg mice.  Sources of PC contaminants due to dead microorganisms in diet
and bedding were significantly limited in the gnotobiotic environment in order to
maintain a sub-threshold level of PC contamination.  Because PC is an abundant
environmental contaminant found in many antigens both dietary and microbial,
conventional wild type (WT) BALB/c mice have naturally high levels of anti-PC serum
antibodies.  However, germ-free BALB/c WT mice normally express very little to no
anti-PC serum antibodies (54) in the absence of immunization.  Results showed that
M167µk Tg germ-free, as well as conventional, mice spontaneously secreted elevated
levels of anti-PC antibodies (54).  Elevated levels of anti-PC antibodies were detected in
sera of these Tg mice as early as 16 days of age, at a time when normal non-Tg mice are
not fully immunocompetent (summarized in Table 5).  In vitro studies also showed that
Tg B cells, in contrast to non-Tg B cells, spontaneously secreted PC-antibodies without
the presence of antigen.  Therefore, the authors concluded that a triggering antigenic
stimulus was not necessary to evoke production of the anti-PC antibodies in M167µk Tg
mice (54).
Table 5. Reported levels of PC Ab in M167µk Tg mice.  Levels of PC Ab in germ-free
gnotobiotes and conventionally housed mice at 16 days of age (54).
Germ-free (gnotobiotes) Conventional
M167µk Tg very high very high
Non-Tg littermates low to none high
BALB/c WT low to none high
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Several reports indicate that M167µk Tg mice can respond to T cell dependent PC
antigens.  Pinkert et al. (54) reported that M167µk Tg B cells of mice pre-immunized
with T-cell dependent PC-hemocyanin (Hy) antigen had an increased frequency of PC-
responsiveness by using in vitro splenic fragment cultures.  In this experiment, recipient
F1 mice were injected i.p. with 100 µg of T-cell dependent PC-Hy antigen in IFA,
boosted i.p. with 100 µg Hy in saline at 4 weeks.  Another 4-8 weeks after the boost,
these recipient mice were whole body irradiated 1-4 hours before receiving M167µk Tg
B cell transfers.  Fragment cultures were prepared from the spleen of recipient mice and
stimulated with PC-Hy for 3 days.  Culture medium tested for PC antibody production
over a period of 28 days determined that the Tg B cells were responsive to PC antigen.
Kenny (48) reported that M167µk Tg mice can respond to PC-KLH in vivo.  In
addition to PC, M167µk Tg mice can respond normally to other antigens and are not
immunocompromised by conventional conditions.  The M167µk Tg mice can respond to
endemic pathogens when reared in a conventional colony (54).  These mice also have the
ability to produce endogenous antibodies to such antigens as the KLH protein carrier and
FITC molecules (48), as well as to DNP, or dinitrophenol  (54).
BALB/c.M167µk Tg Mice
The original M167µk Tg (207-4) line was maintained and studied on a C57BL/6
genetic background, a strain resistant to PCT induction by pristane, where the transgene
could be detected using specific antibodies against the allotypic µa marker on the IgM
heavy chain (BALB/c µa vs. C57BL/6 µb).  The M167µk transgene needed to be
expressed in conventionally raised PCT-susceptible BALB/c mice in order to conduct
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plasmacytoma induction studies.  BALB/c.M167µk (207-4) Tg mice were a gift of Dr. J.
Kenny (National Institute on Aging, GRC, NIH, Baltimore) and had been previously
backcrossed to BALB/c at least 20 generations.  The mice used in the studies reported
here are maintained in a conventional mouse facility at the NIH, Bethesda.  C.M167µk
Tg+ male mice were backcrossed to female BALB/cAnPi mice at least 4 more
generations (N24) before beginning PCT induction studies.
Peripheral blood lymphocytes (PBL) from progeny were typed for presence of the
transgene by flow cytometry using anti-B220 and an anti-VH1-specific antibody.  Non-Tg
mice have <1% VH1 expression on PBLs, whereas almost all B220+ B cells are VH1+ in
Tg mice (Figure 9).  The rat anti -VH1 antibody (56) from hybridoma T68.3 specifically
recognizes the transgenic VH1 heavy chain, in combination with various light chains, was
a gift of Dr. J. Kenny, originally obtained from Dr M. Scharff, Albert Einstein College of
Medicine, Bronx, NY.
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Figure 9. Transgenic Typing of PBL.  Flow cytometry is used to type C.M167µk mice
for presence or absence of the transgene using peripheral blood cells.  Cell staining with
antibodies against anti-B220 (FITC) and anti-VH1 (PE) heavy chain.
The T15 subfamily (currently classified as S107 VH family) contains four gene
segments, designated V1, V3 (defective), V11, and V13 (57).  The four genes have a 75%
nucleotide homology with each other and all are structurally very similar.  V1 (VH1) is
the VH gene family found in most PC antibodies.  VH1 can pair with 3 different L chains
to form 3 different families of PC-binding antibodies: T15, M167, and M603 (Table 2).
The anti-VH1 antibody used for typing the Tg mice can recognize the VH1 gene product
used in any of the PC-antibodies.  An antibody’s idiotype refers to the collection of
idiotopes (or determinants) created by a particular H+L chain combination.  Three
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idiotypes found in PC antibodies are T15-id (VH1/Vk22), M167-id (VH1/Vk24), and
M603-id (VH1/Vk8).  Anti-idiotypic antibodies can recognize idiotypes.
VH1 and M167 BCR expression levels
Splenic B cells were screened from our C.M167µk Tg mice to determine whether
the expression levels of the Tg VH1 heavy chain were comparable with previous reports.
Flow cytometry analysis shown in Figure 10 confirms that the transgene is expressed on
most splenic B cells in Tg mice.  The anti-VH1 antibody (56) specifically recognizes the
transgenic VH1 heavy chain (clone T68.3) used in the M167µk Tg.  As seen in Figure
10a, the VH1 heavy chain Tg is highly expressed on most B cells (> 95%) in the spleen,
whereas non-Tg (WT) littermates have only a small population of VH1 B cells (< 3%).
These expression levels agree with previously reported levels (48).  The VH1 histogram
in Figure 10a, however, shows two distinct levels of heavy chain surface expression on
Tg B cells.  An anti-M167 antibody (rat, clone 28-6-20) that recognizes the Vk24 light
chain was utilized to determine levels of M167 idiotype expression (49, 58).  Figure 10b
show that the Tg-encoded M167 B cell receptor is expressed at low to high surface
densities on splenic B cells in Tg mice.
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Figure 10. Transgene expression in C.M167µk Tg mice.  Splenic B cells were gated on
using either CD19 (a B cells surface marker) or B220. (A) The rat anti-VH1-id
hybridoma, T68.3, recognizes all antibodies utilizing a VH1 heavy chain. VH1 is highly
expressed on B cells in Tg+ mice.  (B) The rat anti-M167-id hybridoma, 28-6-20,
recognizes only the M167 Vk24 light chain, which can be paired with various heavy
chains. The Tg-encoded M167 Vk24 light chain is expressed at low to high surface
densities on B cells in M167µk Tg mice.
Anti-PC antibody Sera Titers in M167µk Mice
To determine whether anti-PC antibodies sera levels of C.M167µk Tg study mice
used in the plasmacytoma studies were elevated, comparable to previously published
levels, their sera were compared to BALB/c non-Tg littermates as well as from
conventional C57BL/6 M167µk Tg mice from J. Kenny’s colony.  BALB/c WT mice are
known to naturally produce PC antibody in serum (59).  We show here that conventional
BALB/c (non-Tg littermates) mice have high levels of natural PC antibodies, as can be
seen in Figure 11.  Because PC is an abundant environmental antigen, conventional
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BALB/c titers are equivalent to the M167 protein (ascites) positive control.  However,
both C57BL/6 and BALB/c M167µk mice have naturally higher levels of anti-PC
antibodies in the serum of unimmunized mice than their WT controls as they are elevated
~10 fold over non-Tg mice (Figure 11).  The conventional C.M167µk Tg mice that were
rederived by caesarean section into an SPF colony also have elevated sera titers
comparable to their conventional counterparts (data not shown).  I conclude that anti-PC
sera titers in our conventional and SPF Tg mice are spontaneously elevated due to the
presence of the PC-specific M167µk Tg and are comparable to previously published
reports.
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Figure 11. Serum titers of anti-PC antibodies in conventional M167µk Tg mice.
High levels of background anti-PC antibodies are detected in the serum of unimmunized
transgenic mice compared to WT BALB/c mice in a conventional colony.  C57BL/6 sera
(n=3) from another facility and BALB/c sera (n=3) from our conventional colony were
tested and have comparable titers. RPC5 (a non-PC binding myeloma protein) was used
as a negative control.  M167 ascites (1:100) was our positive control. (Titers are from
n=3 mice in each group, sera dilution factor x 100.)
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Expression of Endogenous sIgD on M167µk Tg B cells
Expression of the M167µk transgenes does not prevent VDJ rearrangement of
endogenous H chain genes and their subsequent expression on the surface of Tg B cells
in our conventional BALB/c M167µk mice.  As described earlier, the M167µ transgenic
construct does not include the IgD gene (47) and therefore cannot produce an IgD heavy
chain protein.   Kenny et al (48) originally reported that the majority of B cells in
M167µk Tg mice do not express IgD on their cell surface, and co-expression of
endogenous IgM occurs on only 4 - 30% of the Tg B cells (48, 55).  Our BALB/c
conventionally housed M167µk Tg mice clearly express cell surface IgD on all B cells,
shown in the flow cytometry profile of B220+ spleen cells in Figure 12, indicating that
endogenous Ig is being expressed on the cell surface of Tg B cells.  The two IgD+ groups
gated are the mature B cells (IgMlow IgDhigh) and the immature and marginal zone B cells
(IgMhigh IgDlow).  Unfortunately, after backcrossing the M167µκ Tg from C57BL/6 to
BALB/c, easily distinguishing surface expression of transgene from endogenous IgM on
B cells is no longer possible using IgM allotypic markers as Kenny’s laboratory had
done.  The transgenic IgMa is now allotypically indistinguishable from the endogenous
BALB/c IgMa allele.  However, knowing that IgD is not included in the transgene, this
observation leads me to conclude that most of the IgM+ B cells in these Tg mice are co-
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Figure 12. Expression of IgD on mature and immature/marginal zone B cells in
C.M167µk Tg mice. Splenic cells were stained with B220 PerCp, IgM-FITC and IgD-
biotin/SAV-APC.  Unlike previously published reports, our conventionally housed
BALB/c M167µk Tg mice express IgD on the surface of splenic B cells, indicating heavy
chain VDJ rearrangement and expression of endogenous IgM/IgD genes.  There are two
IgD+ populations of splenic B220+ B cells shown above.  IgDhigh/IgMlow B cells are
mature (M) follicular B cells, whereas IgDlow/IgMhigh B cells are immature (Imm)
follicular B cells or marginal zone (MZ) B cells.  Note the increased percentage of
IgMhighIgDlow B cells seen in the Tg+ mice (26.9%) compared to non-Tg littermate mice
(13%).  This difference is examined in the following section.
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expressing endogenous IgM and IgD genes in addition to the M167µ and k Tgs2.  These
results are one of the large differences between my study mice and their C57BL/6
M167µk Tg counterparts, which have little to no IgD expression on their B cells.
Increased Marginal Zone B cell population in M167µk Tg Mice
Upon examining IgM/IgD B220+ populations in Tg and non-Tg mice in Figure
12, we noticed a significantly enlarged IgMhighIgDlow population in the Tg mice.  In order
to further define which type of B cells were increased in the M167µk Tg mice, Tg and
non-Tg B cells were stained with CD21-FITC, B220-PerCP, and CD23-biotin/SAV-APC
and analyzed by flow cytometry.  As seen in Figure 13, the phenotypic CD21highCD23low
MZ B cells are significantly expanded in Tg spleens.  MZ B cells make up 15-25% of the
B220+ cells as compared to 5-10% of B220+ cells in non-Tg littermates.
The Ig BCR displayed on B cells plays an important role in determining the
phenotype a mature B cell will eventually adopt (such as a B1, MZ or FO phenotype).   It
has been demonstrated in some Ig transgenic mice that the specified VH/VL BCR
generated by the Tg dictates such a B cell phenotype (as discussed in
                                                 
2 If IgD is expressed on the B cell’s surface, then it is due to an endogenous
IgM/IgD allele being rearranged and expressed.  IgD is formed from alternate splicing of
a primary RNA transcript that includes the rearranged variable region VHDHJH and both
the IgM and IgD gene segments.
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in the introduction).  B cells utilizing the M167-idiotype B cell receptor in normal mice
and in M167µ only transgenic models are selected into the MZ B cell compartment
where they are more adept at responding rapidly to blood-borne T cell independent
particulate antigens (42).  I have shown here that the double transgenic C.M167µk Tg
(C.207-4) mice also have an increased IgMhigh, IgDlow, CD21high, CD23low MZ B cell
population compared to their non-Tg littermates, providing more confirmatory evidence
that M167-id drives development of the MZ phenotype.
Figure 13. Increased MZ B cell Population in C.M167µk Tg mice.  Flow cytometry
analysis of B220+ splenic cells show an increase in the CD21high CD23low MZ population
of M167µk Tg+ mice compared to non-Tg littermates.   Data are representative of five
mice in each group.
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High Surface Density of M167-id BCR Produces MZ B cell phenotype
Differences in surface density of Tg receptor on the surface of B cells were first
observed when examining VH1 heavy chain expression in splenic B cells (Figure 10).
Two distinct peaks were clearly seen in the M167µk Tg spleen cells that indicated the
presence of two populations of B cells with different levels of Tg VH1 expression:
low/intermediate VH1and high VH1.  To determine the phenotype of the VH1
high and
VH1
low B cells, spleen cells were stained with anti- CD21-FITC, VH1-PE, B220-PerCP,
and CD23-biotin/SAV-APC.  The FO (CD21low, CD23high), MZ (CD21high, CD23low), and
NF (CD21low, CD23 low, newly formed) B cells compartments were compared between
the VH1 low and high populations.  As shown in Figure 14, B cells with lower surface
levels of VH1 contain mostly FO and NF B cells, but lack the MZ cells.  Tg B cells with a
high density of VH1 surface expression contained the MZ B cells (14-17% VH1
high B cells
are MZ) and distinctly lack the NF population.  This evidence led me to conclude that a
high receptor density of VH1 Tg is driving B cells to develop into MZ B cells.
As demonstrated, the VH1
high population contains the CD21high, CD23low MZ B
cells.  The M167 VH1 is only one of the two Ig transgenes expressed in Tg B cells; the
M167 Vk24 Tg is also expressed.  The VH1 heavy chain pairs with Vk24 to make the
M167-id antibody.  However, endogenous heavy chains and possibly endogenous light
chains, are also present on the surface of B cells.  Also, the VH1 may be pairing with any
endogenously expressed light chains
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Figure 14. VH1 expression on M167µk Tg splenic B cells.  Tg+ spleen cells have two
distinct densities of VH1 Tg (low/intermediate vs. high) surface expression on their cell
surface.  Spleen cells were stained with CD21-FITC, VH1-PE, B220-PerCP, and CD23-
biotin/SAV-APC and their FO (CD21low, CD23high), MZ (CD21high, CD23low), NF
(CD21low, CD23 low) B cell compartments are shown.  The VH1high B cells contain the
MZ B cell population (shown in the 14% and 16.6% gates in the two bottom dot-plots.
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present, and therefore, not creating as high a density of M167-id BCR on the cell surface.
Because the density of M167-id receptors could be diluted by the presence endogenous
Ig, the levels of M167 idiotype expression on FO and MZ (CD21/CD23) B220+ splenic
B cells, as well as on the mature and immature/MZ (IgM/IgD), were examined.  In both
instances, B cells with M167-idhigh were found in the MZ compartments (Figure 15 and
Figure 16), supporting the hypothesis that M167high receptor density plays role in
selecting a MZ phenotype.  B cells with M167low receptor density were found in FO
compartment.
Tg MZ B cells have higher expression of M167 receptor than the Tg FO B cells
(Figure 15).  Although almost all of the B cells in the M167µκ Tg mice express the
M167 receptor, those with the highest densities of M167 adopt a marginal zone
phenotype rather than a follicular phenotype.  In non-Tg WT mice, the M167 positive B
cells are found strictly in the marginal zone B cell compartment.  These results agree with
the data published by Martin et al. (42) where M167 idiotype positive (Id+) B cells are
shown to localize in the MZ compartment of normal mice as well as in M167µ only Tg
mice.
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Figure 15. High surface expression of M167 BCR in Tg MZ B cells.  Marginal zone B
cells express higher levels of cell surface M167 BCR than follicular (FO) B cells in both
Tg and non-Tg mice. M167-id positive B cells in non-Tg WT mice are strictly found in
the MZ compartment, not in the FO B cell compartment.  Data are representative of five
mice in each group.
In Figure 16, the enlarged IgMhighIgDlow fraction, which includes both the
immature as well as MZ B cells, also contains the M167high B cells.  Taking the evidence
as a whole, I believe that Tg B cells with the higher cell surface densities of VH1 were
able to pair with Vk24 light chain to make higher levels of M167-idiotypic receptor, and
are directed by a receptor-mediated event to become marginal zone (MZ) B cells.
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Figure 16. B cells with high expression of M167 BCR are found in the IgMhigh/IgDlow
compartment of spleen in M167µk Tg mice.  A subgroup of IgMhigh/IgDlow B cells has
higher expression of M167-idiotype on their cell surface (dotted line, Mature B cells;
solid line, immature and marginal zone B cells). This population includes the MZ B cells
and supports the previous observation that the high VH1 receptor density on Tg+ B cells
results in the MZ phenotype.
Peritoneal B Cell Populations in C.M167µk Tg Mice
Peritoneal cells were analyzed to determine if the M167µk Tg caused any changes
to occur in the B cell repertoire, particularly in the B1 compartment.  Figure 17 shows
that Tg and non-Tg (WT) littermates did not have any significant differences in the size
of the various peritoneal B cell populations, except where the presence of the VH1 Tg was
concerned.  VH1 was expressed on 88% of Tg peritoneal B cells, whereas only 2% of the
non-Tg peritoneal B cells carried the VH1 heavy chain.  CD5+ IgM- T cells were similar
(13% and 12.2% of PEC lymphocytes in Tg and non-Tg, respectively.)
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Tg+    non-Tg   Tg+           non-Tg
Figure 17. Peritoneal B cells from C.M167µk Tg and non-Tg mice.  In our
conventional colony mice, Tg and non-Tg mice have the same size populations of B1 and
B2 cells in their peritoneal cavities.  B1 cell surface markers, CD5 and MAC-1, have
similar expression profiles on peritoneal B1 cells in both Tg+ and non-Tg littermates.
The two IgM/IgD fractions, B1 and B2 cells, are the same size in both Tg and non-Tg
mice.  The main difference between the peritoneal B cells is the expression of VH1. (SPF




• The BALB/c M167µk Tg mouse expresses the transgenic M167-id B cell
receptor on the cell surface of 97-99% of splenic, peritoneal and MLN B cells.
• Confirming the observations of Jim Kenny in C57BL/6 M167µk Tg mice, I
found a striking reduction in the peripheral B cell population in the BALB/c
M167µk Tg mice.
• M167µk Tg induces a shift in B cell population - the marginal zone (MZ) B
cell population in spleen is expanded in M167µk Tg mice (Figure 13).
• There is variation in surface density of Tg VH1 heavy chain on B cells
o Figure 10 shows two distinct population of VH1+ B cells
o VH1 low/intermediate and VH1 high (Figure 14) and M167-id (µ+k) B
cell receptor (Figure 15).
• Contrary to previous reports in the literature, IgD was found to be expressed
on >90% of peripheral IgM+ B cells in M167µk Tg mice (Figure 12).
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CHAPTER 4
Analysis of the Immunoglobulins Produced by PCTs from
C.M167µk Tg mice
One of the main characteristics shared by a PCT and its precursor B cell is the Ig
they produced.  This chapter examines the immunoglobulins produced in PCTs derived
from M167µk Tg mice in order to learn which type of B cells give rise to PCTs.
Analysis of the PCT immunoglobulins is divided into two sections: (I) secreted Ig
proteins and (II) expressed Ig gene sequences.
I.  Analysis of the Secreted Immunoglobulin Proteins
Electrophoretic Analysis of Secreted Ig Proteins from C.M167µk Tg PCTs
Do PCTs generated in M167µk Tg mice secrete large quantities of monoclonal
M167-IgM transgenic protein?  Plasma cell tumors, such as the original MOPC167 (IgA),
typically secrete a monoclonal “myeloma” protein.  One of the side effects of pristane
injection in mice is the generation of ascites fluid in the peritoneal cavity.  This fluid
contains the immunoglobulins secreted from the plasma cell tumors.  Electrophoresis of
ascites on polyacrylamide gels was done to determine whether a monoclonal M167
immunoglobulin protein was being secreted by plasma cell tumors generated in M167µk
Tg mice.
The Potter lab has observed for many years that the ascites from a primary PCT
may not have an unequivocal Ig band, but ascites from the transplanted tumor usually
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does.  Therefore, PCTs from M167µk Tg mice were transplanted into pristane-primed
WT BALB/c mice, although not all transplanted tumors successfully grew.  Ascites from
mice carrying first generation (g1) of transplanted Tg PCTs were compared to normal
ascites on Paragon serum protein electrophoresis (SPE) gels (top panel, Figure 18A.)  Tg
PCTs that did not grow in transplant are presented in the second panel of Figure 18B as
primary ascites (g0).  Ascites from WT PCTs (either primary and transplanted) are shown
in Figure 18C.
It appeared that the Tg PCTs were not secreting large quantities of M167µk Ig, as
an IgM monoclonal (M) component could not be identified in the SPE profiles of Tg
ascites.  If the Tg-derived PCTs were secreting a large amount of monoclonal transgenic
product, we would expect to see a large Ig band of M167 IgM transgenic product running
at or near the origin (center).   However, each of the Tg tumors had a unique Ig banding
profile.  The presence of the monoclonal (M) components of different mobilities indicates
that many PCTs were secreting Ig other than the one controlled by the transgene.  Many
of the M components had gamma (γ) mobility that suggested that the tumors were
producing M proteins from endogenous Ig genes.  It was not possible to distinguish





Figure 18. SPE gels of PCT ascites.  Serum protein electophoresis in a non-reducing
polyacrylamide gel.  (A) Tg g1, (B) Tg g0, and (C) WT g1 and g0 ascites.  Ascites (1 µl)
from M167µκ Tg and non-Tg WT primary (g0) and transplanted (g1) PCTs were run
beside normal ascites from a pristane mouse with no PCT.  Black dots (•) indicate Ig
proteins bands detected in some of the PCTs.  The anode (+) is at the top and the cathode
(–) is at the bottom of the gel.  Ascites was loaded at the center (origin, indicated by
arrows).
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Of those PCTs analyzed by SPE, 18 Tg and 3 WT PCTs had detectable
monoclonal Ig bands located below the origin, as indicated by black dots in Figure 18.
Eight Tg PCTs appeared to have monoclonal bands at or near the origin that could be the
IgM transgenic product (49, 53, 61, 65, 70, 136, 153 and 157), also notated by black dots.
Only 6 of the PCTs induced in Tg mice (51, 56, 61, 70, 125, 153) and 2 of the PCTs from
the WT mice (40 and 109) produced very large amounts of monoclonal Ig protein.  Even
though the IgM, IgA, and IgG often have characteristic electrophoretic patterns, it was
not possible to determine isotype with the banding patterns produced here.3
Are the Ig proteins being secreted by M167µk PCTs from the M167 transgene or
from endogenous Ig?  The next step was to determine by an ELISA whether the tumors
were secreting PC-binding antibodies (reflecting antigen-specific stimulation of the Tg
anti-PC receptor on precursor B cells) and if those PC antibodies were using the
transgenic M167 idiotope.  Further, the Ig isotypes produced by the PCTs were examined
by an ELISA to determine whether the transgenic IgM isotype was present or if other
isotypes were being expressed.
                                                 
3 In the SPE gel shown in Figure 18, there is a strong albumin protein band at the top
(anode) and another distinct band at the origin, both of which can be seen in the normal
ascites control lanes.  IgM is known to run around the origin (at the center of gel where
ascites is loaded).  IgG runs toward the negative electrode (below the origin) and IgA
towards the positive (above the origin).
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Tg+ PCTs Secrete anti-PC, M167-id Antibodies
The primary question regarding the M167 Tg plasma cell tumors was whether
they secrete monoclonal anti-PC antibodies, and specifically, whether the PC-binding
antibodies have the M167 (µ+k) idiotype.   If precursor B cells were initially activated
through the transgenic B cell receptor (M167µk) by PC antigen, it could be expected that
the plasma cell tumors would produce monoclonal Ig of transgenic origin.
The Tg and non-Tg WT tumors were tested for PC-specific antibodies using
ELISA to screen ascites fluid.   PC antigen (PC-BSA) was used to capture anti-PC
antibodies from ascites on a 96-well plate, and an HRP-labeled secondary antibody
detected any mouse (H+L) immunoglobulin that could bind PC.  The ELISA results show
that every PCT derived from M167µk Tg mice secreted anti-PC antibodies (Figure 19).
Only one of the 12 non-Tg PCTs (#40WT) produced antibodies with specificity for PC
antigen.
Because the Tg-derived PCTs were secreting PC-specific antibodies, ascites from
these tumors were further screened for PC antibody containing the unique (idiotypic)
specificity of the M167 protein.  J. Kenny prepared such a M167 specific antiserum
(clone 28-6-20), which he kindly donated.  Once again using the PC-ELISA assay to
capture secreted PC-binding antibodies, the ascites was screened for M167-idiotopes
using the anti-M167-id antibody.  Figure 20 shows that the Tg tumors did indeed secrete
PC-binding M167-id antibodies, while the non-Tg (WT) tumors were negative for M167
idiotopes.  Although the Ig protein from #40WT PCT binds PC (Figure 19), this WT
tumor does not secrete an M167-id antibody.  (This tumor will be analyzed further in
later sections).
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Figure 19. M167µk Tg PCTs are secreting anti-PC antibodies.  Peritoneal ascites
fluid was analyzed by ELISA for presence of secreted anti-phosphorylcholine (PC)
antibodies.  ELISA plates were coated with PC-BSA antigen.  Anti-PC antibodies are
detected in ascites from all Tg+ PCTs (n=27), and in only one of the non-Tg (WT) PCTs
(n=12).  Positive and negative controls were ascites from M167 (IgA, anti-PC) and 4081
(IgG2b, unknown specificity), respectively.  OD reading reported at 1/400 dilution of
ascites.
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Figure 20. M167µk Tg PCTs are secreting M167-id Antibody.  Peritoneal ascites fluid
was analyzed by PC-ELISA for presence of secreted Tg M167-id antibody.  ELISA
plates were coated with PC-BSA antigen to capture PC-specific antibodies from ascites.
M167-idiotypic antibody is detected in ascites from Tg PCTs (n=27), but not in non-Tg
(WT) PCTs (n=12).  Positive and negative ELISA controls were the anti-PC binding
idiotypic antibodies, M167 and T15, respectively.  OD reading reported at 1/400 dilution
of ascites.
The 28-6-20 Ab was provided and used as an anti-idiotypic Ab for M167.
However, it is not truly an anti-idiotypic antibody as its specificity is for determinants
found on the Vk24 L chain.  This antibody can detect Vκ24 L chains in combination with
any type of heavy chain, including VH1 and non-VH1 heavy chains.  Evidence thus far
indicates that Vk24 is rarely found paired with other heavy chain genes and appears to be
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the unique light chain partner for VH1 in anti-PC antibodies. Therefore, for it serves our
purpose as a detector of M167 antibody.
Isotyping of Igs from M167µk PCTs: IgM, IgA, IgG ELISA
The isotypes produced by the Tg PCTs were initially examined to determine
whether the transgenic IgM isotype was being utilized.  The Tg PCTs were shown to
secrete M167-id PC-specific Ig, which should have an IgM constant region as dictated by
the transgenic construct.   Additionally, the presence of monoclonal bands with different
mobilities seen on the SPE gels indicated that the Tg PCTs were also secreting Igs other
than the one controlled by the transgene.
Using an ELISA, I screened ascites for the presence of IgM, IgA, and IgG
isotypes secreted from Tg PCTs.   Murine Ig proteins were captured on a 96-well plate
using a goat anti-mouse (H+L) antibody.  The individual isotypes present in ascites fluid
were identified with HRP-labeled anti-IgM, anti-IgA, and anti-IgG (a mix of anti-G1, -
G2a, -G2b, and -G3) antibodies.  All of the PCTs generated from Tg mice had IgM
antibodies present in their ascites (Table 6).  Secreted IgM antibodies were expected in
Tg PCTs because the transgene has an IgM isotype.  Significantly, most of the Tg
positive PCTs (90%) also secreted IgA antibodies in addition to the IgM antibodies.  The
remaining 10% secreted IgG in addition to the Tg IgM, but these two tumors were not
able to be further analyzed.  Unlike the IgM antibodies, the presence of secreted IgA (or
IgG) from the Tg PCTs was a surprise.  The presence of possible IgA Igs being secreted
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Isotyping of PCT Ascites (ELISA)
WT PCT IgM IgA IgG
5 – + –
13 – + –
35 – – –
40 + – –
50 – + –
99* – + –
109* – + +
129 – + +
139 – + –
152* – + +
160 – – +
TG PCT IgM IgA IgG
2 + + –
37 + + –
51 + + –
58 + + –
61 + – +
64 + + –
65 + + –
84* + + –
TG PCT IgM IgA IgG
90* + - +
111* + - +
112* + + –
114* + + –
123* + + –
125 + + –
136* + + –
143* + + –
149 + + –
150 + + –
151 + + –
153* + + –
156 + + –
157* + + –
159* + + –
164* + + –
608* + + –
618* + + –
632* + + –
T15-IgA - + -
4081-IgG2b - - +
Table 6. Isotyping (IgM, IgA, IgG) peritoneal ascites from PCTS of C.M167µk Tg and
non-Tg (WT) mice. The isotypes were determined using ELISA.  A positive (+) isotype was
designated if the OD was >0.2 at a 1:12,800 dilution.  A * denotes ascites from the primary
(g0) PCT; otherwise, the ascites tested was from a transplanted g1 PCT.
by the Tg tumors might mean either (1) the M167 IgM heavy chain transgene had switched
to IgA in these tumors or (2) that the tumors have rearranged an endogenous heavy chain
locus and are secreting separate species of isotype switched antibody.   However, the M167µ
Tg does not contain switch regions, so isotype switching of the transgene is unlikely to
explain the presence of IgA protein.
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Of the 11 non-Tg (WT) PCTs tested, one secreted an IgM protein (#40WT), eight
secreted IgA, and one secreted IgG (#160WT).  Three WT PCTs had both IgA and IgG
isotypes detectable in the ascites.  Tumor #35WT did not have a detectable Ig isotype of any
kind and, therefore, is probably a non-secreting PCT.  Further, all of Tg and WT tumors
secrete kappa light chains, and not lambda light chains (data not shown).  These isotyping
data were used for further sequencing analysis of Ig from the PCTs.
Immunohistochemistry:  Secreted M167, IgM, and IgA Proteins in Tg PCTs
Immunochemical staining of tissue sections was used to confirm that individual
tumor cells from Tg PCTs were secreting IgA as well as the Tg IgM isotype.  Serially cut
sections of mesentery oil granuloma from 5 of the transplanted g1 Tg PCTs were fixed and
stained with HRP-labeled anti-M167-id, anti-IgM, or anti-IgA antibodies.
Immunohistochemical staining of individual plasma cells in the Tg tumors confirmed the
presence of both IgA and IgM, as well as Tg M167-id antibodies.  Figure 21 shows staining
of a representative tumor, PCT #58Tg, where all tumor cells in the mesentery oil granuloma
tissue stain positive for IgM and IgA, as well as for the transgenic M167-idiotype (IgM+,
IgA+, and M167+).
Because it appears that Tg PCTs secrete both IgM and IgA antibodies, we wanted to
know if these antibodies were either (1) isotype-switched transgenic M167-id IgA or (2)
endogenous Ig genes being rearranged and secreted as IgA antibodies.  If the latter is true,
then are the endogenous Ig proteins contributing to the production of PC-specific antibodies?
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Figure 21. Immunohistochemical staining of PCT #58Tg in mesentery oil granuloma
tissue.  Plasmacytoma cells from PCT #58Tg have stained positive for the transgenic M167-
id and IgM proteins.  However, the same monoclonal tumor also stains positive for IgA
antibody, which indicates another species of antibody utilizing endogenous IgA.  Staining for
IgG1, IgG2a, and IgG2b was negative on PCT #58Tg cells (not shown).
IgM from Tg PCTs Binds PC Antigen, but IgA Does Not
A simple immunoprecipitation assay using g1 ascites from #37 Tg PCT (37g1) and
PC antigen (from LB4 bacterial cell wall) mixed in a capillary tube provided a visual
confirmation that #37 Tg PCT produces antibody proteins with a specificity for PC antigen
by the formation of an Ab/Ag precipitate.  The PC-reactive #37 Tg PCT has been previously
shown to secrete IgM and IgA isotypes (ELISA isotyping, Table 6) as well as the anti-PC
M167-id (ELISA, Figure 20).  However, we still didn’t know which of the antibody isotypes
(IgM, IgA, or both) produces the anti-PC reactivity.
An immunoelectrophoresis (IEP Paragon) gel was used to separate the Ig isotypes in
ascites and test the individual Ig proteins with an antigen of interest to see which of the
isotypes will react with the PC antigen.  The anti-PC monoclonal antibody, T15, has an IgA
isotype (anti-PC/IgA) that serves as a positive control for PC-specific IgA.  The IEP assay
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shown in Figure 22 demonstrates that the IgM antibody from #37 Tg PCT reacts to PC
antigens, but the IgA component does not.
The T15-IgA/PC precipitation arc shows where the IgA reaction would have taken
place had the IgA antibody in #37 Tg PCT contributed to PC specificity.  There is no
precipitation reaction between IgA and PC in the #37 Tg PCT ascites, as seen in theT15-IgA
control lane. This provides evidence that the IgA does not contribute to the anti-PC binding
Figure 22. Immunoelectrophoresis (IEP) of 37Tg167PCT precipitated with PC antigens.
Ascites from a M167µk Tg PCT (37g1) and PC-specific T15 (IgA) control both react to
various PC antigens: PC-BSA, PC-Hy (PC attached to hemocyanin protein), and PC-LB4
(PC antigen in bacterial cell wall of Lactobacillus). IgM protein runs at the origin, as seen in
37g1.  IgA runs toward the anode (above the origin), as seen in the IgA protein, T15.  The
IgM antibody from #37 Tg PCT binds PC, but there is no IgA in this tumor that reacts to PC.
If PC-reacting IgA antibodies were present, they would be detected at the same position as
the control T15-IgA.
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antibody repertoire produced in Tg PCTs.  Therefore, the IgA is probably not isotyped-
switched PC-binding M167 H chain.  (As demonstrated in a later section, RT-PCR testing of
Tg tumors for the presence of M167-IgA transcripts corroborates this result.)
Thus far, we can conclude that PCTs arising in M167µk Tg mice are secreting the
transgenic M167-IgM antibody, as shown by ELISA and immunohistochemical staining.
Further, the electrophoretic analysis showed that the tumors from Tg mice collectively
produced a variety of different M components (monoclonal Ig proteins).  These Igs were not
the products of the M167µκ transgene.  IEP analysis provided evidence that the secreted Tg
IgM is the only species of Ig present that binds PC antigen (Figure 22).
II. Analysis of Expressed Immunoglobulin Gene Sequences
M167-IgM and M167-kappa RNA Expression in PCTs
As shown in the previous section, the PC-binding M167-id antibody protein is
secreted into ascites by Tg tumors, but not by the non-Tg PCTs.  To confirm that the
plasmacytoma cells from Tg mice are expressing mRNA for both the transgenes, total RNA
from Tg and non-Tg WT PCT cells were screened for transcripts of transgenic M167 IgM
heavy and M167 kappa light chains.  Total RNA was extracted from tumor tissue and first
strand cDNA was generated from mRNA using oligo d(T) primers.  Tg-specific primers at
the 5’ end of the variable framework 1 region (VH or Vκ FW1) and a 3’ constant region
primer (positioned at the most 5’ end of the IgM or kappa Kc region) were used to amplify
the variable regions of the M167 Tg heavy and light chains by PCR (shown in Figure 23A).
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Figure 23. Tg mRNA transcripts from PCTs.  (A) Tg-specific primers in FW1 of the
variable region were paired with at the corresponding 3’ constant region primer to amplify
the VκJ and VHDJ variable regions of the M167 transgenes.  (B-C) RT-PCR products show
expression of Tg M167 light (B) and heavy (C) chain genes in a panel of Tg (+) and non-Tg
WT (-) PCTs.  Variable region RT-PCR products were sequenced to confirm expression of
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the transgenes. A 100 bp ladder was used as a size marker, the brightest band being 600 bp,
and the V region bands were ~400bp. Sequencing of the smaller, non-specific IgM heavy
chain band in 40WT (C: lane 6) shows that it is not M167-IgM, but VH6 (VH22.1)-dsp2.8-
Jk3 IgM.   Weak Vκ bands in #13WT and #40WT PCTs (B: lanes 4 and 6) were non-specific
products: Vκ19-15/Jκ2 (#40WT) and Vκ19-15/Jκ1 (#13WT).  One of the Tg PCTs (#54Tg,
lane 11) does not express the Tg M167 Vκ24 light chain, but does express the M167 V1-IgM
heavy chain.
Figure 23(B-C) shows a panel of PCT tumors that were screened by RT-PCR for the
presence of Tg M167 kappa and M167 IgM transcripts.  PCTs generated from Tg mice all
contained RNA transcripts of both the M167 light and heavy chain transgenes.  The one
exception was #54Tg PCT, which only contained the mRNA transcript for M167 IgM heavy
chain, but was not positive for the M167 Vκ24 light chain transgene mRNA. (Figure 23, B
and C, lane 11).  Supporting these data, ascites from #54Tg PCT tested by ELISA does not
contain the M167-id antibody (data not shown), which is consistent with the lack of RNA
expression of Vκ24 to pair with the expressed M167µ VH1 transgene.  PCTs from non-Tg
WT littermates did not contain M167 heavy or light chain mRNA.  All of the variable region
RT-PCR products were sequenced to confirm they were actually the M167µκ transgene
sequences.  Strict precautions were taken to control for PCR cross-contamination between
samples.  Samples were independently prepared and separate benchtop areas, pipettes, and
disposables were used for each of the nucleic acid isolation, amplification, and sequencing
steps. Importantly, nucleic acid was prepared and sequenced from multiple samples of frozen
tumor to confirm accuracy of the Ig sequences.
Two non-Tg PCTs (#13WT and #40WT) had very weak, non-Vκ24 products that
when sequenced were actually unique gene products from the Vκ19 family (closest
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homology to gene Vκ19-15), not the M167 Vκ24 transgene.  There is an IgM RT-PCR
product in #40WT PCT that is smaller than the transgene VH-IgM product, and sequencing
showed that it is not the M167µ transgene.   The IgM in #40WT PCT uses the VH6(VH22.1)
gene combined with DJ genes dsp2.8 and JH3.
Tg PCTs do not have Isotype-Switched M167 VH-IgA mRNA Transcripts
Serum analysis showed that the Tg tumors were also secreting IgA antibodies in
addition to IgM.  To find out if the M167µ heavy chain transgene was able to switch to IgA, I
screened mRNA from Tg PCTs for M167VH-IgA transcription products.  Tg mRNA was
tested by RT-PCR using the 5’ Tg-specific M167 VH FW1 primer paired with a 3’ IgA
constant region primer.  No transgenic M167 heavy chain IgA transcripts were detected by
RT-PCR (Figure 24) in any of the Tg PCTs, but the control cDNA from the original
M167(IgA) tumor was successfully amplified.  Further, ELISA could not detect M167-id IgA
antibodies in the ascites of these Tg PCTs (data not shown).  Therefore, the IgA antibodies
detected by ELISA isotyping are not a result of M167Tg-switched antibodies. The lack of
M167-IgA transcripts is further evidence of the inability of M167-IgM transgene to isotype
switch from its location on chromosome 2/3 with endogenous IgA locus on chromosome 12.
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Figure 24. PCR of M167-IgA transcripts.  RT-PCR using 3’ M167-specific framework
(FWR1) and 5’ IgA constant primers were run on an agarose gel to see if any isotype
switched M167-IgA transcripts were being produced by the Tg PCTs.  Lanes 1-14 are Tg
PCT cDNA (37,2,61,112,123,154,162,27,64,65,153,62,160, 5), 15 is M167-IgA cDNA, and
16 is H20.  The M167(IgA) positive control cDNA (lane 16) has a band at the appropriate
size (VHDJ ~400bp), but no M167-IgA transcripts were detected in the Tg PCTs tested.
A100 bp ladder size marker was used, the brightest band being 600 bp, and the M167VH-
IgA product size is ~400bp.
Sequencing of Coexpessed Endogenous lg Genes
If the IgA antibodies are not from isotype-switched M167Tg, their source must be
from endogenously rearranged IgH genes.  To determine whether there are species of
endogenous Ig heavy and light chain genes being rearranged and expressed in Tg PCTs, RT-
PCR was used to amplify the unknown IgA transcripts and any possible unknown IgM, IgG
or kappa transcripts.  In four independent reactions, four different degenerate VH primers
(named SG1, 2, 3, and 4; Huppi and Smith-Gill (52), see pg166 in M&M) were paired with
the 3’ primer of the heavy chain constant region (IgA, IgG, or IgM) to amplify unknown VH
regions from PCT mRNA.  Each of these degenerate (or mixed base) primers includes
multiple species of oligonucleotides that are homologous to the framework 1 (FW1) region
of VH genes within related families.  In this manner, one or more of the four 5’VH primers
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would amplify the unknown VH region expressed by a tumor.  Similarly, one 5’ Vκ
degenerate FW1 primer (5’ Mκ) paired with the 3’ kappa constant region primer (3’ Kc) was
comprehensive enough to amplify the Vκ region of all PCTs screened.
RT-PCR routinely produced a single distinct DNA band for Vκ products, and
sequencing of these bands always gave specific unique kappa sequences.  For the VH
products, occasionally non-specific banding products were present.  For each tumor, the
correct size VH band (~400bp) was excised from an agarose gel and purified before
sequencing.  Independent preparations of RNA were made from multiple tissue samples of
the same tumor to confirm Ig sequencing results and to prevent PCR cross-contamination of
samples.  Several independent RT-PCR reactions were performed at different times on each
RNA prep.  Sequencing was routinely repeated at least twice on each RT-PCR reaction with
forward and reverse primers in order to ensure accuracy of base calls during sequencing.
Identification of VH and Vκ family genes was done using a blast search of the NCBI
database of germline Ig mouse genes.   The D and J genes were identified by greatest
homology to germline genes reported in the NCBI IgBLAST database.
All the transgenic PCTs co-expressed endogenous heavy and light chain mRNA
(Table 7) in addition to the transgenic M167 IgM and M167 Vκ mRNAs.  PCTs from non-
Tg littermates were also sequenced and are reported in Table 8.
Table 7. M167µk Tg PCT: endogenous Ig sequences (n=24).  Endogenously expressed Vk
and VH Ig genes from PCTs generated in BALB/cAnPt M167µk Tg. VH families are
classified on the basis of homology to reported germline genes as reported in the NCBI
IgBLAST.  Vk families classified on basis of homologous germline gene segments as
reported by Thiebe et al. (60).  ND= not determined.
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M167µk Tg PCT: endogenous Ig sequences (n=24).












































































































































Table 8. M167µk non-Tg PCT: endogenous Ig sequences (n=10).  Endogenously
expressed Vk and VH Ig genes from PCTs generated in BALB/c M167µk non-Tg (WT). VH
families are classified on the basis of homology to reported germline genes as reported in the
NCBI IgBLAST.  Vk families are classified on basis of homologous germline gene segments
as reported by Thiebe et al. (60). ND= not determined.
WT PCT
(non-Tg)



























































Analysis of the endogenous VH sequences shows that the endogenous antibodies
found in Tg PCTs do not use the V1 (S107/VH7) family genes known to form PC-binding
antibodies (61).  The exception is  #114Tg PCT, which expresses an IgA heavy chain using
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an endogenous V1 allele recombined with DH and JH genes (V1/DFL16.2/JH4-IgA).  This
VDJ gene rearrangement is different from the M167µ transgene (V1/DFL16.1/JH1).
Further, only three kappa light chains that pair with the V1 gene to form PC-binding
antibodies: Vκ8, Vκ22, Vκ24.  Further, Segal, et al. studied the antigenic binding site of the
PC-binding myeloma M603, and reported that residue 96 (leucine) in the kappa light chain
makes contact with the PC hapten (62).  Jk5 is the only J region coding for a leucine at this
position (49).  All the Vk genes expressed in PC-binding myelomas and hybridomas have
included the Jk5 gene segment (63).  Only two of the Tg PCTs, #2Tg and #135Tg, utilize one
of these three kappa genes and neither of these PCTs rearranged an endogenous V1 heavy
chain gene. PCT #2Tg expresses a Vk8/Jk1 gene and #135Tg expresses a germline
(unmutated) Vk24/Jk5 that was similar, but not identical, to the M167 Vk transgene.   The
endogenous kappa genes may be able to bind to the Tg V1 heavy chain to form a PC
antibody.  Finally, the PCT with an endogenous V1 heavy chain gene, #114Tg PCT,
expresses an endogenous Vk21/Jk1 gene, which is not one of the three kappa genes involved
in PC-binding antibodies.  However, it is possible that the endogenous V1 gene expressed in
the #114Tg PCT could pair with the Tg Vk24 gene to form a PC-binding antibody.
Because the majority of Tg PCTs are expressing endogenous VH genes that are not
from the V1 family, they are unlikely to be contributing to the Tg tumors’ specificity for PC
antigen.  This supports the evidence that the endogenous IgA antibodies are not contributing
to the PC reactive antibodies secreted by Tg PCTs (as shown by IEP analysis, Figure 22).  In
all probability, the endogenously rearranged VH and Vk genes form antibodies that are
specific for an antigen other than PC.  In conclusion, the Tg PCTs are co-expressing
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endogenous H and L chain genes, however, the PC-specificity of the Tg PCTs appear to be
due solely to the M167µk transgenes.
Analysis of VH Family Usage in Endogenous Igs of M167µκ Tg PCTs
The endogenous heavy chains expressed in Tg and non-Tg primarily used variable
region genes from the most commonly utilized VH families, VHJ558 (63%) and VH36-60
(13%) as shown in Table 9.  The presence of the M167µk Tg does not appear to dramatically
skew the choice of VH genes found in Tg PCTs, as the non-Tg WT PCTs utilize a similar
pattern of VH family
Table 9. VH Family Usage in C.M167µk Tg and non-Tg PCTs.  VH families are classified
on the basis of homology to germline genes as reported in the NCBI IgBLAST. C.B20
tumors analyzed were included as a control, and are reported later in the chapter.  The most
frequently utilized VH family from each of the three groups of PCTs in VH1/J558.  The J558
VH family is the dominant group of V genes used in the Igs of the normal B cell repertoire in
mice.
VH family Tg Non-Tg C.B20
VH1/J558 15/24 63% 3/10 30% 6/9 67%
VH2/Q52 1/10 10% 1/9 11%
VH3/36-60 3/24 13% 1/10 10% 2/9 22%
VH5/7183 2/24 8%
VH6/J606 1/24 4% 3/10 30%
VH7/S107 1/24 4%




genes.  Although the M167µk Tg PCTs show a heavier usage of J558 family VH genes
(63%) than PCTs from non-Tg littermates (30%), a separate analysis of VH genes used in
PCTs from C.B20 mice show an identical usage (67%) of J558VH as the Tg mice.  A more
accurate analysis of VH gene usage would include higher numbers of sequenced
immunoglobulins from PCTs in each of the BALB/c WT and C.B20 control groups.
Tg M167µk RNA Remains Unmutated
In an attempt to learn something of the natural history of the tumors and their
precursor B cells, we asked whether the M167-IgM transgene had undergone somatic
hypermutation, a hallmark of germinal center activity within lymphoid tissues, in any of the
tumors.  As previously described, M167µ and k mRNA transcripts were detected by RT-PCR
from total RNA preps of PCT tumor cells. Sequence analysis of the M167 mRNA transcripts
revealed no evidence of somatic hypermutation in µ or k copies of the transgene in any of the
PCTs from Tg mice (data not shown).
Published data suggest that potential SHM mechanism is somehow confined to the λ,
H, and k chain gene complexes (chromosomes 6, 12, and 16) and is not global in the nucleus.
Transcription of the M167µk Tg from chromosome 2/3 may be excluded from the SHM
mechanism.  Examples of PCTs with endogenous H and L chain genes that are highly
mutated will be discussed later, whereas no mutations were found when sequencing Tg
mRNA transcripts from any of the tumors.  However, if somatic hypermutation did occur in
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one or more copies of the M167 transgenes, it is likely not detectable among the mRNA
transcripts produced from the multiple copies of heavy and light chain Tgs inserted in the
genome.   Other possibilities will be addressed in the discussion section.  Therefore, to
examine the mutational status of the PCT immunoglobulins generated in this study, the
endogenous Ig genes were sequenced and studied rather than the M167µk transgenic Ig
genes.
Analysis of SHM in Endogenous Ig Genes
Accumulation of mutations in Ig genes is a generally accepted indication that
activated B cells have been exposed to somatic hypermutation (SHM) processes in germinal
centers of lymphoid tissues.  Pre- and post-germinal center B cells can be distinguished
through lack of or presence of mutations in the V genes.  A clustering of mutations in and
around an Ig’s hypervariable CDR regions suggests that antigen played a role in B cell
selection. The mutational status of the Ig V gene in numerous B cell cancers, such as multiple
myeloma (MM), follicular lymphoma (FL), and B cell chronic lymphocytic leukemia (B-
CLL), is being recognized as an important factor in the clinical severity of the disease and
has a significant impact on patient survival (64).  In sequence studies of VH genes in human
multiple myeloma, a pattern of extensive hypermutation is seen in neoplastic plasma cells
(65).  These findings suggest that the malignant plasma cell in humans arises from an
antigen-selected B cell at a mature, post-germinal stage of B-cell development.
One factor considered critical in plasmacytoma development is the role of antigen in
selecting precursor B cells, and therefore, I was interested in studying the Ig genes produced
in the PCTs to see if there were variations from germline genes, particularly mutations
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concentrated in the CDR hypervariable regions.  Is there a difference in Ig mutational status
between M167µk Tg and non-Tg PCT groups?  With more complete databases of the murine
genome now available from the NCBI GenBank and Celera, it becomes easier to compare Ig
sequences from murine PCTs to germline genes.
NCBI has a collection of murine germline V genes that includes functional V genes
and V genes with Open Reading Frame (ORF) for the heavy chain and the kappa and lambda
light chains.   Only one gene sequence is included for each V, D or J gene and, therefore,
does not include polymorphism information.  IgBLAST uses the collected germline genes to
report the top three V, two D and J genes for a query sequence.  Ig sequences from PCTs
were searched against the Genbank Ig sequences database for information regarding germline
gene polymorphisms and to other rearranged Ig sequences seeking to find the best homology.
Gene searches resulted in homologous sequence information, but Celera’s murine
genomic database has not been fully annotated.  Polymorphism data was also not available.
The kappa V genes reported by Thiebe et al. (60)  in the NCBI IgBLAST germline database
found perfect matches in the Celera genomic database.  Germline information on the VH
genes was not as consistent between the two databases as it was with the Vκ genes.   This
may have to do with the lack of a fully annotated VH locus.  Information on germline VH
genes was collectively considered from both the Celera and the NCBI databases for each Ig
heavy chain sequence to determine the mutational status of a PCT Ig gene.
I sequenced endogenously rearranged heavy (VDJ) and light (VJ) chain variable
regions from Tg M167µk plasma cell tumors.  In order to compare V regions used in PCTs
from M167µk Tg mice to those from normal BALB/c mice, I also sequenced and analyzed
variable regions from PCTs generated in the non-Tg BALB/c littermates and C.B20 mice.
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Vκ and VH Ig genes from nine PCTs generated in C.B20 mice were sequenced (Table 10) in
order to utilize the C57BL/6 IgH locus that is found in these genetically susceptible BALB/c
congenics for germline gene comparisons in the available databases.  Concern about
polymorphic differences between mouse strains that would hinder analysis of somatic
mutation levels in the Ig genes prompted the inclusion of C.B20 tumors in SHM analysis.
Most of the IgH sequences reported in the NCBI database were from other strains of mice
than BALB/c, and were predominantly of C57BL/6 origin.  A fairly comprehensive (but not
Table 10. CB20 PCT Ig sequences.  Sequencing of endogenously expressed Vk and VH Ig
genes from nine tumors induced in C.B20 mice were done in order to utilize the C57BL/6
IgH locus in a genetically susceptible BALB/c congenics.  VH families are classified on the
basis of homology to germline genes as reported in the NCBI IgBLAST.  Vk families are
classified on the basis of homologous germline gene segments as reported by Thiebe et al
(60).















































quite complete) set of germline genes from the largest VH family, J558 VH1, were sequenced
from BALB/c mice by Brodeur (66) and added to NCBI Ig Sequence database in 2001.
The C.M167µk Tg and non-Tg (WT) tumors all utilized endogenously rearranged
kappa light chains.  In the Tg PCTs, the endogenous kappa genes were different from the
M167 Vk24 transgene.   Both Tg and WT PCTs primarily had isotype-switched IgA heavy
chains, as shown previously by ELISA isotyping in Table 6.  As described earlier, 5’
degenerate VH region primers for the FRW1 region were paired with primers in the IgA or 5’
degenerate Vk region primers with a kappa 3’ constant region primer to amplify VH and Vk
from tumor cDNA.
I observed that a small percentage of tumors in all three groups, C.M167µκ Tg, non-Tg
(WT), and C.B20 PCTs, contained germline Vk and VH genes, while the majority had
mutated Vk and VH genes (Table 11).  Vk germline genes were observed in 46% (11/24) of
M167µk Tg PCTs, 30% (3/10) of WT littermates PCTs, and 33% (3/9) of C.B20 PCTs.
Heavy chain V genes in the PCTs were compared to both Genbank and then Celera databases
to identify germline genes with the best homology.  In most cases, the best VH gene
homology could be found in the Celera database, although many of the sequences were
located on unannotated scaffolds.
Table 11. Germline vs. Somatic Hypermutated Ig genes in PCTs.  Germline (GL) or
somatically hypermutated (SHM) immunoglobulin genes are identified in pristane-induced
plasmacytomas from 3 groups of BALB/c mice. PCTs are considered germline tumors if both
(VH+VL) Ig genes are rated GL.  The numbers/ percentages of tumors that contained GL VL
genes and those that contained GL VH are also notated.
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VJk      VDJH
2 SHM SHM 5 SHM SHM 2 SHM SHM
37 SHM SHM 13 GL GL 5 SHM SHM
44 GL SHM 35 SHM SHM 6 GL GL
51 SHM SHM 40 GL GL 19 GL SHM
53 GL SHM 50 SHM SHM 23 GL GL
54 GL SHM 109 GL SHM 24 SHM SHM
58 GL GL 129 nd SHM 26 SHM SHM
61 GL GL 152 SHM SHM 27 SHM SHM
62 SHM SHM 154 SHM SHM 35 SHM SHM















VH+VL: SHM 19/24 79% SHM 8/10 80% SHM 7/9 78%
VH+VL: GL           5/24        21%                       GL          2/10        20%                       GL          2/9          22%
GL VH: 6/24 25% GL 2/10 20% GL 2/9 22%
GL VL: 11/24 46% GL 3/10 30% GL 3/9 33%
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One important consideration is that the Celera murine database is not the BALB/c
genome, and therefore, some nucleotide differences are likely to be due to polymorphisms.
VH germline genes were observed in 25% (6/24) of M167µk Tg PCTs, 20% (2/10) of WT
littermates PCTs, and 22% (2/9) of C.B20 PCTs.
Ig genes in PCTs were considered to be germline (GL) if both of the Vk and VH genes
had no mutations. In each of the three PCT groups (Tg, non-Tg WT, and C.B20), ~20% of
the tumors turned out to be germline (Table 11).  Five clear cases of germline sequences
were seen: M167µκ Tg PCTs:  58Tg, 61Tg, 64Tg, 157Tg and 162Tg.   Two of the non-Tg
WT PCTs had germline Igs: 13WT and 40 WT.  C.B20 PCTs also had two examples of
germline tumors: 6CB20 and 23CB20.  The remaining 80% of PCTs had somatically
hypermutated Ig genes and, according to the commonly accepted concepts about SHM of B
cell Igs, must have undergone TD processing in germinal centers.  Mutated VH and Vk genes
of Ig proteins were observed in all 3 groups:  19/24 (79%) M167µkTg, 8/10 (80%) non-Tg,
and 7/9 (78%) CB20.  Interestingly, SHM of Ig genes in PCTs was frequently found in VH
chains only, and not the VL chain.   However, there was only one case where SHM was found
solely in the VL chain and not the VH chain.   Why the Ig heavy chain would be the primary
target for SHM, and not the light chain, is not known.
The #114Tg PCT expresses an endogenous Ig-A gene from the anti-PC forming
VH7/S107 family and is 98% homologous to the V1 germline gene.  Three nucleotide
mutations are found within CDR1 and CDR2 of the VH region of #114Tg, each causing an
amino acid change. There are no mutations in the DHFL16.1 or JH4 regions of #114Tg.
Numerous SHM antibodies are reported in the NCBI GenBank that also have a 98%
homology to the VH region of the #114Tg IgA heavy chain, all of which are anti-PC and/or
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anti-DNA antibodies shown to be produced from as little as a single mutation to change the
anti-PC V1 heavy chain into a DNA binding antibody (67, 68 170:5095).  The endogenous
Vk gene is Vk21 (21-7)/Jk2, which has no known usage in anti-PC antibodies.
   SHM Analysis of FRW & CDR From Endogenous IgH Chain Genes
SHM introduces point mutations, and more rarely deletions and insertions, into the V
region of the Ig gene.  In GCs or in extrafollicular sites, antigen-driven mutation occurs
during the rapid division in the centroblast stage of plasma cell differentiation at particularly
high rates,  ~ 1 x 10–3 bp per cell division (69), the rate of mutation being a function of
transcription efficiency.  Mutations occur at random throughout the V region, but when
amino acid substitutions occur, antigen specificity can be increased or decreased depending
on how the antigen-binding site of the Ig is affected.  The hypervariable complimentary
determining regions (CDRs) of the Ig gene have the greatest affect on an Ig’s ability to bind
antigen, and therefore, amino acid substitutions tend to cluster in and around the CDRs if
antigen selection is occurring through the affinity maturation process.  The heavy chain and
light chain each have 3 such regions (CDR1, CDR2, and CDR3).  CDR3 includes the joining
(J) gene in light chains and the diversity and joining (DJ) genes in heavy chains.
Figure 25 provides a closer look at the locations of SHM point mutations in the Ig
VH regions and whether amino acid changes occurred in PCTs from M167µk Tg and non-Tg
WT mice.  Each red “i” along a gene indicates a mutation resulting in an amino acid
substitution, whereas the blue “I” indicates a silent mutation.  Most of the mutations
occurring throughout the VH sequences resulted in an amino acid change, and many of the
Igs show a clear clustering of mutations around the CDRs.  Some clear examples of this
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include 2, 44, 62, 149, 114, and 26697 in M167µk Tg PCTs and 5, 35, 152, and 160 in non-
Tg (WT) PCTs.  Because clustering of mutations is seen around the CDRs, antigen-driven
selection does appear to play a role in the mutation of the Ig genes in plasma cell tumors.
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Figure 25. Somatic hypermutation in endogenous Ig heavy chain genes rearranged in
PCTs from BALB/c M167µκ Tg and non-Tg (WT) mice.  The 18 M167µk Tg PCTs and 8
non-Tg PCTs with somatic hypermutation are marked showing their mutation sites. The
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framework regions (FWR 1, 2, 3) are shown in yellow, while the three hypervariable
complimentary determining regions (CDR 1, 2, 3) are shown in color and the location of
each nucleotide mutation is marked.  Grouping of nucleic/amino acid changes that occur in
the hypervariable CDRs are a sign of antigen-driven mutation. The red (i) denotes a
nucleotide mutation that resulted in an amino acid change; the blue (I) marks a silent
nucleotide mutation.
Analysis of CDR3 Regions
The CDR3 region of the VH gene plays a large role in the antigen binding region of
the Ig protein and can reflect large differences in size as well as the amino acid composition
among antibodies.  Table 12 shows the VH CDR3 regions of the Igs from PCTs of all three
groups of BALB/c mice: M167µk Tg, non-Tg WT littermates, and C.B20 mice.  In order to
prevent bias in length measurements, CDR3 lengths started at the first residue following the
invariant cysteine (C), which is coded by the VH gene, to the last residue before the invariant
tryptophan (W) that is common to all 4 JH segments.  CDR3 nucleotides are grouped into
their gene segments (VH FRW3, DH, and JH), allowing identification of the intervening N
nucleotides that could not be attributed to the V, D, or J gene segments.
Table 12. CDR3 regions of Igs from M167µk Tg, non-Tg and C.B20 PCTs.  To prevent
bias in length measurements, CDR3 lengths started at the first residue following the invariant
cysteine (underlined, black) coded by the VH gene to the last residue before the invariant
tryptophan that is common to all 4 JH segments.  This means of calculation is based on that
reported by Klonowski (70).  A minimum of 4 homologous and contiguous nucleotides was
required to assign a germline D segment.
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The amino acid lengths of the CDR3 regions vary greatly in the Igs secreted by PCTs
from M167µk Tg and non-Tg mice, ranging from 6 –20 amino acids (aa) (Table 12).
Interestingly, the C.B20 PCTs had a smaller range of from 10 – 16 aa.  However, the overall
mean length does not differ between groups derived from the M167µκ transgenic mice and
the WT control groups.  Also of note, N additions are found between the junctions of the
VDJ genes in most of the CDR3 regions in all three groups of PCTs.  During neonatal
development, N-region diversification of the H chain (71) appears to play little role in the
generation of antibodies and are rarely found in natural IgM antibodies.  Later in B cell
development, the presence of terminal deoxynuceotidyl (Tdt) helps to create antibody
diversity by the addition of N nucleotides in the CDR3 during Ig rearrangements (72).
New studies in mice show that in addition to recruitment from a more restricted
repertoire of naïve B cells, a portion of MZ B cells are selected from the pool of recirculating
and memory B cells that have undergone antigen affinity maturation in GCs (14).  The
hypermutated MZ B cells that are responsive to TI-2 antigens adopt the MZ B cell
phenotype. Recruitment of memory B cells into the MZ would have the benefit of expanding
the B cell repertoire against a wider range of TI bacterial polysaccharide antigens, as these
cells would have developed in the presence of Tdt that generates Ig heavy chain diversity in
the V-region during rearrangement.  Interestingly, the only tumor that did not include N
additions was #40 from a non-Tg WT PCT and was the only IgM-secreting tumor.
The fact that most of the Ig genes from the three groups of BALB/c PCTs, including
the Tg tumors, have N additions and are somatically hypermutated seem to point away from
the natural antibody-producing B cells produced early in ontogeny as precursors of pristane-
induced PCTs in mice, and toward an Ag-selected B cell population.  This Ag-driven B cell
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precursors of PCTs may potentially be from the MZ (or B1) B cell subset.   It is still unclear
how to differentiate from which B cell subset a PCT originated.
I conclude that murine plasmacytoma development involves post-antigen selected B
cells, where 80% of Igs are somatically hypermutated in both M167µk Tg and non-Tg mice.
In most cases, the point mutations cause amino acid changes around the hypervariable CDR
regions, a further indication of antigen selection.  The 20% of PCTs from M167µk Tg and
non-Tg mice with germline VH/Vk genes might be generated either from early GC reactions,
where little to no SHM is seen, or from the natural antibody producing B cells from the B1 or
MZ subsets.  Clear examples of both endogenously rearranged germline and somatically
hypermutated Ig proteins are seen in all three BALB/c congenic groups of PCTs (M167µkTg
BALB/C, non-Tg WT BALB/c, and C.B20 mice).  The M167µkTg does not appear to
influence the occurrence of hypermutation occurring in these PCTs, as the distribution of
germline and mutated Ig genes PCTs (20% GL and 80% SHM) is the same as in non-Tg
BALB/c and C.B20 derived-PCTs.
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Chapter 4 Conclusions:
• Both M167µk Tg and endogenous Ig proteins are expressed in the PCTs
generated from C.M167µk Tg mice.
• Surprisingly, a large monoclonal (M) component of the M167µk protein was
not found in Tg PCTs.
• The M167µk protein was not clearly demonstrable by electrophoresis (Figure
18), but was specifically detected by ELISA (Figure 20).
• The presence of the monoclonal (M) components of varying mobilities on the
SPE gels indicated that many PCTs were secreting Igs electrophoretically
different than the ones controlled by the transgenes.
• The predominant electrophoretic M components in sera from M167µk Tg
PCTs were in fact Ig derived from endogenously rearranged genes.
• The majority of M component generated by endogenously rearranged
immunoglobulin genes (demonstrated by ELISA) was IgA (Table 6).
• Immunohistochemical staining of tumor cells from #58 Tg PCT gave a clear
example of a Tg PCT that produces intracellular Ig not only with the Tg
M167-id, but expresses both IgM (Tg) and IgA (endogenous) antibodies
(Figure 21).
• Immunoelectrophoresis (IEP) on tumor sera (Figure 22) provided evidence
that the endogenous IgA antibodies are not specific for PC antigen.
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Nucleic acid studies
• Confirmed mRNA expression of both the M167µ and M167k transgenes in
PCTs derived from M167µk Tg mice
• M167µ and k Tg transcripts showed no evidence of somatic hypermutation.
• Confirmed mRNA expression of endogenous Ig genes in PCTs derived from
M167µk Tg mice
• VH family usage in endogenous Igs expressed in Tg PCTs is not related to
VH genes used in PC-binding antibodies.
• Endogenously rearranged Ig genes in PCTs from C.M167µk Tg mice are
isotype switched to IgA.
• Of the PCTs from M167µk Tg mice, 80% have somatically hypermutated
endogenous Ig, while the other 20% express unmutated germline gene VH/Vk
regions.
• The IgH CDR3 lengths varied greatly among the M167µκ Tg PCTs, from 6 –
17 aa, with a mean of 11.6 ± 0.7 aa.  All contained N additions of varying
lengths.
• The control group of PCTs derived from non-Tg littermates also showed an
80% to 20% ratio of somatic hypermutation to germline gene usage in the
VH/Vk regions of pristane induced tumors.
• Another control study on PCTs derived from C.B20 mice, BALB/c mice that
have a C57BL/6 Ig heavy chain locus, also had 80% hypermutated to 20%
germline VH/Vk regions.
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• Therefore, I conclude that the presence of M167µk Tg does not influence the
somatic hypermutation status of the endogenously rearranged Ig genes, but is
refractory to SHM itself.
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CHAPTER 5
Functional Properties of The M167µk Tg BCR
Increased plasma cell tumor incidence in M167µk Tg mice suggested that the Tg
PC-specific B cell receptor (and other such BCRs with critical Ag specificities in normal
mice) plays an important role in inducing and accelerating plasma cell tumor
development in the pristane plasmacytoma model.  Accumulation of oncogenic mutations
is potentially greater in B cells that (1) are able to survive longer and (2) are actively
dividing.  Naïve B cell populations are kept alive through ligand-independent activation
(tonic signaling) of their BCRs (73, 74).  The increased number of B cells capable of
responding to a plentiful supply of environmentally available PC antigens could be an
important factor in the increased incidence of plasma cell tumors in C.M167µk Tg mice.
If PC antigen is a major source of B cell activation in the M167µk Tg pristane-induction
model of plasma cell tumor development, the M167µk BCR must be functionally able to
respond to PC stimuli.  A functional PC-specific BCR would bind PC antigen on a
macromolecule and activate a signal transduction pathway that maintains B cell viability,
triggers proliferation, stimulates anti-PC antibody secretion in response to autologous and
exogenous PC antigens, and triggers differentiation of B-lymphocytes into Ig secreting
plasma cells.
What are the sources of PC antigen in the mouse?  Storb et al. (47) proposed that
environmental antigen is responsible for M167µk Tg B cell activation and the secretion
of naturally high levels of Tg antibody in the serum.  In support of this hypothesis, Kenny
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et al. used M167µ-only and M167k-only Tg mice to provide evidence that M167 (H+L)
Tg B cells are selected and expanded in vivo through encounter with antigen – either
autologous or environmental PC – through the Tg antigen-specific receptor (49).
The PC haptenic group is found on commensal bacteria that colonize the mouse
intestinal tract.  PC is also found on apoptotic host cells and on oxidized lipoproteins (37,
75, 76) produced under conditions of oxidative stress (such as the chronic inflammation
existing in the pristane treated mouse.)  These sources of PC antigen have recently been
shown to bind certain anti-PC antibodies (T15, M167, M603, and others) in vivo (37).
Therefore, PC is an important environmental- and self-antigen.  Two sources of PC
antigen that could stimulate B cells and drive PCT development in the pristane induction
model are 1) the pristane produced oil granuloma inflammatory tissue, which is known to
contain apoptotic cells and to increase oxidation through phagocytosis (77) and 2) normal
gut flora.
I. Immunization Studies
One test for functionality of the M167µk Tg BCR on B cells of C.M167µk Tg
mice would be PC-specific antibody secretion in response to PC antigens.  In vivo
immunization with different kinds of PC antigenic macromolecules (such as break-down
products of cell membranes, PC-conjugated foreign proteins and polysaccharides, or PC-
containing whole bacteria) and monitoring primary and secondary antibody levels would
show whether M167µk Tg B cells are capable of responding to PC antigen.
Previous immunization studies with T-cell dependent PC-KLH (48) provided
evidence that the M167µk Tg B cells are able to produce a strong immune response to PC
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antigen after a secondary antigen boost, as determined by detecting secreted Tg+ IgM
PC-antibodies.  These immunization studies indicate that the Tg M167µk BCR is
functional in C57/B6 mice.  I have extended these PC immunization studies to include
the conventionally raised BALB/c M167µk Tg mice used in the pristane model system in
order to show that M167µk Tg B cells can be stimulated by PC-specific antigen to 1)
secrete PC-specific antibodies and 2) to proliferate.  In vivo immunizations were carried
out using various PC antigens and serum anti-PC antibody was measured to monitor
immune responses in these mice.  Pristane, which induces chronic inflammation and
increased production of oxidants during phagocytosis of oil droplets, was also studied as
a potential immunogen that might generate a specific PC immune response by increasing
formation of auto-immunological materials such as oxidized lipids and apoptotic cells.
Further experiments measured M167µk Tg BCR activation through in vitro cell
proliferation in response to various PC antigens and to antibodies that specifically cross-
linked M167-id Tg BCR.
Anti-PC Immune Response to Pristane
Recent studies have demonstrated the presence of PC-containing phospholipids in
apoptotic cells (38) and anti-PC antibodies can bind to determinants on thymoctyes
undergoing dexamethasone-induced apoptosis (37).  Different subgroups of PC
antibodies bind various stages of these apoptosing cells.  Group I (natural PC Abs) bind
PC-determinants on cells in the early stages of apoptosis, whereas group II (mutated PC-
Abs) recognize late stage apoptotic cells.  Shaw et al. (37) also demonstrated the
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autoreactivity of anti-PC antibodies for PC determinants found on atherosclerotic lesions,
which involve chronic inflammation and lipid abnormalities.  The T15 set of natural Abs,
which are derived solely from B1 cells (43) and are the dominant anti-PC clone (78-84)
in BALB/c mice as well as in M167µΔmem Tg mice unable to insert the M167µ chain in
the B cell membrane (49), recognizes not only microbial antigens, but also oxidatively
altered lipoproteins (produced in inflammatory environments under oxidative stress) and
apoptotic cells (37, 75, 76).  Of specific interest among the group I antibodies was the
M167-IgA monoclonal antibody shown to bind to atherosclerotic inflammatory lesions
and apoptotic thymoctyes (37).
Injection of pristane leads to the development of oil granuloma, a chronic
inflammatory tissue in the peritoneal cavity.  The OG contains reactive, cytokine-
secreting macrophages and neutrophils that generate tissue-damaging oxygen radical
molecules.  Similar to the inflammatory atherosclerotic lesions mentioned above, PC
antigen may also be present in OG tissue created by the presence of pristane in the
peritoneal cavity, and thus may be a source of PC antigen for the transgenic M167 B cell
receptor.
Because pristane may be creating a source of PC antigen in oil granuloma that
stimulates B cell precursors of plasmacytomas, anti-PC sera titers were monitored in
pristane “immunized” mice in order to determine if an anti-PC immune response is
generated as a result of i.p. pristane injection.  Anti-PC sera titers were monitored in
C.M167µk Tg and non-Tg littermate mice injected with 0.2 ml pristane, the initial dose
administered in plasmacytoma studies.  A prebleed (PB) for each mouse was taken on
day 0, before i.p. injection of 0.2 ml pristane.  Sera were collected for time points
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spanning the primary (day 0) and secondary (day 60) doses of pristane given in a
plasmacytoma study.  PC-binding antibody titers were analyzed by PC-ELISA for days
10, 20, 35, and 50 and were reported as the OD (450 nm) reading for 1/1600 sera dilution
(Figure 26).  No changes in anti-PC titers in either group were seen within the first 60
days after the injection of pristane to indicate a chronic stimulation of anti-PC B cells.
Several injections of the non-metabolizable pristane may be necessary, providing a
cumulative affect of PC-antigen generated by the inflammatory tissue, before a PC
immune response in detectable.  However, sera tested at day 150, after all three injections
of pristane were administered, still did not generate a change in anti-PC sera titers over
prebleed (day 0) controls in M167 Tg or non-Tg mice (data not shown).  However,
plasmacytomas can be drastically accelerated by use of the Abelson murine leukemia
virus (85) or the BclX L anti-apoptotic transgene in BALB/c pristane-treated mice (BclX L
x C.M167µk Tg F1 mice, Figure 40 in appendix).  This evidence suggests that the
influence of antigen stimulation on B cells driving proliferation and differentiation would
probably occur in the early stages of pristane induction.
PC antigen may still be provided by apoptotic cells and/or oxidatively modified
LDLs in the OG, but it clearly does not generate a systemic anti-PC immune response.
Rather, the main function of the OG in plasmacytoma-genesis is probably to provide a
persistent inflammatory environment rich in oxidative stress and growth factors that
nurtures PCT development, instead of generating a primary source of antigen.  Thus,
exogenous sources of PC - the environmental antigens from microorganisms of the
natural gut flora, diet, and bedding - is probably the principal stimulus of B-cells in
C.M167µk Tg mice.
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Figure 26. Anti-PC antibodies in response to pristane.  One injection of pristane (0.2
ml, injected i.p. on day 0) produced no increase in the anti-PC immune response within
the first 50 days of a pristane induction in either Tg+ or non-Tg BALB/c M167µk mice.
Each mouse was bled on day 0 (PB), 10, 20, 35 and 50.  Sera titers are reported at 1/1600
dilution.  Values represent the arithmetic mean ± SEM of n=4-5 mice.
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Immune Responses to PC-KLH (TD Ag) and PnC (TI Ag) Were Poor
Initial in vivo immunization experiments with PC antigen (described below)
included soluble 1) a PC-conjugated hemocyanin protein carrier (PC-Hy) that induces a
T-cell dependent (TD) immune response, and 2) PnC, a PC-containing bacterial cell wall
polysaccharide that is a T-cell independent (TI) antigen.  For an explanation of T-cell
dependent and independent antigens and immune responses, see Appendix (page 180).
However, results from intraperitoneal (i.p.) immunization in M167µk Tg mice were
surprising in that neither of these PC antigens produced the expected high levels of anti-
PC antibody immune response in Tg mice, although large anti-PC responses were seen in
non-Tg control mice.
PC-Hemocyanin (Protein) in CFA
As previously mentioned, Kenny, et al (48) showed that intraperitoneal (i.p.)
immunization of M167µκ Tg mice with 200 µg PC-KLH in CFA on day 0 and 14
produced a T-cell dependent immune response (at day 21) as indicated by increased
levels of anti-PC IgM antibodies in the serum.  Kenny measured serum antibody by
capturing PC antibodies from serum on PC-BSA coated plates and using secondary
antibodies to detect IgM, IgG, VH1-id, or T15-id.  His results showed an increase in PC-
antibodies using IgM (1586 µg/µl) and VH1-id (>1000 µg/µl), but very little IgG (19
µg/µl) and no T15-id (<1 µg/µl).
Similar immunization experiments were performed in our conventionally raised
C.M167µk Tg mice using PC-conjugated hemocyanin (PC-Hy) in order to show the PC-
specific M167 Tg BCR is functional in mice used for plasmacytoma studies.  The
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hemocyanin protein carrier used in the following experiments is slightly different, as
Kenny used keyhole limpet hemocyanin (KLH) and in the studies described here,
horseshoe crab hemocyanin (Hy) was used.  C.M167µκ Tg and non-Tg littermate mice
were i.p. immunized at 12 - 20 weeks of age with PC-Hy/CFA (100µg or 200µg) or
PBS/CFA on day 0 and again on day 14, or were left completely untreated (naïve,
unimmunized mice).  Day 7 (primary response) and day 21 (secondary response) sera
were collected and analyzed by ELISA for total anti-PC specific antibodies.  Total anti-
PC antibodies (instead of specific IgM or IgG antibodies) were detected using a goat anti-
mouse Ig(H+L) antibody.
In both groups of Tg and non-Tg mice, the sera from injected PBS/CFA control
mice had identical amounts of anti-PC antibody as sera from unimmunized, naïve mice
(Figure 27).   The naïve and PBS-treated Tg mice have significantly higher amounts of
PC-specific antibodies (3-4x more) than their non-Tg littermates.  However, an attempt to
induce a robust T cell dependent immune response in M167µκ Tg mice with PC-Hy
antigen was only moderately successful, as shown in Figure 27.   OD readings for anti-
PC antibodies are reported at 1/160 sera dilution.  Immunization of C.M167µκ Tg mice
with 100 µg PC-Hy/CFA generated no anti-PC Ab response at all.  However, a moderate
increase in anti-PC Abs is seen with 200 µg PC-Hy/CFA in Tg mice, and the secondary
immune response is no higher than the original primary response.  In comparison, the
non-Tg littermates responded with large increases of anti-PC Abs, and had even higher
levels during the secondary response.
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PC-specific Antibody Titers after PC-Hy/CFA Immunization
Figure 27. Anti-PC Antibody Responses to PC-Hy/CFA.  C.M167µk Tg and non-Tg
mice were injected i.p. with either, PBS/CFA, 100 µg, or 200 µg PC-Hy emulsified in
CFA adjuvant, or were left immunized (naive).  On day 14 after initial immunization,
mice were given a second injection of PC-Hy or PBS in CFA.  Sera were collected on
both day 7 and day 21 and anti-PC Ab titers were assayed by PC-ELISA.  Transgenic
naive (Tg) and PBS control (Tg PBS) mice have a significantly higher amount of anti-PC
antibody compared with naive (non-Tg) and PBS-treated (non-Tg PBS) littermates.  In
C.M167µk Tg mice, anti-PC Ab titers were not increased with immunization using 100
µg PC-Hy.  Tg mice responded to 200 µg PC-Hy/CFA at day 7 and 21, but no significant
differences were seen between the primary (day 7) and secondary responses (day 21).
Non-Tg littermate mice showed a much greater anti-PC immune response to both
concentrations of PC-Hy antigen at both 7 and 21 days.  The non-Tg mice had an initial
primary anti-PC Ab response and anti-PC Ab titers were further boosted in the secondary
immune response, as expected in a T cell dependent response.  Values represent the
arithmetic mean ± SEM of n= 3-5 mice/group.
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The same data is presented in an alternate form in Table 13 as anti-PC Abs titers
for the PC-Hy/CFA immunization experiment, emphasizing a moderate response to TD
PC-antigen in Tg mice compared to the prolific anti-PC immune response in the non-Tg
littermates.   There was a small, 2 fold immune response in Tg mice with 200 µg PC-
Hy/CFA, although no further increase was seen between day 7 and day 21, after mice
were boosted a second time with PC-Hy antigen.  Non-Tg littermate mice responded to
PC-Hy antigen with an 8-16 fold (day 7) and >64 fold (day 21) increase in anti-PC Ab
sera titers for both concentrations of PC-Hy.
Table 13. Serum titers for the T-cell dependent PC-Hy/CFA immunization study.
Reported is the lowest titer that had an OD > 0.25 (at 450nm).  The fold differences are
noted in parenthesis.  The anti-PC antibody day 0 (prebleed) titers of Tg mice are 4x
higher than non-Tg day 0 titers.  A 2x difference is seen in Tg mice between day 0 and
day7 or 21 given 200 mg of PC-Hy/IFA.  Non-Tg mice responded with 8x to >64x
increases in PC Ab titers given PC-Hy/IFA.
Serum Titers for PC-Hy/CFA Immunization Study
Mice Day 0 Day 7 Day 21
Tg+  (100µg/PC-Hy) 1/320 1/320 1/320
Tg+  (200µg/PC-Hy) 1/320 1/640 (2x) 1/640 (2x)
Non-Tg  (100µg/PC-Hy) 1/80 1/640 (8x) 1/5120 (64x)
Non-Tg  (200µg/PC-Hy) 1/80 1/280 (16x) > 1/5120 (>64x)
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Kenny (48) reported large increases in total anti-PC antibody in Tg mice
[B6.CBA/N x M167Tg F1 females] from day 0 (46 µg/ml) to day 21 (1605 µg/ml) after
immunization with 200 µg PC-KLH in CFA, whereas the non-Tg littermates had
increases in anti-PC titers from day 0 (<1 µg/ml ) to day 21 (3961 µg/ml), both
significant increases in PC-antibody titers.  Compared to these previously reported
immune responses, the anti-PC antibody responses seen in BALB/c.M167µk Tg study
mice were lower than expected.  Therefore, these low responses are a cause of concern in
my study that the mice are not responding to PC-antigen as expected.
PnC (Polysaccharide) Produces no Anti-PC Ab Response in Tg mice
A second immunization with T-cell independent type 2 antigen pneumococcal C
polysaccharide (PnC) was also performed.  A soluble extract made from S. pneumoniae
R36A was tested in M167µk Tg mice.  Emulsified PnC/IFA (100 µg) or PBS/IFA was
injected i.p. into C.M167µk Tg and non-Tg littermate mice at day 0 and again on day 14.
Day 7 and day 21 sera were collected and analyzed by ELISA for anti-PC specific
antibodies.  Intraperitoneal immunization with PnC elicited no anti-PC immune response
in M167µk Tg mice (Figure 28); there were no increases in anti-PC antibody titers after
injections with PnC antigen in IFA.  PnC immunized M167µk Tg mice had titers at day 7
and 21 that were similar to non-immunized Tg control mice.  Immunization of WT
controls, non-Tg littermates, was successful as there was a 4-fold anti-PC antibody titer
increase at day 21 after two injections with PnC in IFA.
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PC-specific Antibody Titers after PnC/IFA Immunization
Figure 28. PC-specific Antibody Titers after PnC/IFA Immunization.  C.M167µk Tg
and non-Tg mice were injected i.p. with 100 µg of the T-cell independent antigen
pneumococcal C polysaccharide (PnC/IFA), or with PBS (PBS/IFA).  Mice were boosted
again on day 14.  Day 7 and 21 sera were analyzed for PC-specific Ab titers.  There is no
increase in the anti-PC Ab sera titers in Tg mice at either day 7 or 21 after 100 µg PnC
immunization compared to unimmunized Tg control sera. However, non-Tg littermates
showed a definitive spike in anti-PC antibodies with both 100µg and 200 µg PnC
polysaccharide antigen at day 21 (n= 3-5 mice/group ± SEM).
The lack of responsiveness to PnC in M167µk Tg mice has been previously
reported by Caulfield and colleagues (86).  Using C57BL/6 M167µk Tg mice, Caulfield
et al. found that Tg B cells were unresponsive to R36A-derived pneumococcal cell wall
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polysaccharide (PnC) antigen, delivered without the use of adjuvants.  Even repeated
injection of PnC in their experiments did not significantly increase the basal levels of
anti-PC antibodies in Tg mice.  However, C57BL/6 M167µk Tg mice could respond to
PnC antigen if it was given as a preformed antigen/antibody complex with the BALB/c
anti-PC IgA myeloma antibodies, T15 or M603 (these complexes were also injected i.p.
without adjuvant) (86).  The authors had previously reported a strain-specific genetic
restriction to PnC and PnC/T15 immune complex responsiveness: C57BL/6 non-Tg
littermates were low responders to both PnC and PnC/T15 complexes, whereas the
control BALB/c mice were high responders (84) and are able to produce large amounts of
anti-PC antibody.  Their data also showed that these strain-specific PnC responses
correlated with expression levels of the dominant anti-PC T15 idiotypic antibodies
produced in response to PC antigen.  In the early 1970’s, certain genetic strains were
shown to have naturally high levels of T15 antibodies in their serum, while other strains
had little to no T15 serum antibodies (81).  Strains such as BALB/c and A/J that express
high levels of T15 idiotype are high responders to PnC antigen and T15/PnC immune
complexes, whereas strains that genetically express low levels of T15 antibody (C3H,
AKR, C58 and CE/J) are poor responders to PnC and T15/PnC immune complex (84).
The carrier antibody’s idiotype, rather than the strain specific allotype of the IgCH region,
is an important factor in determining responsiveness to PnC or PnC/Ab complexes (84).
The immune response to PnC/T15 antigen/antibody complex is dependent on
CD4 T cells, as shown by the abrogation of immune response when anti-CD4 was used in
vivo to remove T cells (86).  The PnC-antigen/antibody complex acts as a special case of
the classical hapten-carrier conjugate, allowing the immune system to respond in a T cell
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dependent manner to PC groups on the polysaccharide component.  Polysaccharide
antigen (PnC) cannot be presented by the MHC II molecules that are necessary to achieve
T cell help (and is therefore classified as a T-cell independent antigen).  Instead, B cells
that recognize PC antigen will process ‘carrier’ epitopes (or the idiotypic determinants on
the T15 Ab) from the immune complexes and present them to helper T cells.  The
stimulated T helper cells secrete cytokines that stimulate B cell antibody production in
the PC-reactive B cells.  The provided T cell help is therefore a non-cognate response.
These data presented by Caulfield suggest the M167µk Tg B cells that are unresponsive
to soluble T cell independent PnC-antigen are not autoreactively tolerized cells, but rather
lack the T cell help necessary to stimulate an immune response.
M167µk Tg mice on BALB/c background had not been tested for their immune
responses to PnC or T15/PnC complexes.  The studies reported here show that
BALB/c.M167µk Tg mice do not respond to soluble PnC free antigen (Figure 28),
despite being on a high responder genetic background.  PnC antigen (from
S.pneumococcus or LB4 bacteria) mixed with T15 Ab to form immune complexes were
injected i.p. (without adjuvant) into C.M167µk Tg mice.  PnC/T15 immune complexes
(100µg and 200 µg, based on the concentration of protein present in the complex) were
able to elicit an anti-PC immune response in BALB/c M167µk Tg and non-Tg study mice
and corroborated Caulfield’s results.  These data are not shown.
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In Vivo Immunization with R36A Pneumococcal Bacteria
Martin et al. showed that M167-id B cells respond to the particulate bacterial
antigen, R36A Streptococcus pneumoniae, injected i.v. or i.p. without the use of
adjuvants (42).  As shown earlier, BALB/c.M167µk Tg mice have an increased
population of marginal zone B cells, dependent on the higher surface density of the
M167-id receptor on many of its B cells.  Therefore, the M167 receptor in these
BALB/c.M167µk Tg mice is probably highly susceptible to stimulation by particulate
bacterial or immune-complexed PC-antigens.  Taking into consideration Caulfield’s
evidence that PnC antigen had to be presented as an immune complex and Martin’s report
that M167-id MZ B cells responded to particulate bacterial antigens, C.M167µκ Tg mice
were immunized with heat-killed particulate R36A S. pneumoniae bacteria.
Figure 29 shows results from i.p. immunization with R36A in C.M167µk Tg and
non-Tg mice.  Intraperitoneal injection of R36A bacteria (without adjuvant) induced a
significant PC-antibody response.  There was a 2-3 fold increase in PC Abs detected in
sera of Tg mice at day 7.  PC-Abs remained elevated and were even higher after
secondary boost with R36A on day 14.  Non-Tg WT mice had a 4-6 fold increase in anti-
PC Abs at day 7 and on day 21.  Overall, the anti-PC Ab titers in immune sera of Tg mice
were much higher than those reached in the non-Tg mice (5000 µg/ml in Tgs vs. 1500
µg/ml in non-Tgs) in response to PC+ bacteria.  M167µk Tg mice can respond to
particulate whole PC+ bacteria by secreting anti-PC Abs despite not being able to
respond to soluble forms of the T-cell independent PnC antigen.
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Immunization with S. pneumoniae R36A Bacteria
R36A R36A
Figure 29. Anti-PC immune response to PC-containing bacteria, R36A. M167µk Tg
(n=8) and non-Tg (n=7) mice were immunized by i.p. injection with R36A heat-killed
Streptococcus pneumoniae (1x108 CFU/mouse) on day 0 and again on day 14.  Sera were
collected on day 0, 7,14, 21 and 28 for analysis of anti-PC antibody titers.  A T15 Ab
standard was used to quantitate anti-PC Ab levels in sera.  M167 Tg mice immunized
with PC+ R36A bacteria had a significant increase in anti-PC Ab titers, indicating that Tg
B cells have functional PC receptors that respond to PC antigen on bacteria.  Values
represent the arithmetic mean of anti-PC Abs ± SEM (*p < 0.05).
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In vivo i.p. immunization with heat-killed, particulate R36A S. pneumoniae was
successful in stimulating increased anti-PC antibody production in both Tg and non-Tg
C.M167µκ mice (Figure 29) indicating that the PC antigen from R36A specifically
stimulated PC-specific receptors.  However, with the co-expression of endogenous heavy
and light chains on M167µκ Tg B cells (as demonstrated in Figure 12), it is possible that
other “mixed molecule” antibody combinations could be contributing to the PC-
specificity of the surface receptors.  In order to prove that the B cells in transgenic mice
can be activated specifically through the Tg M167µκ BCR, not the endogenously
expressed receptors, in vitro proliferation assays were done to target the M167-id BCR.
II. Induction of In Vitro Cell Proliferation In M167µk Tg B cells
Stimulation of M167µk Tg BCR: CFSE In vitro Proliferation Studies
To directly show that activation of the M167 receptor on Tg+ B cells could
initiate cellular proliferation, M167-specific Ig was used to stimulate proliferation in vitro
by cross-linking the M167µk receptors on the cell surface with anti-M167 idiotypic
antibodies.  This mechanism has been shown in many other studies to be a way to trigger
cell proliferation in B cells (58).  I used CFSE (5,6-carboxyfluorescein succinimidyl
ester) labeling of B cells (see below) to determine the number of proliferative cycles
M167µk Tg+ B cells underwent when stimulated by various crosslinkers.  I confirmed
that the M167µk Tg B cell receptor in B cells of conventional C.M167µk Tg mice would
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proliferate when specifically activated by anti-idiotypic antibodies to M167 idiotypic
receptors.
CFSE is a membrane-permeable dye can be cleaved by intracellular esterases,
enabling it to be excited by a 480 nm argon laser and detected in the fluorescein (or
green) channel of a flow cytometer.  The cells are stably labeled because the cleaved
molecules are highly reactive with the amine groups on cytosolic proteins, which they
bind, and therefore, cannot easily escape from the cell.  Proliferation of CFSE-labeled
cells can be tracked by flow cytometry because the high fluorescent signal of stained
undivided cells is reduced by half with each cell division.   A limited number of cell
divisions that can be detected before the dividing cells look like unlabeled control cells
(background), perhaps 8-10 divisions.
Although M167µk Tg B cells have been shown to respond normally to both in
vivo (48) and in vitro  (87) immunization with T-cell dependent PC-KLH, they fail to
proliferate when treated with soluble anti-M167 idiotype, anti-IgM, or other anti-IgG
antibodies (55, 88).  However, anti-IgM and anti-M167 idiotypic antibodies (28-5-15,
anti-VH1/Vk24; 28-6-20, anti-Vk24; and 28-4-3, anti-Vk24) conjugated to sepharose
beads were able to induce proliferation of PC-antigen specific M167µk Tg B cells in
vitro (58).  This is not surprising because the M167Tg BCR appears to respond best to
large particulate antigens, such as whole bacteria or immune complexes that are more
efficient in crosslinking the BCRs, rather than soluble ones.
Therefore, the anti-M167 idiotypic antibody, 28-5-15, which recognizes antigenic
determinants formed by elements of both the M167Vk and M167VH polypeptide chains,
was used to stimulate Tg B cells in cell culture.  Anti-IgM sepharose, PC-sepharose, and
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unconjugated sepharose beads were included as controls.  Splenic B220+ B cells were
purified, stained with CFSE, and stimulated for 3 days in vitro, then harvested and
analyzed on the flow cytometer.  Proliferation was induced by the anti-M167-sepharose
complexes in 25% of the B cell population (Figure 30), but not in non-Tg B cell controls.
One possible explanation for this is that only 25% of splenic B cells have a surface
density of Tg M167-id BCR high enough to cross-link with the anti-idiotypic antibody in
vitro.  The M167-id Tg receptor being diluted by endogenously expressed receptors.  PC-
sepharose could promote proliferation in over 50% of the cells, although non-Tg B cells
also were able to divide in response to the PC antigen.  The proliferation seen in the non-
Tg B cells is more excessive than expected for a heterogeneous population of antigen-
specific cells, and the proliferation may be due to a mitogenic antigen contamination
(such as LPS) of PC-sepharose reagent.  The PC-sepharose was obtained from Jim
Kenny’s lab, but should have been screened for the presence of LPS contamination
before use in culture.  Proliferation in Tg B cells was not induced with soluble anti-IgM
or soluble anti-M167 (data not shown), confirming previously reported data.
112
Figure 30. Proliferation of M167µk Tg B cells in vitro.  Purified B220+ B cells stained
with CFSE+ from Tg and non-Tg M167µk mice were stimulated with anti-IgM-, anti-
M167- (28-5-15, VH1/Vk24), PC-conjugated or unconjugated sepharose beads.  Numbers
inside gates indicate the percent of B cells that divided in response to stimulant.  Anti-
M167 sepharose caused 25% of B220+ B cells to divide in Tg cultures, whereas non-Tg
B cells were not stimulated to divide with anti-M167Ab.
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Figure 31 shows forward (FSC/size) and side (SSC/complexity) scatter graphs of
stimulated B cells.  FSC/SSC data show that the naïve B cells become larger and more
complex blast cells when stimulated to divide.  Unconjugated sepharose controls show
background levels of stimulation, where most of the cells are still small, non-complex B
cells (long, thin arrow indicates naïve B cells, whereas short, thick arrows indicate blast
cells in Tg cultures).  Tg B cells produced blasts in all three treatments, whereas non-Tg
B cells blasted in response to anti-IgM and PC, but not anti-M167.  The FSC/SSC plots
support CFSE proliferation data shown in Figure 30.
Figure 32 shows the number of divisions cells have gone through in response to
each of the sepharose-conjugated stimulants.  IgM and PC produced higher number of
cell divisions in both Tg and non-Tg cells (4 to 7 cell divisions), while the M167-
responders in Tg B cell cultures had only undergone one to two cell divisions by day 3.
Figure 30 shows that 25% of these Tg splenic B cells were stimulated into cell division
by anti-M167-sepharose.
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Figure 31. FSC/SSC plots of stimulated B cells. Purified B220+ B cells from Tg and
non-Tg M167µk mice were stimulated in vitro with IgM-, M167-(28-5-15, VH1/Vk24),
PC- or unconjugated sepharose beads.  Long, thin arrow indicates population of naïve,
unstimulated B cells; short, thick arrow indicates the larger, more complex B220+
plasmablasts.  Tg+ B cells can be stimulated by anti-IgM-, anti-M167- as well as PC-





Figure 32. CFSE: In vitro cell division in Ag stimulated Tg+ and non-Tg C.M167µk
B cells.  (A) Shows overlays of stimulated B220+ cells from Tg+ and non-Tg C.M167µk
mice.  Anti-M167 sepharose stimulates cell division only in M167µk Tg B cells.  (B)
Shows the number of cell divisions in each of the stimulated B cell cultures as measured
by a decrease in CFSE signal.
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Figure 33 shows stimulation through other mitogenic receptors using LPS is
normal in M167µk mice - most of the M167 Tg B cells were stimulated to divide (non-
Tg WT B cells responded with identical vigor, not shown).
Figure 33. LPS stimulation of C.M167µk Tg B cells.  Stimulation through other
mitogenic receptors using LPS is normal in M167µk Tg mice.  Proliferation algorithms in
the FlowJo analysis program performed cell division calculations.
R36A Heat-Killed Bacteria Promotes Proliferation of Tg B Cells In Vitro
As previously demonstrated in Figure 29, R36A heat killed bacteria stimulated
M167 Tg B cells to secrete the M167 IgM PC-binding antibody in vivo.  Here, I show
that heat-killed R36A whole bacteria also stimulate proliferation of PC-specific Tg B
cells in vitro (Figure 34).  R36A bacteria was used to stimulate CFSE-labeled C.M167µk
Tg and non-Tg B cells in cultures that were >85% B220+ purified B cells.  As reported in
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M167µk Tg spleen cells – Day 3 in vitro stimluation
Figure 34. In vitro stimulation R36A heat-killed bacteria, LPS, or anti-M167-
sepharose beads.  Day 3, M167 Tg+ splenic B cells: overlay histograms (left) and
individual histograms (right) showing number of cell divisions.  By day 3, 38.3% of the
Tg+ B cells had responded to 107 R36A bacteria, dividing up to 3 times.  Non-Tg B cells
had little to no division with 107 R36A (0% divided) compared to PC-specific Tg B cells.
Background proliferation in PBS cultures was typically 0-4%.  Cell division histograms
were reported for proliferation controls using anti-M167 Ab (VH1/Vk24) and LPS also
reported. See Table 17 for summary of cell division in M167µκ Tg and to non-Tg B cell
controls.
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Figure 34 and Table 14, 107 R36A stimulated proliferation of 38% of the Tg B cells in
culture, but not in non-Tg WT B cells.  M167-id sepharose beads were able to stimulate
42% of Tg B cells to divide up to 3 times, compared to 0 % of the non-Tg B cells.
Table 14. In vitro proliferation of C.M167µk purified splenic B cells.  Percentage of
purified B cells that divided after 3 days of in vitro stimulation, as calculated by the
FlowJo proliferation algorithm. *1:100 dilution of anti-M167 (28-5-15, VH1/Vk24)
sepharose beads.
In Vitro Proliferation of Purified Splenic B cells
% Cell Division (Max # cell divisions)
M167µk Tg Non-Tg littermates
107 R36A bacteria 38.3% (3 divisions) 0% (0 divisions)
LPS (10µg/ml) 52.1% (5 divisions) 67% (3 divisions)
Anti-M167-sepharose* 46.3% (3 divisions) 0% (0 divisions)
PBS 0.9% (0 divisions) 0% (0 divisions)
III.  Effect of Immunization on PCT Induction
Role of PC-Hy Immunization on PCT Development
Pristane induction of plasmacytomas in C.M167µk Tg mice produced twice as
many PCTs in Tg mice that had anti-PC BCRs as in non-Tg littermates.  Despite the lack
of systemic anti-PC immune response detected in M167 Tg and non-Tg BALB/c mice in
response to pristane, stimulation of Tg B cells with PC antigen is predicted to be
necessary to drive proliferation of B cells and, ultimately, plasma cell tumor
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development.  To this end, we sought to test the hypothesis that pre-stimulation of B cells
with low doses of PC antigen in a pristane induction study would enhance incidence of
PCTs, particularly in M167Tg mice.
In order to determine if chronic stimulation of B cells with PC antigen would
increase or decrease PCT incidence in C.M167µk Tg and non-Tg littermate mice, a
pristane induction study using PC-Hy antigen was designed to pre-immunize mice with
PC antigen before each pristane injection.  In previous experiments (48), Kenny et al. had
shown that M167µk Tg mice respond very well to the T-cell dependent antigen, PC-
keyhole limpet hemocyanin (KLH).  Therefore, the PC antigen used for immunization of
study mice was PC conjugated to horseshoe crab hemocyanin (PC-Hy).  Taking into
account that under physiological conditions, environmental PC would be present at
chronic, yet low levels, the preparation of PC-Hy was ultracentrifuged to remove highly
immunogenic particulates and i.p. injected at a concentration of 100µg/mouse (based on
protein concentration in conjugate).  The immunization schedule was administered as
follows: 3 doses of pristane were injected i.p. at day 0, 60 and 120 (.2 ml, 0.5 ml, and 0.5
ml) as usual; 100µg of PC-Hy emulsified in IFA was injected i.p. 7 days before each
injection of pristane (at -7, 53 and 113 of the pristane schedule).  IFA (Incomplete
Freund’s Adjuvant) is a mix of 0.85 ml mineral oil and 0.15 ml mannide monooleate
emulsifier that was used to help slow release of the antigen and stimulate long-lasting
antibody responses
To determine if 100 µg PC-Hy/IFA produced an anti-PC immune response in pre-
immunized pristane study mice, sera was collected after the initial i.p. immunization at
day 7 and again at day 17 (10 days after the first pristane injection).  The anti-PC
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antibody titers for C.M167µk Tg and non-Tg mice at day 7 (A) and day 17 (B) post-PC
immunization are reported in Figure 35.
Anti-PC Sera Titers (Day 7 and 17) in
PC-Hy/IFA pre-immunization PCT Pristane Study
   
A. B.
Figure 35. C.M167µk Anti-PC sera titers from PC-Hy/IFA pre-immunized mice.  Tg
and non-Tg mice were injected i.p. with the T-cell dependent antigen, PC-Hemocyanin
(100µg PC-Hy in IFA) or with PBS (in IFA) as a negative control.  (A) Day 7 (no
pristane) and (B) day 17 (day 10 post pristane, PP) sera were analyzed for PC-specific Ab
titers.  Normal sera titers in Tg mice are naturally elevated and were similar to IFA
controls.  No change of anti-PC Ab levels was seen at day 7 or day 17 post-immunization
from normal, PBS/IFA treated mice.  Non-Tg control mice, however, did have a
significant anti-PC immune response to PC-Hy antigen at day 7 and 17.  (n= 5
mice/group ± SEM, statistics analysis using the Student’s T test, * p < 0.05).
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 In non-Tg littermates, PC-Hy/IFA caused increased anti-PC Ab titers, indicating
a normal secondary T cell dependent immune response to PC-Hy antigen, and providing
a positive control for the integrity of the PC-Hy antigen injected.  Surprisingly, in the
M167µk Tg mice there were no detectable increases in anti-PC Ab sera titers between
PC-Hy/IFA and PBS/IFA injected mice on either day 7 or day 17 of immunization,
indicating a lack of immune response to PC.  These results were of concern because the
M167µk Tg BCR did not appear to be responding to this PC antigen, and may not be
functioning as expected.
Results of PC-Hy immunization/PCT pristane induction study are reported in
Figure 36.  Pre-immunization with 100µg PC-Hy had no affect on PCT incidence in
BALB/c WT mice as compared to untreated mice (29% in PC-treated mice vs. 33% in
untreated mice).  In C.M167µk Tg mice, pre-immunized PC treated mice had a decreased
incidence of PCTs compared to the pristane only or IFA/pristane treated mice (40% vs.
60-65% PCTs).  Because there was no detectable anti-PC immune response in Tg mice to
PC-Hy antigen, it is not clear what the reason for the decrease in PCTs might be.  The
20% decrease seen may be due to Tg B cells either being deleted or “tolerized” by too
much PC antigen, and therefore the anti-PC B cell population is not able to respond as




Figure 36. PCT pristane induction results in mice pre-immunized with untreated,
PBS/IFA or PC-Hy/IFA.  M167µk Tg+ mice (A) and non-Tg WT mice (B).  In
C.M167µk Tg mice, the pristane and IFA+pristane control groups had similar induction
curves and the same numbers of PCTs generated in this study.  However, a decrease in
the numbers of PCTs generated when PC-Hy+IFA was administered.  The injection of
PC-Hy + IFA didn’t change the number of PCTs that developed in non-Tg WT BALB/c
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mice.  However, IFA only did cause a small 12% increase in the number of PCTs.  IFA
has been noted to cause an increase in pristane PCTs in BALB/c mice (data not
published, Mike Potter, personal communication), but the the mechanism of the increase
is not understood.
Interestingly, PBS/IFA causes acceleration of and increased incidence of PCTs in
WT mice (Figure 36), although the explanation for this result remains unclear.  This
intriguing result has also been seen in other IFA-treated PCT pristane induction study
groups (Potter, personal communication).  As shown in Figure 35, the initial pre-
immunization of non-Tg mice did generate higher titers of anti-PC antibody responses to
PC-Hy antigen at day 7 and day 17.  The initial anti-PC immune response seen at day 7
and 17 (Figure 35) indicates stimulation of PC-specific B cells in non-Tg BALB/c mice,
although it did not result in an increase incidence of PCTs.  Serological analysis was not
documented for 2nd and 3rd injection of PC-Hy + pristane in this study.  The type of PC
antigen and the immunization schedule used in this study may be not have been suitable
and further investigation is warranted.
 As demonstrated earlier in Figure 27, immunization of C.M167µk Tg mice with
100µg PC-Hy (in CFA) did induce an anti-PC Ab immune response, seen after the
secondary boost with antigen.  In the pristane induction study reported here, an attempt
was made to mimic low levels of endogenous PC antigen suspected to be present in a
pristane treated mouse.  The preparation of PC-Hy antigen had been ultra-centrifuged to
remove all particulate complexes from solution, leaving only soluble protein.  The
M167µk Tg B cells do not appear to respond as well to soluble antigen, but rather need a
particulate antigen presented in an immune complex or as part of a whole bacterium
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suggested by our successful R36A bacterial immunization studies.  Repeating the study
using either particulate PC-Hy or R36A bacteria to ensure a detectable anti-PC immune
response is advisable.
Thus far, I have three independent examples where the M167mk Tg has caused
increased PCT incidences in BALB/c mice in pristane induction studies (Table 15).
Table 15. Three examples where the M167µk Tg increases PCT incidence.  M167µk
Tg mice consistently generate more pristane induced PCTs than non-Tg WT littermates.
Non-Tg M167µk Tg
% PCT %PCT
Pristane only 33 60
Pristane + IFA 45 65
Pristane + PC-Hy/IFA 29 40
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Chapter 5 Conclusions:
• C.M167µk Tg B cells can respond to PC antigens administered in the form of
immune complexes.
• C.M167µk Tg B cells can respond to PC on whole bacteria, as demonstrated
by the generation of secreted PC-specific antibody in vivo and by undergoing
several rounds of cell division in vitro.
• The M167µk BCR can be specifically cross-linked using anti-idiotypic
antibody that also stimulates proliferation in vitro. Together, these results
provide proof that the Tg receptor is indeed functional in the M167µk Tg mice
used in plasmacytoma induction studies.
• Pristane does not generate a systemic anti-PC immune response.  PC antigen,
however, may still be provided by apoptotic cells and/or oxidatively modified
LDLs in the OG tissue (not directly demonstrated).  The alternative source of
PC - the environmental antigens from microorganisms of the gut flora - is




This project was conceived to study plasma cell tumor development in
immunoglobulin (Ig) transgenic conventional BALB/c An mice as there were no reports
in the literature on this topic and to ask if an Ig transgene could be expressed in plasma
cell tumors.  I focused on Ig transgenes whose products were associated with binding to
phosphorylcholine and phosphatidylcholine antigens, as much was known about the
antibodies against these antigenic haptens.  Several of these Ig transgenes had previously
been constructed by other researchers (47, 50) and the mice were available.  Further,
plasmacytomas that secreted immunoglobulins with anti-phosphorylcholine activity had
been described, the best known of these were T15, M603, and M167 monoclonal Igs.
Most Ig transgenes are either rearranged L or H chains, but the M167µκ transgenic
mouse had a tandem cluster of both M167µ (H) and M167k (L) transgenes.  Two
reproducible studies on M167µk Tg mice showed that when these mice were treated with
pristane, there was a statistically significant increase in PCT incidence from 35% in WT
controls to 63% in the Tg mice.  Further this occurred with a decrease in the mean latent
period from 240 days in WT to 200 days in the Tg mice.  These intriguing results
suggested that the M167µk Tg had changed the immune responsiveness of mice carrying
the Tg that predisposes the mouse to an increased risk of developing a PCT.   This thesis
explores some of the changes in the M167µk Tg mouse that contribute to this
predisposition.
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Changes in the B cell populations of M167µκ Tg mice
1) Reduction in total B-cells
2) Increase in MZ population
Previous studies in the laboratory of James Kenny demonstrated that a high
percentage of B cells (>97%) in M167µk Tg mice express M167 H + L chain B cell
receptor on the plasma membrane where it has the potential to interact with PC
containing antigens and transmit signals to the B cell to proliferate and differentiate to the
plasma cell stage.  The transgenic M167µk BCR expressed in conventional BALB/c
M167µk Tg mice causes changes to the overall B cell population that are likely to have
impacted their susceptibility to develop increased numbers of PCTs.  Two such
interesting changes are a reduction in the total number of splenic B cells and an
enlargement of the splenic MZ B cell subset in C.M167µk Tg mice.
Kenny reported that the number of IgM+ B cells in C57BL/6 M167µk Tg mice
can range from a low of 18% to a close to normal 45% of the total splenic cells (48). On
average, IgM+ B cells make up about 25% of spleen cells in Tg mice, whereas normal
mice have about 50% IgM+ B cells in the spleen.  Further, Kenny reported that Tg mice
contain fewer total spleen cells (3-4 x 107 spleen cells) than their non-Tg littermates (1 x
109 spleen cells) (48), which means that there is a 5x reduction in the number of B cells in
Tg mice compared to non-Tg mice (see Table 16).  I confirmed this observation in the
BALB/c M167µk Tg mice, which also have a reduced number of total spleen cells and
fewer total B cells in the spleen.  Therefore, the effect of the M167µk transgenes on B
cell number does not appear to be regulated by the genetic background of the mice.  This
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reduction in B cell numbers was of great interest because, despite having only 1/5 the B
cells of non-Tg littermates, M167µk Tg mice are more than twice as likely to develop
plasmacytomas due to the presence of the Tg PC-specific receptor.
Table 16. Splenic B cell numbers in M167µk Tg mice.  These numbers were confirmed








Tg 3-4 x 10^7 25% 0.75-1.0 x 10^7
Non-Tg 1.0 x 10^8 50% 5.0 x 10^7
Kenny does not offer an explanation as to why the M167µk Tg mice might have
reduced numbers of total spleen and B cells.  The presence of the rearranged M167µk Ig
transgene has apparently affected the immune system’s ability to regulate B cell
development and maintain a normal number of B cells.  With a significantly reduced B
cell population that is also skewed toward PC-binding antigens, the antigen-binding B
cell repertoire in M167µk Tg mice must be more limited than normal WT mice.
The other major change in the B cell population is an increased percentage of MZ
B cells found in the spleen compared to non-Tg mice.  For the first time in the M167
double transgenic mice, I have presented data that shows that the CD21high/CD23low
marginal zone B cell population is expanded in the C.M167µk Tg mice (15-25% of
129
B220+ cells) compared to non-Tg mice (5-10% of B220+ cells) in Figure 13.   It is the
M167high B cells in M167µk Tg mice that are found in the MZ compartment, as are the
M167+ B cells in non-Tg BALB/c mice.  My observations in M167µk Tg mice agree
with previously published data by Martin and Kearney that show certain B cell clones
like M167 are favored to become MZ B cells (42) and that heavy chain only M167µ Tg
mice, which have an enriched number of M167-Id+ B cells, also have an enlarged MZ B
cell subset (42, 89).
Further calculation reveals that the absolute numbers of MZ B cells are generally
much lower in M167µk Tg mice than in non-Tg mice (Table 17).  Tg mice have 1.5 – 2.5
million MZ B cells compared to the 2.5 - 5 million MZ B cells in non-Tg littermates.
Although Tg mice do not have greater numbers of MZ B cells, a much greater proportion
of the splenic B cells are MZ B cells, which may be potential B cell precursor to pristane
induced PCTs.
Table 17. Absolute number of splenic MZ B in M167µk Tg mice.
atotal splenic B cells calculated in Table 16; bpercentage data from Figure 11
Total number
Splenic B cellsa
% MZ B cells
in Spleenb
Absolute number
MZ B cells in spleen
Tg 1.0 x 10^7 15-25% 1.5 – 2.5 x 10^6
Non-Tg 5.0 x 10^7 5-10% 2.5 – 5.0 x 10^6
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Changes and characterizations of the B cells themselves in M167µk
Variations in M167 BCR density
IgD co-expressed with Tg Ig
Proliferation activity of B cells to aggregated, but not soluble, PC Ag
Significance of proliferation and generation t12;15 myc activating CT
Characterization of the M167µk Tg B cells in our conventional BALB/c mice
turned up some interesting observations and highlighted certain differences from those in
published reports of C57BL/6 M167µk Tg mice.  First, there were variations in the
density of M167 receptor on the surface of Tg B cells, first noted when looking at the
histogram of VH1 expression, which showed two distinct subsets of Tg B cells: VH1
low
and VH1
high (Figure 10). This variation in the surface density of antigen receptors is
particularly important to plasmacytoma studies in the M167µk Tg mice, as these mice
have a larger proportion of splenic B cells with the MZ phenotype.
Figure 14 showed that MZ B cells in Tg mice are among B cells with higher
surface densities of Tg VH1.  This discovery was further extended to include B cells with
a high receptor density of the paired M167 VH1 + Vk24 BCR, specifying the M167
high B
cells such as those that develop the MZ B cell phenotype (as shown in Figure 15).
Secondly, the M167µk Tg mice express surface IgD on most of the peripheral Tg
B cells in the BALB/c study mice, where the original characterization of peripheral B
cells in C57BL/6 M167µk Tg mice distinctly showed a lack of IgD expression (48).  The
M167µk Tg mice used in PCT induction studies co-express the Tg M167µ heavy and
M167k light chains as well as endogenously rearranged IgA heavy and κ light chains.
The presence of sIgD on B220+ cells in M167µk Tg mice (Figure 10) indicated
expression of endogenous IgH.  We know that this IgD must have originated from an
endogenous non-Tg heavy chain, as the M167-IgM transgene does not contain an IgD
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segment.  Endogenous Ig light chains are also likely to be present (as sequencing of
tumor Igs showed both H and L chains were rearranged from endogenous Ig genes).  If
endogenous heavy and light chains on the cell surface pair with the transgenic M167
heavy and light chains, there would be multiple antigen binding specificities present on
each peripheral Tg B cell.  Kenny et al., using B cells from F1 hybrid mice that expressed
two IgM allotypes (IgMa and IgMb), provided evidence that the M167µk Tg B cells were
capable of this mixed pairing of Ig chains on the cell surface using anti-IgMa and IgMb
fluorescent antibodies in flow cytometry.  His lab initially reported that ~10% of the B
cells in C57BL/6 M167µk Tg mice produce mixed molecules (µa + µb) antibody
molecules on their surface (48), coupling one Tg heavy chain and one endogenously-
derived heavy chain to make a single antibody molecule.
One could argue that the C.M167µk Tg mice are expressing endogenously
rearranged Ig genes on most of the B cells because the antigenic stimulation provided in a
conventional colony makes it necessary for adequate immune function.  Expression of
multiple antigen binding specificities would expand the B cell repertoire and guard
against immune incompetence.  However, C.M167µk Tg mice that have been rederived
into an SPF colony have the same percentage of IgD on their IgM+ B cells as the
conventional mice (data not shown), so this may not be a primary reason for co-
expression of the endogenous Ig chains along with the Tg receptor.
Another possibility might be that the endogenous Ig chains are rescuing the PC-
specific M167+ Tg B cells from an autoreactive fate.  Autoreactive B cells are regulated
in one of three ways, depending on what developmental stage the B cell encounters
132
antigen and/or the affinity of the autoreactive BCR for self-Ag: 1) receptor editing, 2)
tolerance induction, or 3) deletion (90).
Sieckmann and Kenny had suggested that the transgenic sIgMhigh sIgDneg B cell
phenotype they reported in B cells from the M167µk Tg C57BL/6 mice was similar to
that of recently emigrated immature B cells from the bone marrow and thus might be
more susceptible to tolerance induction (55, 88).  Tolerance results from an autoreactive
BCR previously encountering antigen during its early developmental stages, and thus the
B cell is rendered non-functional (i.e. cannot proliferate or secrete Ab in response to
antigens).  The increase of PCTs in our conventional BALB/c M167µk Tg mice may be
due to the “rescue” of the autoreactive M167 PC receptor with the additional
rearrangements of endogenous Ig, where otherwise the Tg B cell might exist in a
tolerized state, as suggested by Kenny, and not able to proliferate in the presence of
antigen.  If Tg B cells expressed only the M167µk receptor, there might not have been an
increase in plasma cell tumors due to tolerized autoreactive PC-binding B cells, and there
may have even been a decrease in PCTs.
Further studies by Kenny’s lab suggested this mechanism of receptor co-
expression contributed to the rescue of self-reactive cells from deletion, as autoreactive
anti-PC B cells created in Rag2 -/- M167µk Tg mice are rescued from deletion by
expressing multiple antigen receptors on their cells (91).   In these experiments, because
Rag2 deficient mice are not able to rearrange and express endogenous Ig genes, the Tg B
cells can only express the already rearranged M167µk chains, thus allowing autoreactive
anti-PC B cells to persist.  The autoreactive anti-PC Tg B cells in Rag2-/- mice were
developmentally arrested in the bone marrow, could not secrete antibody, and were
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functionally anergic (or non-functional).  Introducing a second light chain resulted in
mixed molecule BCR expression, where both PC and non-PC specific antibodies were
expressed on the B cell’s surface (91).  The dilution of the autoreactive BCR specificity
with endogenous BCR rescued these cells from a tolerized B cell fate, and allowed them
to be responsive to antigen.  Based on these experiments, it may be that the C.M167µk
Tg mice in my study are re-arranging endogenous Ig genes in order to compensate for the
autoreactive M167-Id PC receptor, as well as to expand their Ig repertoire to deal with
antigens present in a typical conventional environment.
There are further implications involved in the expression of multiple B cell
receptors in regards to mature B cell phenotype.  Two factors have been shown to play
significant roles in determining whether a B cell becomes a mature B-1, MZ, or FO B
cell: (1) the antigen specificity of the BCR and (2) the receptor density of the BCR on the
cell surface (8, 91, 92).  Key experiments using Ig Tg mice with B cells that could dilute
their surface B1 specificity (VH12f, anti-PC) with a B2 receptor (either glD42 anti-DNA
or B1-8 anti-NP) showed that B1 segregation depended on a threshold level of the B1
receptor expression (8).  If the B1 receptor density on the cell surface was diluted below
this threshold density, then the B cell developed a B2 phenotype instead of a B1
phenotype.  Further, comparisons between the receptor density of hemizygous and
homozygous anti-RBCµk Tg mice (with an autoreactive B1 phenotype) showed that
threshold levels of BCR expression are required to regulate not only the number of
peritoneal B1 cells, but also the efficiency of endogenous H+L allelic exclusion (92).
Higher levels of the B1 receptor in the homozygous mice more efficiently inhibited
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endogenous H + L gene expression and also created a larger peritoneal B1 compartment
(thought to be a reflection of enhanced signals through sIg by the RBC self-antigen (92)).
These two examples of receptor dilution in Ig Tg mice reflect what I believe is occurring
in the C.M167µk Tg mice, as it is the B cells with a high surface density of PC-specific
M167-Id (i.e. the ones without multiple antigen receptors from endogenous Ig) that
become MZ B cells, resulting in a population of B cells more quickly activated by PC
antigen due to their hyper-activated phenotype.
Antigen-driven proliferation of B cells is a key factor in generating t(12;15)
chromosomal translocations during plasma cell tumor development.  It was necessary to
investigate the proliferative capability of the M167µk Tg B cells, as Kenny’s group
suggested that tolerance induction was occurring in the IgMhigh, IgDlow Tg B cells.
Previous studies done in C57BL/6 mice had shown that M167µk Tg B cells
respond normally to both in vivo (48) and in vitro (87) immunization with T-cell
dependent PC-KLH.  However, the M167µk Tg B cells failed to proliferate when treated
with soluble anti-IgM, anti-M167 idiotype, or other anti-IgG antibodies (55, 88).  In vitro
assays that I performed with the conventional BALB/c M167µk Tg B cells using soluble
anti-IgM and anti-M167 antibodies to activate B cells through BCR cross-linking
experiments also failed to stimulate proliferation.  Further, my initial immunization
studies in C.M167µk Tg mice with PnC and low amounts of ultra-centrifuged, soluble
PC-KLH failed to produce stimulation of an anti-PC antibody immune response.
Caulfield and Stanko had previously demonstrated this lack of B cell responsiveness to
PnC antigen, a T cell independent type 2 antigen, in C57BL/6 M167µk Tg mice.
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However, the B cells were able to respond if the PnC was presented as an
antibody/antigen complex (PnC/T15 immune complex) (86) and further evidence
suggested that this lack of responsiveness to PnC was not a result of tolerance in Tg B
cells, but rather was due to a lack of T cell help (86).  I was able to initiate Ab response to
PC using PnC/T15 complexes in the BALB/c M167µk Tg mice, but not using soluble
PnC.
The in vivo immunization experiments I carried out in conventional BALB/c
M167µk Tg mice and the in vitro proliferation assays on M167µk Tg B cells using
various PC antigen to stimulate the M167µk BCR are summarized in Table 18.  The
results of these experiments showed that the M167 BCR in C.M167µk Tg mice was
indeed functionally able to respond to various T-dependent particulate PC antigens and
PC+ bacteria by initiating both antibody secretion and B cell proliferation.  The anti-
M167 sepharose conjugated antibodies that crosslink the Tg BCR and particulate PC+
bacteria stimulated splenic B cells to proliferate an average of 3 cell cycles after three
days in vitro, most of the proliferation likely due to the MZ B cells, as there were no T
cells present in the cultures.
This proliferative capability of C.M167µk Tg B cells to respond to PC antigen
was an important point to demonstrate as repeated and vigorous proliferation is thought
to be necessary for the generation of t(12:15) chromosomal translocations found in PCTs.
I am suggesting that environmental/autogenous PC antigen increases the number of
activated, proliferating B cells from the pool of anti-PC M167µk Tg B cells, leading to
increased plasma cell tumor development.  Dendritic cells may also play an important
role by providing a stable source of antigen that stimulates the further rounds of B cell
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proliferation (93) necessary to generate the t(12:15) chromosomal translocation that
deregulate the myc gene.
Table 18. Functional Studies of M167µk Tg BCR.  In vivo anti-PC antibody
production.  Antigens used to test for production of anti-PC antibody responses:  PC-
conjugated hemocyanin (PC-Hy); pneumococcal C polysaccharide (PnC); LB4 is a PC-
containing antigen from French-pressed extracts of Lactobacillus sp.4.  In vitro
proliferation studies.  PC-antigens and antibodies to cell surface receptors found on
M167µk Tg B cells used to stimulate proliferation of splenic cells in vitro.
Functional Studies of M167µk Tg BCR
Anti-PC Ab ResponseIn Vivo Immunization Studies M167µk Tg Non-Tg
PC-Hy (PC-hemocyanin, a TD Ag) –/+ +
PnC (pneumococcal C polysaccharide, a TI Ag) – +
R36A S.pneumoniae heat killed bacteria + +
PnC/T15 or LB4/T15 Immune complexes + +
Pristane – –
Pristane with IFA – –
Pristane with PC-Hy/IFA (TD Ag) – +
Cell ProliferationIn Vitro Proliferation Assay M167µk Tg Non-Tg
Rat anti-M167-id sepharose (28-5-15) + –
Goat anti-IgM sepharose + +
PC-sepharose + +
R36A heat-killed bacteria + –
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PC Antigens likely to bind to and stimulate M167µk BCRs and trigger proliferation
(autogenous vs. exogenous)
Antigen has been implicated as having an important role in plasma cell tumor
development, as it initiates an immune response that ultimately leads to B cell
proliferation that is essential for the chance generation of the oncogenic t(12:15)
chromosomal translocation.  The link between PC antigen and plasmacytoma
development was established early on, when immunoglobulins from a number of
individually derived PCTs were identified as having a common specificity for PC (the
best known are T15, M603, and M167).   Gut flora provides the largest source of PC as
well as the other bacterially derived antigens identified as targets for PCT
immunoglobulins.  The PC hapten plays an important role in the immune system’s
attempts to protect itself against microbial infections, and normal BALB/c mice have a
plentiful supply of natural antibody-producing B cells, particularly of T15-Id+ B1 cells in
the peritoneal cavity, that are specific for PC antigen.
Autogenous PC antigen may be an important source of immune stimulation
during plasma cell tumor development.  Apoptotic cells are one such source, recently
demonstrated by researchers to present PC on the surface of apoptotic blebs (94) and
available for presentation to immune cells and anti-PC antibodies.  Apoptosis occurs
throughout the body during the normal processes of immune regulation and
inflammation.  The oil granuloma, as an inflammatory tissue, produces an abundance of
apoptotic cells.  Oxidatively modified low density lipoproteins (LDLs), also found in
inflammatory lesions, express PC groups (38) and are another possible autogenous source
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of PC antigen that could stimulate an immune responses during plasma cell tumor
development.
A recent and important finding that various forms of PC-specific antibodies,
including M167 and T15, recognize the PC hapten on apoptotic blebs and modified LDL
(37) provides another connection between these autogenous antigens and pristane-
induction of plasmacytomas.  One of my original premises was that pristane might, at
least indirectly, be an initiator of B cell immune responses in PCT development by
creating antigen in the form of apoptotic cells and/or oxidatively modified LDLs during
the formation of OG tissue.  With the large population of the dominant anti-PC clones
present in the M167µk Tg mice, I thought an antibody response to PC might be
detectable.  Pristane was not an effective stimulator of the anti-PC immune response in
either M167µk Tg or non-Tg BALB/c mice, as there were no detectable changes in anti-
PC antibody response in either group.  However, since my studies were limited, this
needs to be more fully investigated.  Therefore, the primary role of the oil granuloma in
plasma cell tumor development may not lie in generating PC antigen that triggers B cell
activation, but in providing a cytokine-rich environment for the circulating plasmablasts
to survive, to proliferate, and to be exposed to oxidative stress that is potentially
important in creating t(12;15) chromosomal translocations.  Apoptotic cells and/or
oxidatively modified LDLs generated in the inflammatory tissue of the OG may be a
secondary source of PC antigen initiating B cell proliferation in plasma cell tumor
development, but more likely, the primary source of PC is from environmental bacterial
antigens.
139
For a number of reasons bacterial antigens (particularly the PC-containing
bacterial antigens in C.M167µk Tg mice) are thought to be the most likely principal
stimulus of B cells that become PCTs after induction with pristane.  There is the dramatic
decrease in the incidence of PCTs that occurs in BALB/c mice housed in SPF colonies,
where sources of bacterial antigen are stringently restricted.  Many PCTs have been
shown to make monoclonal Igs with specificity for a variety of TI type 2 bacterial
antigens found in the gut (95).   And importantly, one such Ig against the bacterial PC
antigen, M167, has now been shown to increase the number of PCTs induced by pristane
when it is displayed as the dominant BCR on B cells in C.M167µk Tg mice.
The predominant usage of IgA by the M167µk Tg and non-Tg PCTs is another
indication that gut microflora are involved in the initial immune activation of B cell
precursors.  Hypermutated secretory IgA plays an important role in defense against
microbial invaders and in maintaining the commensal bacteria in the gut (23, 96).
Normal IgA secreting cells are found at mucosal linings in the respiratory and intestinal
tracts where they provide a protective barrier of secreted IgA molecules.  And
interestingly, 50% of the IgA-secreting plasma cells in the mucosal lining of the intestine
are B1 cell derived (97, 98).
Clues from the Igs produced by PCTs in M167µk mice
Plasma cell tumors are a reflection of the susceptible B cell population.  By taking
a careful look at the Ig proteins produced in PCTs derived from M167µk Tg and non-Tg
control mice, we can get some idea about the B cells that originated the tumors. Sera and
cells were studied from primary (g0) PCTs from Tg mice, as well as from PCTs from Tg
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mice that had been transplanted (g1) into non-Tg BALB/c mice.  Analysis included
determining the amino acid sequence of secreted Ig proteins found in ascites, as well as
sequence analysis of both transgenic and endogenously rearranged Ig genes from tumor
mRNA in Tg PCT cells.
 One expectation from study of tumor serology was that the tumors produced in
Tg mice would secrete a large amount of monoclonal M167 protein.  But this was not the
case.  Instead, I found that the panel of Tg PCTs produced a variety of monoclonal (M)
protein components with different electrophoretic mobilities, instead of each tumor
producing the same large M167-IgM band.  This indicated that the Tg PCTs were
secreting Ig molecules other than the one controlled by the M167µk transgene.   There
are no switch sequences in the M167µ construct to allow for isotype switching of the
transgene.  Therefore, since many of the M components seen on the SPE gels had what
appeared to be gamma (γ) mobility (Figure 18), this suggested the Tg tumors were
producing Ig proteins using endogenous Ig genes.
It was not possible to detect a separation of M167µk product from endogenous Ig
products using the serum protein electrophoresis, but further testing of ascites for the
M167 idiotype by ELISA showed that M167 protein is, in fact, being secreted by the Tg
PCTs, but not as the predominant antibody species.  PCTs from Tg mice, but not the non-
Tg controls, secrete a PC-binding M167 antibody protein (Figure 20).  An unexpected
result from isotyping the PCT ascites was that the majority of Tg PCTs also secreted IgA
M-component antibodies, in addition to IgM from the M167 Tg.   The isotyping data
from ELISA supported the electrophoretic evidence that other Ig isotypes were being
expressed, as most of the Tg PCTs had high levels of IgA protein present in the ascites.
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Immunohistochemistry on cells from Tg PCT#58 provided a clear example of an
individual PCT cell that secreted the M167-id antibody and both IgM and IgA antibody
species (Figure 21).  The M protein from endogenously rearranged genes appears not to
have PC specificity, as demonstrated in the example of PC-immunoprecipation of Tg
PCT #37 ascites.  Only IgM antibodies, and not the IgA, precipitated with PC antigen
(Figure 22).  Even if PC antigen were the original activator of the Tg M167 BCR in these
Tg PCTs, as supposed, the endogenous Ig expressed by the B cell precursor is likely
passively produced by the plasma cell tumor as the ‘natural’ Ig of the B cell, even though
it’s antigen specificity is not related to PC antigen.
To conclusively prove that the IgA proteins being produced were from
endogenous Ig genes, I sequenced the rearranged IgA sequences from tumor mRNA.
Endogenously rearranged Ig transcripts in M167µk Tg PCTs were present and, in almost
every case, were IgA isotype.  Table 7 reported the variety of VH and Vk genes utilized
by the endogenous Igs in M167µk Tg PCT, but their antigen specificities is not known.
Based on gene analysis alone, none appear to be PC-binders, with the possible exception
of #114 Tg.  Further analysis of M167µk Tg PCTs, revealed that 80% of the endogenous
Ig genes were somatically hypermutated, indicating that a large number of the B cell
precursors probably went through mutational processes in germinal centers of follicles,
while the remaining 20% of PCTs had both VH/Vk germline Ig genes.  This same 80% to
20% ratio of mutated to germline Igs also occurred in PCTs examined from the non-Tg
(WT) BALB/c control group, as well as from C.B20 mice, which carry the C57BL/6 IgH
loci.
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Somatic hypermutation (SHM) and class switch recombination (CSR) of Ig genes
are considered hallmarks of GC reactions and both are dependent upon the expression of
activation-induced cytidine deaminase (AID) (99, 100).   AID initiates the mutation of Ig
genes by deaminating DNA (converting cytosine to uracil nucleotides within the V
region), which is then “repaired” using error-prone DNA polymerases and/or mismatch
repair enzymes.  AID is specifically found in germinal centers where both SHM and CSR
occur simultaneously in B cells with the assistance of T cells.  Antigen activation of B
cells through the BCR and subsequent CD40 interactions with CD40L on T cell initiate
both processes.  Transcription of DNA and DNA cleavage are also essential elements
involved in both CSR and SHM, but the DNA repair mechanisms differ (100).
Interestingly, even though both SHM and CSR occur in the same time and place, they can
occur independently from one another.   Isotype switched Igs do not have to have SHM
(and vice versa) (100), as is reflected in the IgA derived from PCTs, as 20% had germline
genes in both the VH and Vk chains.
Curiously, the M167µk Ig Tgs are not mutated.  There are several possible
explanations as to why the M167µk Tg complex does not undergo SHM.  One reason
may be a low transcription rate associated with the transgenes.  The first and essential
step in SHM is transcription of the targeted Ig DNA, where the Ig enhancers are generally
thought to be necessary for targeting SHM to the Ig V gene (101).  Genes with high
transcription rates, such as those of Ig genes in activated B cells, may be more likely to
become mutated by AID, as suggested by Martin and Scharff (69).  The M167µk
transgenes may have a low transcription rate, and therefore have little to no mutation,
because the DNA is not accessible to AID.  I am uncertain of the status of promoters and
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enhancers included with the M167µk transgenes.  However, Storb et, al. reports high
levels of splenic RNA expression in early generations of the founder M167µk Tg mice
(102).  Further, although there may be B cell specific factors involved in targeting AID to
the V region of Ig genes, they are as yet unknown.  Therefore, another possibility for the
lack of somatic hypermutation may be because the transgenes do not provide a target
sequence for AID.
Finally, the transgenes may actually be mutated, but the mutant sequences cannot
be detected from mRNA analysis.  The reason for this may be due to the multiple copies
of the M167 H + L chain genes that were integrated into the chromosome.  If any of the
numerous transgene copies were mutated, transcripts from the mutated copy could be
obscured by transcription from multiple copies of unmutated transgenes.
Therefore, despite its direct effect of creating an enlarged splenic MZ B cell
population that is associated with non-germinal center TI immune responses, the M167µk
Tg BCR does not appear to influence somatic hypermutation events that occur in the Ig
of PCT precursor B cells.
Why and how M167µk Tg did not decrease, but increases incidence of PCT
The M167µk Tg creates an increase in the incidence of PCTs by putting
proliferative stress on the available B cell population, forcing them all to react with the
same environmental antigen, PC, which is very abundant in a conventional mouse
colony.  PC-containing particulate bacteria and immune complexed bacterial antigens can
induce proliferation of a greater number of functional B cells in M167µk Tg mice than in
non-Tg mice.  This large-scale B cell proliferation occurs within a stressful inflammatory
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environment induced by pristane that likely causes systemic effects on regulation of
lymphoid proliferation, SHM, and isotype switching, such as changes in cytokine levels
throughout the animal.  MacLennan, et al. (93) has shown that activated B cells that turn
into plasmablasts need dendritic cells to differentiate into the end stage plasma cells.
This requirement may effectively be a bottleneck to the response in Ig Tg mice where a
large number of Tg B cells are activated, as speculated by Qian et al. (103).  Most antigen
specific B cells die as plasmablasts because they are unable to associate with dendritic
cells.
An autoreactive Ig Tg, one not rescued by co-expression of endogenous Ig, would
likely have reverse affect on the incidence of PCTs, decreasing or suppressing their
development altogether.  B cells that were tolerized due to their autoreactive nature
would not be able to react to antigen and undergo proliferation necessary for progression
to PCTs.  The M167µk Tg also creates an excess of splenic MZ B cells, as well as a
homogenous PC-specific B1 population, that exist in a pre-activated state and are ready
to collectively and rapidly respond to bacterial (PC) antigens.
Can the greater percentage of M167-id+ MZ B cells seen in the spleen of M167µk
Tg mice explain the increases in pristane induced PCTs?  It is possible that both PC-
specific MZ and B1 B cells are particularly susceptible precursors of PCTs due to their
hyper-activated phenotype that responds particularly well to bacterial antigens.  Splenic
MZ B cells are strategically placed at the blood-lymphocyte border in the spleen where
exposure to endothelial cell and professional antigen presenting cells, such as
macrophages and dendritic cells, assist their function to filter blood-born antigens (15).
The MZ B cells exist in a “pre-activated” state that allows them to respond with rapid and
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intense plasmablast production to viral and bacterial blood-borne antigens (15, 89, 104).
MZ B cells, in contrast to recirculating FO B cells, are able to generate plasma cells faster
in response to T-cell independent polyclonal activators, such as LPS (104), and respond
more rapidly to bacterial T-cell independent antigens (89).  The MZ B cells differentiate
into plasma cells within 3 days of stimulation, whereas it take at almost 2 weeks for FO B
cells to generate peak T cell dependent immune responses in GCs.
Splenic MZ B cells have similar functional abilities as B1 cells, found
predominantly in the peritoneal cavity and also in the spleen (see appendix for a
comparison of B cell types).  Both MZ and B1 B cells normally have low affinity,
polyreactive B cell receptors with a broad range of antigen specificities, particularly
against TI type 2 bacterial polysaccharide antigens and self-antigens.  Specific B cell
clones are selected into the MZ or B1 subsets based on antigen interaction with the BCR
and the strength of their BCR signaling.  Each of these subsets shows signs of this
previous interaction with antigen, which is reflected in upregulation of various activation
markers.  B1 cells, in particular, have been shown to be selected through interaction with
self-antigens (105), but at least one MZ clone (M167) has been identified that can bind
autoantigens on oxidatively modified low density lipoprotein (LDLs) and apoptotic cells.
Instead of being deleted, receptor edited, or tolerized because of their autoreactive
natures, B1 and MZ B cells are sequestered to special microenvironments where local
regulatory factors keep these cells in check, so that the B cell clones are available to help
protect against bacterial and viral infections.
Current dogma suggests that B1 and MZ B cell subsets are a part of the first line
of defense by providing early immune responses against bacterial antigens in the
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peritoneum/gut (B-1 B cells) and blood-born antigens (MZ B cells) (106). Located at
sites such as these, where they can encounter bacterial antigen early and help prevent
systemic infection.  Because of their anatomical locations and their ability to respond
early and rapidly to pathogens, MZ and B-1 B cells are considered to be a bridge between
the immediate reactions of the natural innate immunity and the slower, adaptive immune
responses of follicular B cells that generate high affinity antibodies and establish immune
memory.
Monoclonal immunoglobulins from a number of PCTs have been shown to have
T-cell independent antigen specificity for numerous microorganisms found in gut flora,
food, and bedding (95).  New studies suggest the MZ and B1 cells that are optimized to
respond to bacterial TI type 2 antigens are linked together during immune responses, as
the presence of both cell subsets seem to be required for the production of specific IgM in
response to different repetitive polysaccharide antigens (107).  These experiments using
splenectomized mice, show that the presence of the spleen, including the MZ B cells, is
not sufficient for an adequate response to TI-2 antigens in mice where B1 cells are
absent.  Conversely, mice possessing B1 cells but lacking a spleen and MZ B cells also
show an impaired response to the TI-2 antigen TNP-Ficoll after intraperitoneal
administration (108).   These data imply a close relationship between MZ and B1 cells
and include them both as connected precursor populations for PCTs in BALB/c mice.
Peritoneal B1 cells are ideal PCT precursor candidates due to their location in the
peritoneal cavity, their enhanced ability to respond to bacterial antigens, and their
involvement in providing 50% of the IgA-secreting plasma cells and secreted IgA in the
gut (44, 45).  In addition, although most of the B1 cells are located in the peritoneal
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cavity and to a lesser extent in the spleen, it has been suggested that B1 cells are able to
migrate to sites of infection (107).  Wardemann, et al. detected B1 cells in the peripheral
blood (107) and B1 cells have also been found in the lungs of mice after infection with
influenza (109). The ability of B1 cells to circulate via the blood to sites of infection
could be an important mechanism to prevent systemic infection of invading pathogens.
The TEPC15 plasmacytoma would be a perfect example of having originated from a B1
cell, in as much as Masmoudi et al. demonstrated that Igs with the T15-id are produced
by the B-1 cell subset (43).
It is my belief that the original MOPC167 PCT (with the M167-idiotypic BCR)
was derived from a splenic MZ B cell, as this receptor idiotype characteristically
develops a CD21high, CD23low, IgMhigh, IgDlow phenotype and is enriched in the MZ
subset of the spleen.  Despite their remote location from the site of plasma cell tumor
development, MZ B cells are potential precursors of pristane-induced PCTs.   MZ B cells
would rapidly be activated during the later stages of infection, once bacteria had entered
the bloodstream trying to spread throughout the body.  Local effects of pristane in the
peritoneum may contribute to the release of gut bacteria into the circulatory system of
blood and lymph.  Blood-derived dendritic cells (DCs) can also carry bacterially-derived
antigen from sites of infection to the marginal zone of the spleen where the presented
antigens can activate MZ B cells, T cells and macrophages (110).
My results from the pristane induction study in C.M167µk Tg mice provide new
evidence to support the hypothesis that MZ B cells are highly susceptible precursors.
Having an enlarged PC-binding M167-Id+ MZ B cell population and greater than 97% of
the B cells expressing varying levels of the anti-PC M167 BCR, the C.M167µk Tg mice
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are twice as susceptible to PCT induction as non-Tg BALB/c mice.  It would be of great
interest to test Ig Tg mice with an anti-PC T15-id transgene in a plasmacytoma pristane
induction study to see if the B1 derived T15 B cell receptor would increase the incidence
of plasmacytomas, as does the MZ-derived M167 BCR.  I predict that it would.
Therefore, I suspect that the best candidates for PCT precursor B cells are hyper-activated
B1 cells of the peritoneal cavity and spleen and splenic MZ B cells.
What might happen during plasma cell tumor development to a MZ B cell once it
is activated by (PC) antigen?  Within hours of antigen stimulation, activated MZ B cells
move out of the marginal zone and within 3 days either become plasma cells in the red
pulp or enter the B-T cell border of follicles and become rapidly dividing plasmablasts
(111).  MZ B cells can also enter the B-T follicles, but not much is known about the MZ
B cell immune responses in germinal centers. MZ-derived plasmablasts from the spleen
might then travel via the lymphatic system into the peritoneal oil granuloma tissue, where
they could continue proliferating and complete their oncogenic transformation into
plasma cell tumors under the pressure of oxidative stress and increased availability of
cytokines such as IL6.
SHM in potential MZ precursors
Most of the Igs from C.M167µk Tg PCTs (80%) were hypermutated, indicating
antigen selected B cell precursors.  Antibody mutations normally occur in germinal
centers (GC), and SHM, affinity maturation, and isotype switching are generally accepted
hallmarks of T-cell dependent GC processing (112, 113).  The TD immune responses
generate GCs over a period of at least 2 weeks.  In newly formed germinal centers, VH
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genes in B cells have few to no mutations (112, 113).   Cells generated in the GCs during
this initial period of B cell growth could explain the lack of SHM in the remaining 20%
PCTs if they arose from GC B cells.
I suspect that the hyper-activated B1 and MZ B cells are particularly susceptible
precursors to PCTs, both being optimally responsive to T-cell independent (TI) bacterial
polysaccharide antigens.  But how does one explain that 80% of Igs produced in PCTs
are mutated when it is generally thought that TI immune responses do not generate SHM
since they do not receive T cell help in GCs?  TI immune responses provide short-term
antibody production, fail to induce GC formation (with a few exceptions), do not
generate memory or affinity maturation, and have a more restricted Ig isotype profile
(which is mostly IgM and IgG3 in mice) (114).  There is some evidence that certain types
of T-cell independent (TI) antigens, such as bacterially derived α(1→6)dextran, can
initiate the formation of GCs (115, 116).
Studies in rats have shown that the MZ compartment in spleen contains memory
B cells generated from immune response to both TD and TI type 1 antigens (117-120).
The memory B cells in the MZ have been derived from B cells that have undergone
antigen-driven proliferation.  They are no longer in cell cycle but can be induced to re-
enter cell cycle by subsequent exposure to antigen. These B cells have a phenotype
characteristic of other marginal zone B cells.   In addition, there is another subset of MZ
B cells that respond to the repetitive polysaccharide TI type 2 antigens, but these do not
generate B cell memory (117).   In rat MZ B cells, most VH genes are germline (naive
MZ-B cells) but a minor fraction (about 20%) of the MZ-B cells carry somatic mutations
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(memory MZ-B cells).  Human splenic MZ B cells include highly mutated post-switched
memory MZ B cells (121-123).   In mice, MZ B cells may be recruited directly from
immature B cells (42), but memory B cells from germinal centers can also colonize the
MZ (14, 119).   The memory B cells that populate the MZ and adopt a MZ B cell
phenotype (IgMhigh, IgDlow, CD21high) are associated with a responsiveness to TI type 2
polysaccharide antigens (14).  This study showed that IgM+ memory B cells in mice are
recruited into TI-2 antibody responses (14).
Marginal zone B cells are not restricted to TI Ab responses.  Song (124) provide
evidence that MZ B cells also respond to TD antigens with 1) early antibody forming cell
responses and 2) GC/memory responses.   Each of these MZ B cell responses originates
from different MZ precursors in what appears to be a heterogeneous population.
Interestingly, the GCs derived from MZ B cells were similar to those derived from FO B
cells, with respect to the usage of VH genes, level of SHM, and production of secreted
antibody.  Further, recent research on SHM and isotype switching in extrafollicular
immune responses suggests that it is possible for TI immune responsive MZ B cells to
generate hypermutated Igs.
These studies support the idea that MZ B cells can generate the types of
hypermutated Igs that have been found in plasma cell tumors from in pristane-induced
BALB/c mice.  Figure 37 depicts the specialized B cell subsets found in the spleen and
peritoneal cavity, and the highlights the MZ B cells’ potential as precursors of
plasmacytomas.
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Figure 37. Marginal zone B cells are potential precursors of peritoneal
plasmacytomas.  Marginal zone (MZ) B cells have a preactivated phenotype that enables
them to quickly respond to blood-born bacterial antigens, particularly the TI-2 type
polysaccharide antigens that the Igs from PCTs are known to bind.  In large part, the
splenic MZ B cells in mice are BCR-selected with polyreactive, germline Igs that are
typically derived from naïve B cells.  However, a small subset of these MZ B cells are
now shown to be hypermutated memory B cells, selected from the follicular B cells (FO)
that were previously antigen selected and hypermutated during T cell dependent (TD)
processing in germinal centers (GC).  These mutated memory B cells that are responsive
to TI-2 bacterial antigens can take up residence in the MZ and adopt a MZ B cell
phenotype.  Upon activation by antigen, the MZ B cells rapidly divide and become
plasmablasts within 1 – 3 days.  This rapid division and differentiation process could be a
potential opportunity for developing oncogenic mutations.  B1 cells are also a
polyreactive, BCR-selected subset that responds to TI-2 bacterial antigens that end up
sequestered in the peritoneal cavity instead of the marginal zone.  The B1 cells are of
considerable interest as PCT precursors due to their location, as plasmacytomas develop
within the pristane-induced oil granuloma tissue in the peritoneal cavity.  It is not
inconceivable, however, that once MZ B cells have been activated by blood-born antigen
in the spleen, they leave the MZ, enter the circulation and end up in becoming trapped in
the peritoneal cavity milieu of the oil granuloma.
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IgA in PCTs
In addition to most of the Igs being hypermutated, nearly all of the
plasmacytomas from both Tg and non-Tg C.M167µk mice secreted a rearranged
immunoglobulin expressing the IgA isotype.  Conventional thinking about Ig
hypermutation and class switching is that these processes must occur in a T-cell
dependent manner in the germinal centers of lymphoid tissue.
Generation of IgA+ B cells occurs in germinal centers of intestinal Peyer’s
patches (PP) and are the precursors of the IgA secreting plasma cells in the lamina
propria of the gut (96, 125).  Gardby et al. found that somatically hypermutated mucosal
gut IgA against T-cell dependent antigens can occur without GC formation in PPs, as
demonstrated in studies with mice that cannot form GCs (126).   In addition to the T-cell
dependent induction of IgA in PPs, new studies report a primitive mechanism of IgA
class switching against commensal bacteria that is independent of T cell help and occurs
outside of germinal centers in gut tissues (127).   In this manner, a large part of the
intestinal IgA against cell wall antigens and proteins of commensal bacteria is derived
mostly from B1 cells without germinal center formation or the help of T cells.  This GC-
and T-cell independent generation of IgA is probably assisted by mucosal dendritic cells
and stromal cells (96).
T-cell independent CSR can occur in human B cells though the interaction of
BlyS (B-cell-activating factor) on cytokine-activated DCs and its receptor BR3 on B
cells.  The B cells of the MZ and intestinal lamina propria are able to class switch in this
manner (100, 128).  IgA production has been documented in patients with CD40L-
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defiencies, which suggests that the B-T cell CD40/CD40L interactions are not absolutely
necessary in CSR (100, 129, 130).
The recent data that CSR and SHM is possible without T cognate interactions
supports the theory that Ag-activated B1 and MZ B cells stimulated by TI polysaccharide
antigens could be a source of these plasmacytomas with somatically mutated IgA
antibodies without requiring the B cell precursors having to migrate to germinal centers.
The B-1 cells, which provide 50% of the IgA secreting plasma cells in the gut (98) appear
able to migrate to sites of infection in other mucosal tissues, and the MZ B cells of the
spleen are both cell subsets that are hyper-activated to quickly respond to TI bacterial
antigens and able to differentiate into plasmablasts faster than the normal recirculating
FO B cell.
Preferential switching and differentiation to IgA secreting plasma cells is assisted
by stromal cells in the lamina propria that secrete cytokines involved in IgA+
development, such as IL6, TGF-β, and IL10 (131).  Pristane oil granuloma provides a
rich source of these kinds of cytokines, especially IL6 and TGF-β.  Pristane may have an
effect on the overall immune system responses, such as deregulating expression patterns
of cytokines, causing IgA switching to occur in areas other than the normal GCs of
Peyer’s patches in the intestine.  Antigen stimulated MZ B cells may undergo IgA isotype
switching due to these influences.
In order for IgA secreting plasmacytomas to develop in the OG, the IgA-secreting
B cells/plasmablasts must leave the site of original antigenic stimulation, circulate, and
end up trapped in the rich environment of the oil granuloma tissue. The oil granuloma
may preferentially sequester IgA+ B cells if they express other IgA homing chemokines,
154
such as TECK/CCL25 or MEC/CCL28 or CXCL12.  TECK (thymus-expressed
chemokine) is normally expressed within the epithelial crypts of the small intestine, and
preferentially attracts IgA-, but not IgG- or IgM-expressin B cells from spleen, PPs, and
mesentery lymph nodes (MLN) (132).  MEC (mucosal-associated epithelial chemokine)
is expressed on other types of mucosal cells and also preferentially attracts IgA+, but not
IgM+ or IgG+, B cells.   IgA+ B cells express α4β7 integrin and home to the cells that
express MADCAM-1 (mucosal addressin cell adhesion molecule 1), such as high
endothelial cells in the lamina propria of the gut.
Uniqueness of PCT induction in M167 compared to VH12 and VH2-12 Ig Tgs
In addition to the C.M167µk Tg mouse, I have conducted pristane-induced
plasmacytoma studies on several other BALB/c Ig transgenic mouse lines, including
C.VH12µ Tg and C.VH2-12µ Tg mice.  The majority of B cells in VH12µ Tg mice
display the VH12/Vk4 anti-phosphatidylcholine B1 cell receptor (50) and VH2-12µTg
mice display an autoreactive anti-Sm B1 cell receptor .  What I have discovered thus far
is that Ig transgenes do not universally affect the susceptibility of BALB/c mice to
plasmacytomas.  Only the anti-PC M167 receptor caused an increase in PCTs, while anti-
PtC and anti-Sm receptors have not effected any changes in PCT incidence.
What is the key factor regarding a specific BCR that increases or decreases a B
cell’s susceptibility to PCTs?  It may be due to the particular type of antigen specificity
conferred by the B cell receptor, such as autoreactive BCR that can react to an auto-
antigen.  Alternatively, it might be a function of the mature B cell phenotype (B1, MZ or
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FO) that was positively selected due to strength of antigen signaling though the BCR
during the maturation process.
Because its VH12 heavy chain preferentially pairs with endogenous Vk4 light
chain, VH12µ Tg mice express a PtC-specific BCR on most of the B cells (50).  In
addition to having a single antigen specificity for PtC, all the peripheral B cells with anti-
PtC activity display a CD5+ B1 cell phenotype, making the these B cells interesting
precursor candidates for PCT induction.  And much like anti-PC B cells, normal mice
have a naturally abundant number of peritoneal B cells that are specific for PtC (5-15%
of the B cells).  Unlike the M167µk Tg, repeated pristane plasmacytoma studies in anti-
PC BALB/c VH12Tg mice failed to produce a significant increase in development of
PCTs.
Interestingly, unlike the various PC-specific antibodies studied, the VH12/Vk4
anti-PtC antibodies do not stain apoptotic cells nor are the anti-PtC B cells activated by
apoptotic cells (103), even though selection into the B1 compartment indicates positive
selection from some source of auto-antigen (105).   Perhaps the source of
exogenous/autogenous PtC antigen is not as an abundant or available as PC and,
therefore, less likely to stimulate a generalized proliferation of the Tg anti-PtC B cells.
Alternatively, CD5+ cells are proposed to have previously encountered antigen, and are
being negatively regulated by its expression in order to control polyreactive or
autoreactive B cell receptors.  The expression of CD5 on Tg+ B cells throughout the
VH12µ Tg mouse may keep an overall proliferation of the anti-PtC B cells in check in
the case of pristane-induced plasmacytomas.
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The VH2-12 Tg mouse produces an autoreactive B1 phenotype with specificity
against the ribonucleoprotein Smith antigen (Sm) that is associated with apoptotic blebs
from the late stages of apoptosis (103).  Positively selected anti-Sm B1 cells in the
peritoneum are functional and can respond to antigen.  In this case, Qian et al. (103) have
demonstrated that apoptotic cells specifically activate Sm-specific MZ B cells in the
spleen and the B-1 cells in the peritoneum.  However, many of the splenic anti-Sm B
cells exist in a transitional state and do not fully mature.  Those B cells that do mature
have low affinity for Sm and are tolerized to antigen.  However, the Sm antigenic
specificity conferred by this Ig transgene also did not alter the incidence of
plasmacytomas that develop in BALB/c mice.
Using these three examples of receptor antigen specificity (PC, PtC, and Sm), it
seems probable that particular kinds of antigens are more likely to stimulate a B cell
immune response during pristane induction that result in PCTs.  Antigen accessibility
may play an important role in determining which varieties of B cell receptors are more
likely to increase PCT development. The type of antigen specificity of the BCR displayed
on the B lymphocyte cell surface may play the primary role in determining whether a B
cell is more or less susceptible to becoming a plasma cell tumor under pristane
conditions.  This scenario would require that sufficient antigen was available to signal
through the BCR and stimulate the number of rounds of proliferation necessary to give
rise to the illegitimate recombination process involved in t(12:15) chromosomal
translocation formation.  However, if the antigen specificity of the BCR were highly
autoreactive, as in the case of the anti-Sm mouse, peripheral B cells would be in a
tolerized state having encountered antigen during development.  The functional
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autoreactive B cells are found in privileged compartments such the peritoneum or
marginal zone of the spleen where they can be regulated by local factors.  The impact of
the BCR on what developmental stage or functional state a B cell is able to reach is a
confounding factor.
T15-idiotype in normal mice vs. M167µk Tg mice
The expression of the M167µk Tg product alters the normal immune response to
PC antigen in Tg mice because their PC-binding B cell repertoire is different than
BALB/c non-Tg mice.   In BALB/c wild-type mice, the primary anti-PC antibodies
utilized during an immune response to PC are T15 idiotype antibodies, which use the
unmutated, germline VH1 heavy chain and the Vk22-33 light chain (61, 78, 80-83).
Other strains, such as C.B20, do not have this inherent ability to mount a T15 antibody
response.  The T15 idiotype is not utilized by endogenous Ig during immune responses in
C57B/6.M167µk Tg mice after immunization with PC antigen (48, 54).   In normal
BALB/c mice, the T15 idiotype may be the more expanded PC antibody because it has a
higher affinity for PC than M167-id antibodies (133, 134).   M167-id+ PC-antibodies are
selectively amplified in M167µ Tg mice in an Ag-driven, receptor-mediated process,
resulting in a 100-500x higher number than expected from random pairing with other
endogenous L chains that could also result in PC-binding antibodies (49, 91).  In M167µ
Tg and M167µk Tg mice, Kenny has shown that the Tg M167µ heavy chain can
associate with Vk22 light chain to form a T15-id, but this clone has little to no affinity for
PC.  According to Kenny’s hypothesis that PC-binding B cells need to encounter
environmental or autologous PC antigen in the presence of low levels of cytokines, these
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non-PC reactive T15 B cells cannot be clonally expanded.  This explanation makes sense
as to why there are no T15 antibodies seen in immune responses in M167µ or µk Tg
mice.
It would be interesting to test anti-PC T15 Tg mice in a pristane induction study
to see if the T15 antigen receptor would also increase the incidence of plasmacytomas.
There is a heavy chain T15 knock-in (T15i) mouse, but T15-id+ B cells are not the
dominant PC-binding B cells in the unimmunized mouse.  Only 5-10% of Tg VH1+ B
cells can bind PC, and only 20% of these PC-binders are T15-id+ (135).  However, upon
immunization with PC antigen, the T15-Id+ B cells are expanded 6x and differentiate to
antibody-secreting cells.  Therefore, the ability of the T15+ PC-specific subset to expand
in response to PC may still be enough to generate a larger source of PCT-susceptible
precursors and result in increased PCT development in a pristane study.
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CONCLUSION
In summary, the acceleration of plasma cell tumor development in C.M167µk
mice is a novel result.  The PC-specific receptor, found on the majority (97-99%) of B
cells in C.M167µk Tg mice, increases the incidence and decreases the latency period of
plasma cell tumors over non-Tg littermates. This result suggests that the antigen-specific
receptor is playing a role in the increased development of these tumors and that PC
antigens are playing a key role in stimulating these PC-specific B cells.
Phosphorylcholine, abundantly found on apoptotic cells (present in inflammatory lesions)
and in commensal bacteria inhabiting the gut, appears to be one important antigen that
can stimulate B cell proliferation necessary for the generation of oncogenic mutations
needed in development of plasmacytomas.  The simple fact that there is now a vast pool
of PC-specific B cells, of which an enlarged MZ subset is hyperactivated to antigen, able
to be activated by the abundant bacterially-derived PC antigen is the most plausible
explanation for the increased incidence of PCTs in C.M167µk Tg mice.  The most likely
source of relevant antigens involved in stimulation of the M167µk PC-specific receptors
would be from a systemic immune response generated locally in the mucosal lining of the
intestinal tract.  Evidence indicating that the immune response probably originated in the
intestinal mucosa in response to commensal or pathogenic bacteria is the predominance
of the IgA isotype in the endogenously rearranged Ig genes expressed in the M167Tg
tumors.  Hypermutated IgA B cells are meant to protect the integrity of the mucosal
barrier throughout the host against invading microbes.
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I suggest that the best candidates for PCT precursors are B cells that are hyper-
activated against polysaccharide bacterial TI antigens, which includes both the MZ B
cells in the spleen and the B1 cells of the peritoneal cavity and spleen.  A growing
number of PCT-derived immunoglobulin idiotypes have been identified in B cells that are
consistently selected and enriched into the hyper-activated subsets of marginal zone B
cells (M167-id) and B-1 cells (T15-id).  Adding to this growing body of evidence is the




All studies were carried out according to protocols and methods approved by the
University of Maryland ACUC as well as the National Institutes of Health ACUC.
Transgene typing of M167µk mice
Peripheral blood (>100 µl) was collected by retro-orbital bleeds of anesthetized
mice.  Blood was collected in heparin (Sigma, 200 µl at 1000 units/ml) to prevent
clotting.  Red blood cells were removed using (2x) 3 ml AKC lysis buffer, pH 7.5
(Biofluids) and washed in FACS staining buffer (1xPBS/0.1% BSA/0.1% NaN3 (sodium
azide)).  Cells were blocked with anti-FcR antibody (5% 2.4G2/i10% rat serum/FACS
staining buffer) on ice for 10 minutes to block any non-specific binding to Fc receptors
and then labeled for 20 minutes on ice with anti-B220-FITC and the rat anti-mouse VH-1-
PE (hybridoma T68.3) (56) antibody provided by J. Kenny, GRC, NIH, Baltimore.  Cells
were washed with 2 ml FACS wash buffer (1xPBS/0.1% NaN3), resuspended in 500 ml
wash buffer and analyzed by flow cytometry (FACS).  Tg+ mice had double positive
B220/VH1 B cells, whereas non-Tg mice were B220+ only.
Induction Studies
Three pristane injections of 0.2 ml, 0.5 ml, and 0.5 ml were administered to eight-
to twelve-week-old N24 M167µk Tg+ and non-Tg littermate mice on day 0, 60, and 120,
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respectively.   Plasmacytomas were detected by finding >10 atypical plasma cells in the
peritoneal fluid using Wright-Giemsa stained cytofuge preparations of peritoneal ascites
fluid; mice were sacrificed when 100+ PCTs developed.  The study was carried to 300+
days, at which time mice in the study were euthanized by CO2 inhalation and necropsied.
Kidneys, liver, gut sections, and oil granuloma tissues were fixed in Telly’s fixative and
embedded in paraffin for immunohistochemistry for all study mice. Sections of tumor
tissue from PCT positive mice were either flash frozen in LN2 for nucleic acid recovery
or viably frozen in freeze media [100 ml EMEM with Earle’s Salts, no Glutamine
(Gibco), 15 ml Tryptose Phosphate Broth (Gibco), 15 ml heat inactivated FCS (Gibco),
24 ml DMSO (Sigma), 2 ml 200 nM L-Glutamine (Gibco), and 2 ml 100x Penicillin
(Gibco)].  Either finely minced peritoneal PCT tumor tissue or cells recovered from
ascites were washed and resuspended in 1x PBS, then injected i.p into pristane-primed
BALB/c mice for transplantation of tumors. All mice were bred and maintained in our
conventional facility on the National Institutes of Health Bethesda Maryland campus.
Flow cytometry analysis of B cell populations
Peritoneal washes: The peritoneal wall was carefully exposed by retracting the
skin, 10 ml of cold 1x PBS w/ 10 mM EDTA was injected into peritoneal cavity and
removed using a syringe with a 19g needle.  Spleen and mesentery lymph node cells were
obtained by either teasing the tissue with cold 1x PBS or using a MediMachine, a device
from Becton Dickinson Company which gently disaggregates tissue into single cell
suspension suitable for flow cytometric analysis of surface antigens. Red blood cells were
163
lysed with ACK buffer.  Splenic cells were washed and resuspended in staining buffer
(1x PBS/0.1% BSA/0.1% NaN3).
The following monoclonal antibodies against the following molecules were used
in these studies: M167 and VH-1 antibodies (biotin- or PE-tagged, provided by J. Kenny),
CD45R/B220 (RA3-6B2), CD11b (Mac-1; M1/70), CD5 (53-7.3), CD19 (ID3),
CD21/CD35 (CR2/CR1; 7G6), CD23 (IgE Fc receptor; B3B4), CD43 (Leukosialin; S7),
CD138 (Syndecan-1; 281-2), IgM (R6-60.2), and IgD (11-26c.2a).  Antibodies obtained
from PharMingen (San Diego, CA), were either fluoresceinated, biotinylated, or
conjugated to PE, PerCP, or APC.  In four-color experiments, directly fluoresceinated
and PE-, and APC-conjugated antibodies were combined with biotinylated antibody
revealed with streptavidin-PerCP.
Electrophoresis of Myeloma Proteins from PCTs
One microliter of PCT+ ascites diluted 1:5 in barbital buffer was run on a
polyacrylamide gel using the Beckman Paragon Serum Protein Electrophoresis (SPE)
system to determine whether the plasma cell tumor was secreting a myeloma protein.
ELISA Isotyping of C.M167µk Tg Myeloma Proteins
Secreted myeloma proteins from the C.M167µk Tg PCTs were isotyped by
ELISA using HRP-labeled anti-isotype monoclonal antibodies: goat anti-mouse IgM, IgG
(IgG1, IgG2a, IgG2b, IgG3), and IgA (Southern Biotechnology, Birmingham, Ala).  Goat
anti-mouse kappa and lambda HRP antibodies were used to determine light chain usage.
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Immulon 2 HB plates were coated with 50 µl 1:200 goat anti-mouse (H+L)
antibody-unlabelled in carbonate buffer and incubated o/n at 4°C.  Plates were blocked
with 0.5% gelatin/PBS for 1 hour at 37°C. Twofold serial dilutions of ascites fluid in
0.1% gelatin/PBS are added to plates and incubated for 1 hour at 37°C.  Plates were
washed three times with PBS/0.05% Tween 20 (polyoxyethylene-sorbitan monolaurate,
Sigma).  Secondary isotype-specific antibody goat anti-mouse Ig(H+L)-, IgM-, IgA-, or
IgG-HRP (Southern Biotechnologies) was added at predetermined dilution and incubated
for 1 hour at 37°C.
Conjugation of Phosphorylcholine to BSA and Hemocyanin (Hy)
Phosphorylcholine (PC) hapten was conjugated to the BSA or Hemocyanin
protein carrier as previously described by Wu et al. (136).
Collection of Sera
Peripheral blood was collected by retro-orbital bleeds and serum was harvested by
allowing blood to clot at RT° for 2 hours or overnight at 4°C, then centrifuging at 14,000
rpm for 10 minutes and collecting sera (supernate).
Sera were normalized before analysis in ELISA by diluting sera 1:100 in 1x PBS
and measuring protein content in a spectrophotometer.  Total protein concentration was
determined using following formula: µg/µl = 1.55 x 100df x A280 – 0.67 x 100df x
A260.  The IgG concentration, which comprises the largest portion of antibody in mouse
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serum, was then determined using the average IgG fraction (0.685).  IgG protein was
normalized to 30 µg/µl, and serially diluted starting at 75 µg/µl in ELISA.
PC-ELISA: Detecting anti-PC Abs in Sera/Ascites
ELISA was used to detect isotype- or idiotype-specific phosphorylcholine serum
antibodies: PC hapten was conjugated to BSA protein carrier as previously described
(136) and used to capture PC-specific serum or PCT ascites antibodies. Immulon 2 HB
plates were coated with PC-BSA at 1 µg/well and stored o/n at 4°C. Plates were blocked
with 0.5% gelatin/PBS for 1 hour at 37°C. Twofold serial dilutions of ascites fluid in
0.1% gelatin/PBS are added to plates and incubated for 1 hour at 37°C.  Plates were
washed three times with PBS/0.05% Tween 20 (polyoxyethylene-sorbitan monolaurate,
Sigma).  Secondary isotype-specific antibody goat anti-mouse Ig(H+L)-, IgM-, IgA-,
IgG-HRP (Southern Biotechnologies), or M167-id (clone 28-5-15 FITC, later revealed by
a third step using anti-FITC HRP), was added at predetermined dilution and incubated for
1 hour at 37°C.  Plates washed twice with PBS/0.05% Tween 20.  Color revealed with
TMB substrate (Sigma) at 100 µl/well.  Color reaction stopped with 1M H2SO4.
Absorbance was measured at 450 nm using a VersAmax spectraphotometer.
Sequencing of Ig variable regions
RNA
RNA was obtained from tumor tissue in the following manner.  Tumor was
ground into a fine paste in liquid nitrogen using a mortar and pestle.  Ground tissue was
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lysed in TriReagent (Sigma, MO), a mixture of guanidine thiocyanate and phenol in a
mono-phase solution, according to manufacturer’s instructions, followed by isopropanol
precipitation of RNA.  RNA was washed with 75% ETOH, resuspended in diethyl
pyrocarbonate (depc)-treated H20 and quantitated by OD260.
First strand cDNA
The cDNA was synthesized from purified tumor RNA using reverse transcriptase
(Moloney murine leukemia virus, Gibco BRL) in a mixture of: 5 µl RNA (~1 µg RNA), 2
µl 5x first strand buffer (Promega, Madison, WI), l µl 10 mM dNTPs, (Promega,
Madison, WI), 1 µl oligo(dT)12-18 (0.5 µg, Boehringer Mannheim), 0.1 µl RNAse
Inhibitor (Promega, Madison, WI) and dH2O to the final volume of 20 µl.  After a 10-
minute incubation at 70˚C, the reaction was placed on ice for 1-2 minutes and 5 U of M-
MLV RT was added.  The reaction was then incubated at 37˚C for 1 hour and heated at
99˚C for 10 minutes, and cooled to 4˚C.
Primers
The following 5’ FRW1 degenerate primers for amplifying the variable heavy
chains were obtained from K. Huppi (52).  Four individual PCR reactions, using each of
the four mouse 5’ heavy chain degenerate primers paired with the appropriate isotype
constant region primer, were run for each myeloma RNA.  One or all primer
combinations may produce successful variable heavy (VH) region band between 400 and
500 bp in length.  The mouse kappa light chain degenerate FRW1 primer (103) was
paired with the kappa constant-region primer produces a band between 350 and 400 bp.
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Mouse 5’ heavy chain degenerate primers:
VH-SG1 5’ GTGCAGCTKMAGSAGTCRGG 3’
VH-SG2 5’ CARCTGCARCARYCTGG 3
VH-SG3 5’ GTGAAGCTKSWSGARTCTGG 3’
VH-SG4 5’ GTYCARCTKCARCAGTCTGG 3’
Mouse 5’ Kappa chain FR1 region universal degenerate primer:
5’ Mk: 5’ GAYATTGTGMTSACMCARWCTMCA 3’
Mixed bases:
r = a, g; y = c, t; m = a, c; k = g, t; s = c, g; w = a, t; v = a, c, g; n = a, c, g t
Isotype-specific 3’ primers were designed from the first domain of the constant
region of each heavy isotype gene (51).  All 3’ heavy chain constant region primers
include an EcoR1 cloning site (5’ gga agatct 3’) at the 5’ end.  The primer used in PCR
amplification depended on the previous isotyping of myelomas done using ELISA.
Mouse 3’ heavy chain constant region primers:
IgA: 5’ GATGGTGGGATTTCTCGCAGACTC 3’
IgG1: 5’ ATAGACAGATGGGGGTGTCGTTTTGGC 3’
IgG2A: 5’ CTTGACCAGGCATCCTAGAGTCA 3’
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IgG2B: 5’ AGGGGCCAGTGGATAGACTGATGG 3’
IgM: 5’ GACATTTGGGAAGGACTGACTCTC 3’
Mouse 3’ Kappa chain constant region primer:
3’ Kc: 5’ GGATACAGTTGGTGCAGCATC 3’
The kappa 3’ primer (51) is from the constant region of the kappa light
chain gene and also contains a SphI (5’ ggt gcatgc 3’) cloning site at its 5’ end.
PCR
Variable regions of Ig heavy and light chain genes were amplified by PCR using
the cDNA and Taq polymerase (Perkin Elmer/Roche).  Each PCR reaction contained: 2
µl cDNA, 20 pmol/µl each of 5’ and 3’ primers, 1 µl 10 mM dNTPs, 10 µl 10 X Taq
buffer (15 mM MgCl2), and an additional 2 µl of 25 mM MgCl2 for a final concentration
of 2mM MgCl2, and 2.5 U Taq polymerase.  The final volume was brought to 100 µl with
depc-H2O.  The cycling program used had an initial melt at 94˚C for 3 minutes, followed
by 30 cycles of 1 minute at 94˚C, l minute at 45˚C, and 2 minutes at 72˚C.  Finally, the
reaction was held at 72˚C for 10 minutes and cooled to 10˚C.
VH and VL PCR products were either excised from a low-melt 2% NuSieve
agarose gel or directly purified using the silica based GeneClean Spin kit (BIO 101).
Purified DNA was then eluted from silica in 50 µl TE buffer at 50˚C.  Amersham’s Big
Dye Terminating Kit was used for sequencing of purified PCR products.  Variable light
chain products are sequenced using the kappa 3’ constant region primer, while the cloned
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variable heavy chain fragments are sequenced using M13 Forward or Reverse primers.
The sequencing reaction mix was 4 µl Big Dye mix, 2 µl 3.2 pmol/µl primer, and 4 µl
DNA.  The cycling program for Big Dye is as follows: 25 cycles of 96˚C for 30 seconds,
50˚C for 15 seconds, and 60˚C for 4 minutes.  Reaction products are filtered in Centriflex
Gel Filtration Cartridges (Edge BioSystems) and lyophilized in a speed vac before being
sent to the NCI Sequencing Core Facility for processing.  Sequence data is analyzed and
aligned using Sequencher software.
Sequence Databases
NCBI IgBLAST: http://www.ncbi.nlm.nih.gov/igblast/ is the link for the
National Center for Biotechnology Information’s ‘Immunoglobulin Blast’ website, as
special search database designed to facilitate analysis of immunoglobulin sequences in
GenBank.   Only human and mouse germline genes are included in thee current Ig
germline gene collections. As described on the NCBI website:
“IgBLAST has three functions:
1. Reports the three germline V genes, three D* and two J* genes that show
the closest match to the query sequence.
2. Annotates the immunoglobulin domains (FWR1 through FWR3)
according to Kabat et al.
3. Matches the returned hits from the nr database to the closest germline V
genes, thus making it easier to identify related sequences.
* D and J genes will be reported only for nucleotide sequence query and a stretch
of seven or more nucleotide identity is required for them to be reported.”
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Celera: http://www.celeradiscoverysystem.com/index.cfm
As stipulated in the Celera agreement: "This data was generated through the use
of the Celera Discovery System and Celera's associated database.
Ig variable region sequences are searched using IgBLAST in the NCBI GenBank
database to determine which variable region families the myeloma proteins are derived
and against the Celera mouse database to further search for GL matches to myeloma
genes.
PC-Hy and PnC in vivo immunizations
For immunization experiments using PC-antigens, 200 µl of either 200 µg PC-
Hy/IFA, 100 µg PnC/IFA or PBS/IFA (1:2 Ag:IFA emulsion) were injected i.p into
C.M167µκ Tg and non-Tg littermate mice.  Mice were given a secondary boost at day
14.  Day 7 and day 21 sera were collected by retro-orbital eye bleeds and analyzed by
ELISA for anti-PC specific antibodies.  Control sera were unimmunized mice and
PBS/IFA mice, which were not significantly different.  Sera were normalized before
analysis in PC-specific ELISA.
PnC, or polysaccharide C component (teichoic acid) from Streptococcus
pneumoniae type III bacterial cell wall, contains the PC hapten.  PC-Hy is PC conjugated
to the protein carrier, horseshoe crab Hemocyanin (Hy), as previously described.
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R36A in vivo immunizations
Eight- to twelve-week-old N24 M167µκ Tg+ and non-Tg littermate mice were
immunized with heat-killed Streptococcus pneumonia, R36A (kindly provided by Dr.
Cliff Snapper, USUHS and John Kearney, University of Alabama at Birmingham).
Aliquots of 109 cfu/ml R36A were thawed and 100 ml of bacteria was injected i.p. so that
each mouse received a dose of 108 R36A at day 0 and day 7.  Blood was collected by
retro-orbital puncture according the NIH Animal Care guidelines on day 0, 7, 14, 21, and
28, and the serum titered onto PC-BSA-coated ELISA plates.  PC-ELISA was done as
described above.
Cell Culture
RPMI/10%FCS complete culture media:  RPMI 1640 without Glutamine, 10%
FCS, 4 mM L-Glutamine, 50 µg/ml Pen-Strep (all from Biofluids, Rockville, MD) and
0.05 mM 2-ME (Sigma, St. Louis, MO) were used for culturing cells.
Conjugation of Antibody to Sepharose Beads
Conjugation of M167 (28-6-20, anti-Vk4) and polyclonal goat anti-IgM (Southern
Biotech) to sepharose beads was 2carried out according to the previously published
protocol (55).  Briefly, one gram of cyanogen bromide activated Sepharose 4B (Sigma)
was hydrated in 50 ml of 0.001 M HCl at RT° for 15 minutes.  One gram of hydrated
beads is equal to 3.5 ml wet packed volume.  Hydrated beads were washed thoroughly
using a scintered glass filter funnel attached to a vacuum with 3 liters of 0.001 M HCl,
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which removes the dextrose inhibitor found in the bead preparation.  Immediately
following washing, 1.34 ml of activated beads were scraped into 15 ml screw cap tubes
containing 1.34 ml of the antibody to be conjugated and well mixed overnight on a
rotating wheel at 4°C.   The antibodies had been previously diluted to 1 mg/ml in 0.1 M
NaHCO3-NaCl buffer, pH 8-9.  The pH of the bead/antibody slurry was checked by
placing a small drop on pH paper and adjusted to pH 8-9 with 0.1 N NaOH, if necessary.
The following day, beads were centrifuged at 1000 rpm for 5 minutes; the supernatant
removed and read in a spectrophotometer to determine how much protein did not
conjugate to the beads.  Beads were then washed 2x with 0.1 M NaHCO3-NaCl buffer,
pH 8-9 by centrifugation and decanting of wash fluid.  To block remaining conjugation
sites on the beads, 1 ml of 0.5 M ethanolamine was added to beads and rotated at 4°C for
2 hours. Beads were then washed 2x with 5 ml sterile PBS and finally resuspended at 1
part beads to 1 part PBS/0.02% NaN3.  Bead preparations were sterilized for 1 hour in a
60°C waterbath.
In Vitro Stimulation of B cells with anti-M167 mAb-sepharose
The following rat anti-idiotypic antibodies conjugated to sepharose were used to
stimulate Tg+ B cells: anti-M167 (28-5-15) and anti-M167 (28-6-20).  Clone 28-5-15
(1:50) is M167 heavy-light chain specific, its binding to M167 can be inhibited with PC-
antigen (58).   Clone 28-6-20 (1:100) is specific for the Vk24 light chain in combination
with any heavy chain. PC-Sepharose (1:50), IgM-sepharose (1:100), a goat anti-IgM
polyclonal, and unconjugated sepharose were kindly provided by Ana Lustig, GRC, NIH.
LPS (Sigma) was used as a proliferation control.
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Table 19. Rat anti-idiotypic M167 monoclonal antibodies.  Adapted from Sieckmann,
1997 (58).
Clone              Specificity                  Isotype                       
28-5-15 anti-VH1/Vk24 IgG2b lambda
28-6-20 anti-Vk24 IgG2a kappa
Enriched B cells were obtained from spleens from eight- to twelve-week-old N26
M167µk Tg+ and non-Tg littermate mice.  Lymphocytes were recovered from spleen
suspensions using Ficoll (LSM, ICN Biomedicals, Aurora, OH).  T cells were
cytotoxically lysed using a cocktail of monoclonal rat IgM anti–thy 1.2 (H013-4,
Pharmingen), rat IgG2a anti-CD4 (CT-CD4, Caltag), and rat IgG2a anti-CD8 (CT-CD8a;
Caltag) with rabbit complement (Sigma, St. Louis, MO) (137).  Macrophages were
depleted by “panning” the spleen cells in a petri dish at 37°C for 1-2 hours.   B cells from
Tg+ and non-Tg mice were enriched to between 85% and 95%.
B cells were labeled with the cytoplasmic proliferation dye, CFSE
(carboxyfluoresein succinimidyl ester), as follows.  Cells were aliquoted at 1 x 107/1ml in
PBS/2% FCS and incubated with 20 µl of 500 mM CFSE [10 mM final CFSE] for 10
minutes at 37°C in dark.  Reactions were stopped by addition of 100ul FCS.  Cells were
washed 2 times with PBS/2% FCS and once in RPMI/10%FCS culture media.
CFSE labeled B cells were cultured at 2 x 106 cell/ml with 1000units/ml IL-4 and
stimulated with 10 µg/ml LPS, PC-antigen, dilutions of R36A bacteria/ml, soluble or
sepharose-conjugated anti-BCR antibodies to stimulate proliferation.  Three days after in
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vitro stimulation, cells were harvested, labeled with anti-B220-APC (BD Pharmingen)
and proliferation of B cells was measured using a BD FACSCalibur.  PI was used to gate
out dead cells.
Statistical Analysis
Statistical analysis was performed using the one-tailed Student’s t test.  A value of
p < 0.01 was considered to be significant.
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APPENDIX
Chromosomal location of VH12µ Tg heavy chain
Figure 38. VH12µ Tg on murine chromosome 6.  The transgene is inserted in
chromosome 6 of the mouse.  The VH12µ plasmid was used as a probe.  FISH analysis
was performed by Allen Coleman, Laboratory of Genetics, NIH.
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Chromosomal location of M167µk Tg heavy and light chains
Using the original heavy chain pV167m(13) and light chain pJRD/vk 167
plasmids as probes (47), we used fluorescent in situ hybridization (FISH) to identify
which chromosome the transgenes were inserted onto.  Preliminary reports showed that
the M167k Tg was inserted into either chromosome 2 or 3 (Figure 39, Santiago Silva,
personal communication).
Figure 39. FISH on metaphase chromosomes from M167µk Tg B cells.  The light
chain pJRD/vk167 plasmid was used as a probe to locate the position of the tandemly
inserted M167µk transgenes.  The location of the transgene insertion has been narrowed
to either chromosome 2 or 3 (Dr. Santiago Silva).  The M167 heavy chain (VH1-µ) and
light chain (Vk24) have the same integration site (47).
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The heavy chain gene is reported to be co-inserted with the light chain gene (47).
Work on this project is still in progress.  Susceptibility of mice to plasmacytomas is a
complex genetic trait involving multiple loci.  Resistance/susceptibility genes have been
identified on chromosomes 1, 4, and 11 (51, 52, 138).  The Ig loci are found on
chromosomes 12 (IgH), 6 (Igk), and 16 (Igλ).  The data presented here confirm that the
M167 kappa transgene was not inserted on any of the Ig chromosomes or one of the
chromosomes linked to PCT resistance/susceptibility genes.  However, a more precise
survey of the transgenes’ location is necessary to rule out the possibility of an important
oncogene being deregulated by their insertion.
 (M167µk Tg x Bcl-xL Tg) F1 PCT pristane induction study
The Bcl-xL Tg was introduced onto the C.M167µk Tg background to test how
this anti-apoptotic gene would affect pristane induction of plasmacytomas.  PCTs studies
in C. Bcl-xL Tg mice appeared with reduced latency periods of approximately 40 days
(Potter, personal communication) and increased PCT incidence to 100% of study mice.
Figure 40 shows that the Bcl-xL Tg accelerated the development of PCTs over controls,
while the double transgene (M167µk/Bcl-xL Tg) caused tumor development even earlier
than the Bcl-xL Tg alone.  By day 110 of this study, the M167µk/Bcl-xL double Tg mice
had produced more tumors (100%) than the Bcl-xL Tg mice (95%), the M167µk Tg mice
(45%), or the non-Tg BALB/c WT mice (20%).
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Figure 40.  (C.M167µk Tg x C.Bcl-xL) F1 PCT pristane induction study results.
C.M167µk Tg x C.Bcl-xL (n=9), C.M167µk Tg (n=16), C.Bcl-xL (n=12), and BALB/c
non-Tg (n=5) littermates.  Acceleration of PCT development occurs in the double Tg
M167µk/Bcl-xL mice over Bcl-xL Tg, M167µk Tg, and BALB/c WT mice.  Study also
reconfirms the increased incidence and acceleration of PCTs in C.M167µk Tg over
BALB/c non-Tg WT mice.
Summary of B cell Subtypes
Follicular (FO) B cells (subset of B-2 cells):
• Found in lymphoid follicles of secondary lymphoid organs: spleen, LN, PP
• Represent most of the recirculating cells in adult animals
• Naïve, resting B cell state
• sIgM low sIgD high and CD23 high CD21/CR2 low
• Develop continuously from the progenitor cells in the BM
• Contain a large repertoire of B cells that respond to BCR-dependent antigen
stimulation and participate in T-cell dependent immune responses within germinal
centers
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• In germinal centers, intense proliferation of FO B cells results in production of
high affinity antibodies through somatic hypermutation, isotype switching, and
formation of memory B cells
Marginal zone (MZ) B cells (subset of B-2 cells):
• Found in the marginal zone of spleen- area surrounding the marginal sinus,
bordering the white and the red pulp
• Typically 5% of splenic B220+ cells
• Do not circulate, but remain in MZ until activated
• Persist in a pre-activated state (are larger size, have less condensed chromatin, and
express higher levels of B7-1 and B7-2 co-stimulatory molecules than FO B cells)
• sIgM high sIgD low and CD23 low CD21/CR2 high
• Can be induced to rapidly differentiate into plasma cells within 1-3 days upon
antigen stimulation of BCR
• Have a far greater ability to proliferate and differentiate into plasma cells in
response to T-independent antigens than FO B cells
• Selection of MZ B cells may require a strong BCR signaling threshold
• Positive selection of MZ B cells also appears to be based on preferential selection
of certain antigen specific BCR clones
• Multi-reactive cells with “sticky” antigen receptors appear to be efficiently
recruited into MZ
B-1 cells (B-1a and B-1b):
• Localized in the peritoneal and pleural cavities
• Make up only 1-5% of splenic B cells
• Develop from the neonatal repertoire, are long-lived and self-renewing
• Responsible for production of natural IgM antibodies (low antigen affinity)
• Also responsible for 50% of the intestinal IgA-secreting plasma cells
• Have little or no N sequence additions on their VDJ borders
• Express an activated phenotype
• sIgM+, sIgD+ , CD23low, CD43+
• Peritoneal B-1 cells express Mac 1+ and CD5+ (B-1a)
• Splenic B-1 cells are Mac 1 and CD5 negative
• Have a restricted antibody repertoire skewed toward reactivity to self antigens
• B-1 selection depends on strong self-antigen binding and low threshold signaling
through the IgM receptors
• Decreased BCR activation thresholds lead to expanded B-1 populations, whereas
increased signaling capabilities through BCR decrease B-1 cells
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Table 20. T cell independent and dependent antigen classification.
T-cell independent T-cell dependent













and mature B cells
Activates mature B cells and
inactivates immature B cells
Antibody response includes
isotype switching, affinity
maturation and memory B cells
Requires no direct T helper
cell contact or cytokines for
B cell activation
No direct T helper cell contact
needed, but does need TH
cytokines for efficient B cell
proliferation and class switching
to other isotypes than IgM
Requires T cell recognition of
MHC II presented antigens on B






crosslink BCRs, triggering a
strong signal transduction
pathway to activate B cells
BCR recognizes TD antigens and
are internalized for processing and
presentation to T cells
T cell independent type 2 responses:
• Do not show affinity maturation
• Do not show memory B cell development
• Characterized by early B cell proliferation in all splenic compartments
• Induces differentiation of B cells into antibody-production plasma cells starting at
day 3 after immunization
• Number of plasma cells falls markedly during 2nd week after immunization
• Lack of affinity maturation and memory in T1-2 responses increases the
importance of initial selection of B cells producing high-affinity antibodies
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